BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Tutt A, Robson M, Garber JE, Domchek SM, Audeh MW, Weitzel JN, Friedlander M, Arun B, Loman N, Schmutzler RK, Wardley A, Mitchell G, Earl H, Wickens M, Carmichael J. Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial. Lancet. 2010;376:235-244. [PMID: 20609467 DOI: 10.1016/s0140-6736(10)60892-6] [Cited by in Crossref: 1250] [Cited by in F6Publishing: 639] [Article Influence: 113.6] [Reference Citation Analysis]
Number Citing Articles
1 Chen F, Roberts NJ, Klein AP. Inherited pancreatic cancer. Chin Clin Oncol. 2017;6:58. [PMID: 29307198 DOI: 10.21037/cco.2017.12.04] [Cited by in Crossref: 12] [Cited by in F6Publishing: 8] [Article Influence: 4.0] [Reference Citation Analysis]
2 Murai J, Feng Y, Yu GK, Ru Y, Tang SW, Shen Y, Pommier Y. Resistance to PARP inhibitors by SLFN11 inactivation can be overcome by ATR inhibition. Oncotarget 2016;7:76534-50. [PMID: 27708213 DOI: 10.18632/oncotarget.12266] [Cited by in Crossref: 122] [Cited by in F6Publishing: 108] [Article Influence: 40.7] [Reference Citation Analysis]
3 Aressy B, Greenberg RA. DNA damage: placing BRCA1 in the proper context. Curr Biol 2012;22:R806-8. [PMID: 23017997 DOI: 10.1016/j.cub.2012.07.046] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 0.9] [Reference Citation Analysis]
4 Lim HJ, Ledger W. Targeted therapy in ovarian cancer. Womens Health (Lond) 2016;12:363-78. [PMID: 27215391 DOI: 10.2217/whe.16.4] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 1.8] [Reference Citation Analysis]
5 Wu W, Togashi Y, Johmura Y, Miyoshi Y, Nobuoka S, Nakanishi M, Ohta T. HP1 regulates the localization of FANCJ at sites of DNA double-strand breaks. Cancer Sci 2016;107:1406-15. [PMID: 27399284 DOI: 10.1111/cas.13008] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 2.0] [Reference Citation Analysis]
6 Karginova O, Siegel MB, Van Swearingen AE, Deal AM, Adamo B, Sambade MJ, Bazyar S, Nikolaishvili-Feinberg N, Bash R, O'Neal S, Sandison K, Parker JS, Santos C, Darr D, Zamboni W, Lee YZ, Miller CR, Anders CK. Efficacy of Carboplatin Alone and in Combination with ABT888 in Intracranial Murine Models of BRCA-Mutated and BRCA-Wild-Type Triple-Negative Breast Cancer. Mol Cancer Ther 2015;14:920-30. [PMID: 25824335 DOI: 10.1158/1535-7163.MCT-14-0474] [Cited by in Crossref: 45] [Cited by in F6Publishing: 25] [Article Influence: 9.0] [Reference Citation Analysis]
7 Singh N, Pay SL, Bhandare SB, Arimpur U, Motea EA. Therapeutic Strategies and Biomarkers to Modulate PARP Activity for Targeted Cancer Therapy. Cancers (Basel) 2020;12:E972. [PMID: 32295316 DOI: 10.3390/cancers12040972] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 5.0] [Reference Citation Analysis]
8 Weigelt B, Comino-Méndez I, de Bruijn I, Tian L, Meisel JL, García-Murillas I, Fribbens C, Cutts R, Martelotto LG, Ng CKY, Lim RS, Selenica P, Piscuoglio S, Aghajanian C, Norton L, Murali R, Hyman DM, Borsu L, Arcila ME, Konner J, Reis-Filho JS, Greenberg RA, Robson ME, Turner NC. Diverse BRCA1 and BRCA2 Reversion Mutations in Circulating Cell-Free DNA of Therapy-Resistant Breast or Ovarian Cancer. Clin Cancer Res 2017;23:6708-20. [PMID: 28765325 DOI: 10.1158/1078-0432.CCR-17-0544] [Cited by in Crossref: 112] [Cited by in F6Publishing: 44] [Article Influence: 28.0] [Reference Citation Analysis]
9 Dent RA, Lindeman GJ, Clemons M, Wildiers H, Chan A, McCarthy NJ, Singer CF, Lowe ES, Watkins CL, Carmichael J. Phase I trial of the oral PARP inhibitor olaparib in combination with paclitaxel for first- or second-line treatment of patients with metastatic triple-negative breast cancer. Breast Cancer Res 2013;15:R88. [PMID: 24063698 DOI: 10.1186/bcr3484] [Cited by in Crossref: 123] [Cited by in F6Publishing: 110] [Article Influence: 17.6] [Reference Citation Analysis]
10 Janzen DM, Paik DY, Rosales MA, Yep B, Cheng D, Witte ON, Kayadibi H, Ryan CM, Jung ME, Faull K, Memarzadeh S. Low levels of circulating estrogen sensitize PTEN-null endometrial tumors to PARP inhibition in vivo. Mol Cancer Ther 2013;12:2917-28. [PMID: 24222661 DOI: 10.1158/1535-7163.MCT-13-0572] [Cited by in Crossref: 16] [Cited by in F6Publishing: 12] [Article Influence: 2.0] [Reference Citation Analysis]
11 Zoppoli G, Ferrando V, Scabini S. On biomarkers and pathways in rectal cancer: What's the target? World J Gastrointest Surg 2012;4:275-7. [PMID: 23493582 DOI: 10.4240/wjgs.v4.i12.275] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
12 Telli ML, Sledge GW. The future of breast cancer systemic therapy: the next 10 years. J Mol Med (Berl) 2015;93:119-25. [PMID: 25566982 DOI: 10.1007/s00109-014-1238-y] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 2.0] [Reference Citation Analysis]
13 Vazquez-Ortiz G, Chisholm C, Xu X, Lahusen TJ, Li C, Sakamuru S, Huang R, Thomas CJ, Xia M, Deng C. Drug repurposing screen identifies lestaurtinib amplifies the ability of the poly (ADP-ribose) polymerase 1 inhibitor AG14361 to kill breast cancer associated gene-1 mutant and wild type breast cancer cells. Breast Cancer Res. 2014;16:R67. [PMID: 24962108 DOI: 10.1186/bcr3682] [Cited by in Crossref: 11] [Cited by in F6Publishing: 13] [Article Influence: 1.6] [Reference Citation Analysis]
14 Solimando DA Jr, Waddell JA. Nivolumab and Olaparib. Hosp Pharm 2015;50:356-66. [PMID: 26405320 DOI: 10.1310/hpj5005-356] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
15 Pan MR, Hsieh HJ, Dai H, Hung WC, Li K, Peng G, Lin SY. Chromodomain helicase DNA-binding protein 4 (CHD4) regulates homologous recombination DNA repair, and its deficiency sensitizes cells to poly(ADP-ribose) polymerase (PARP) inhibitor treatment. J Biol Chem 2012;287:6764-72. [PMID: 22219182 DOI: 10.1074/jbc.M111.287037] [Cited by in Crossref: 57] [Cited by in F6Publishing: 33] [Article Influence: 6.3] [Reference Citation Analysis]
16 Hewish M, Martin SA, Elliott R, Cunningham D, Lord CJ, Ashworth A. Cytosine-based nucleoside analogs are selectively lethal to DNA mismatch repair-deficient tumour cells by enhancing levels of intracellular oxidative stress. Br J Cancer 2013;108:983-92. [PMID: 23361057 DOI: 10.1038/bjc.2013.3] [Cited by in Crossref: 22] [Cited by in F6Publishing: 20] [Article Influence: 2.8] [Reference Citation Analysis]
17 Li CH, Karantza V, Aktan G, Lala M. Current treatment landscape for patients with locally recurrent inoperable or metastatic triple-negative breast cancer: a systematic literature review. Breast Cancer Res. 2019;21:143. [PMID: 31842957 DOI: 10.1186/s13058-019-1210-4] [Cited by in Crossref: 20] [Cited by in F6Publishing: 14] [Article Influence: 10.0] [Reference Citation Analysis]
18 Sethi GS, Dharwal V, Naura AS. Poly(ADP-Ribose)Polymerase-1 in Lung Inflammatory Disorders: A Review. Front Immunol 2017;8:1172. [PMID: 28974953 DOI: 10.3389/fimmu.2017.01172] [Cited by in Crossref: 28] [Cited by in F6Publishing: 27] [Article Influence: 7.0] [Reference Citation Analysis]
19 Bal A, Verma S, Joshi K, Singla A, Thakur R, Arora S, Singh G. BRCA1-methylated sporadic breast cancers are BRCA-like in showing a basal phenotype and absence of ER expression. Virchows Arch 2012;461:305-12. [PMID: 22820987 DOI: 10.1007/s00428-012-1286-z] [Cited by in Crossref: 26] [Cited by in F6Publishing: 21] [Article Influence: 2.9] [Reference Citation Analysis]
20 Liu FW, Tewari KS. New Targeted Agents in Gynecologic Cancers: Synthetic Lethality, Homologous Recombination Deficiency, and PARP Inhibitors. Curr Treat Options Oncol 2016;17:12. [PMID: 26931795 DOI: 10.1007/s11864-015-0378-9] [Cited by in Crossref: 23] [Cited by in F6Publishing: 20] [Article Influence: 4.6] [Reference Citation Analysis]
21 Yang L, Zhang Y, Shan W, Hu Z, Yuan J, Pi J, Wang Y, Fan L, Tang Z, Li C, Hu X, Tanyi JL, Fan Y, Huang Q, Montone K, Dang CV, Zhang L. Repression of BET activity sensitizes homologous recombination-proficient cancers to PARP inhibition. Sci Transl Med 2017;9:eaal1645. [PMID: 28747513 DOI: 10.1126/scitranslmed.aal1645] [Cited by in Crossref: 96] [Cited by in F6Publishing: 87] [Article Influence: 32.0] [Reference Citation Analysis]
22 Domagala P, Huzarski T, Lubinski J, Gugala K, Domagala W. Immunophenotypic predictive profiling of BRCA1-associated breast cancer. Virchows Arch 2011;458:55-64. [PMID: 20941507 DOI: 10.1007/s00428-010-0988-3] [Cited by in Crossref: 19] [Cited by in F6Publishing: 13] [Article Influence: 1.7] [Reference Citation Analysis]
23 Poggio F, Bruzzone M, Ceppi M, Conte B, Martel S, Maurer C, Tagliamento M, Viglietti G, Del Mastro L, de Azambuja E, Lambertini M. Single-agent PARP inhibitors for the treatment of patients with BRCA-mutated HER2-negative metastatic breast cancer: a systematic review and meta-analysis. ESMO Open 2018;3:e000361. [PMID: 29942664 DOI: 10.1136/esmoopen-2018-000361] [Cited by in Crossref: 27] [Cited by in F6Publishing: 25] [Article Influence: 9.0] [Reference Citation Analysis]
24 Zhang F, Lou L, Peng B, Song X, Reizes O, Almasan A, Gong Z. Nudix Hydrolase NUDT16 Regulates 53BP1 Protein by Reversing 53BP1 ADP-Ribosylation. Cancer Res 2020;80:999-1010. [PMID: 31911551 DOI: 10.1158/0008-5472.CAN-19-2205] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 8.0] [Reference Citation Analysis]
25 Shao F, Sun H, Deng CX. Potential therapeutic targets of triple-negative breast cancer based on its intrinsic subtype. Oncotarget. 2017;8:73329-73344. [PMID: 29069872 DOI: 10.18632/oncotarget.20274] [Cited by in Crossref: 37] [Cited by in F6Publishing: 37] [Article Influence: 9.3] [Reference Citation Analysis]
26 Mehibel M, Xu Y, Li CG, Moon EJ, Thakkar KN, Diep AN, Kim RK, Bloomstein JD, Xiao Y, Bacal J, Saldivar JC, Le QT, Cimprich KA, Rankin EB, Giaccia AJ. Eliminating hypoxic tumor cells improves response to PARP inhibitors in homologous recombination-deficient cancer models. J Clin Invest 2021;131:146256. [PMID: 34060485 DOI: 10.1172/JCI146256] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
27 Lee HJ, Yoon C, Schmidt B, Park do J, Zhang AY, Erkizan HV, Toretsky JA, Kirsch DG, Yoon SS. Combining PARP-1 inhibition and radiation in Ewing sarcoma results in lethal DNA damage. Mol Cancer Ther. 2013;12:2591-2600. [PMID: 23966622 DOI: 10.1158/1535-7163.mct-13-0338] [Cited by in Crossref: 53] [Cited by in F6Publishing: 32] [Article Influence: 6.6] [Reference Citation Analysis]
28 Ruhen O, Mirzai B, Clark ME, Nguyen B, Salomon C, Erber W, Meehan K. Comparison of Circulating Tumour DNA and Extracellular Vesicle DNA by Low-Pass Whole-Genome Sequencing Reveals Molecular Drivers of Disease in a Breast Cancer Patient. Biomedicines 2020;9:14. [PMID: 33375577 DOI: 10.3390/biomedicines9010014] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
29 Yamamoto N, Nokihara H, Yamada Y, Goto Y, Tanioka M, Shibata T, Yamada K, Asahina H, Kawata T, Shi X, Tamura T. A Phase I, dose-finding and pharmacokinetic study of olaparib (AZD2281) in Japanese patients with advanced solid tumors. Cancer Sci 2012;103:504-9. [PMID: 22145984 DOI: 10.1111/j.1349-7006.2011.02179.x] [Cited by in Crossref: 50] [Cited by in F6Publishing: 42] [Article Influence: 5.6] [Reference Citation Analysis]
30 Srinivasan G, Williamson EA, Kong K, Jaiswal AS, Huang G, Kim HS, Schärer O, Zhao W, Burma S, Sung P, Hromas R. MiR223-3p promotes synthetic lethality in BRCA1-deficient cancers. Proc Natl Acad Sci U S A 2019;116:17438-43. [PMID: 31395736 DOI: 10.1073/pnas.1903150116] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 6.5] [Reference Citation Analysis]
31 Hussain M, Carducci MA, Slovin S, Cetnar J, Qian J, McKeegan EM, Refici-Buhr M, Chyla B, Shepherd SP, Giranda VL, Alumkal JJ. Targeting DNA repair with combination veliparib (ABT-888) and temozolomide in patients with metastatic castration-resistant prostate cancer. Invest New Drugs 2014;32:904-12. [PMID: 24764124 DOI: 10.1007/s10637-014-0099-0] [Cited by in Crossref: 53] [Cited by in F6Publishing: 51] [Article Influence: 7.6] [Reference Citation Analysis]
32 Panou V, Røe OD. Inherited Genetic Mutations and Polymorphisms in Malignant Mesothelioma: A Comprehensive Review. Int J Mol Sci 2020;21:E4327. [PMID: 32560575 DOI: 10.3390/ijms21124327] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 6.0] [Reference Citation Analysis]
33 Hahnen E, Hauke J, Engel C, Neidhardt G, Rhiem K, Schmutzler RK. Germline Mutations in Triple-Negative Breast Cancer. Breast Care (Basel) 2017;12:15-9. [PMID: 28611536 DOI: 10.1159/000455999] [Cited by in Crossref: 28] [Cited by in F6Publishing: 22] [Article Influence: 7.0] [Reference Citation Analysis]
34 Cerrato A, Morra F, Celetti A. Use of poly ADP-ribose polymerase [PARP] inhibitors in cancer cells bearing DDR defects: the rationale for their inclusion in the clinic. J Exp Clin Cancer Res 2016;35:179. [PMID: 27884198 DOI: 10.1186/s13046-016-0456-2] [Cited by in Crossref: 56] [Cited by in F6Publishing: 47] [Article Influence: 11.2] [Reference Citation Analysis]
35 Jubin T, Kadam A, Jariwala M, Bhatt S, Sutariya S, Gani AR, Gautam S, Begum R. The PARP family: insights into functional aspects of poly (ADP-ribose) polymerase-1 in cell growth and survival. Cell Prolif. 2016;49:421-437. [PMID: 27329285 DOI: 10.1111/cpr.12268] [Cited by in Crossref: 45] [Cited by in F6Publishing: 39] [Article Influence: 9.0] [Reference Citation Analysis]
36 Hosford SR, Miller TW. Clinical potential of novel therapeutic targets in breast cancer: CDK4/6, Src, JAK/STAT, PARP, HDAC, and PI3K/AKT/mTOR pathways. Pharmgenomics Pers Med 2014;7:203-15. [PMID: 25206307 DOI: 10.2147/PGPM.S52762] [Cited by in Crossref: 9] [Cited by in F6Publishing: 49] [Article Influence: 1.3] [Reference Citation Analysis]
37 Tung NM, Garber JE. BRCA1/2 testing: therapeutic implications for breast cancer management. Br J Cancer 2018;119:141-52. [PMID: 29867226 DOI: 10.1038/s41416-018-0127-5] [Cited by in Crossref: 69] [Cited by in F6Publishing: 51] [Article Influence: 23.0] [Reference Citation Analysis]
38 Abbotts R, Thompson N, Madhusudan S. DNA repair in cancer: emerging targets for personalized therapy. Cancer Manag Res 2014;6:77-92. [PMID: 24600246 DOI: 10.2147/CMAR.S50497] [Cited by in Crossref: 7] [Cited by in F6Publishing: 20] [Article Influence: 1.0] [Reference Citation Analysis]
39 Guo J, Li W, Shi H, Xie X, Li L, Tang H, Wu M, Kong Y, Yang L, Gao J, Liu P, Wei W, Xie X. Synergistic effects of curcumin with emodin against the proliferation and invasion of breast cancer cells through upregulation of miR-34a. Mol Cell Biochem 2013;382:103-11. [PMID: 23771315 DOI: 10.1007/s11010-013-1723-6] [Cited by in Crossref: 62] [Cited by in F6Publishing: 57] [Article Influence: 7.8] [Reference Citation Analysis]
40 Imyanitov EN, Moiseyenko VM. Drug therapy for hereditary cancers. Hered Cancer Clin Pract 2011;9:5. [PMID: 21819606 DOI: 10.1186/1897-4287-9-5] [Cited by in Crossref: 30] [Cited by in F6Publishing: 24] [Article Influence: 3.0] [Reference Citation Analysis]
41 Zeichner SB, Terawaki H, Gogineni K. A Review of Systemic Treatment in Metastatic Triple-Negative Breast Cancer. Breast Cancer (Auckl) 2016;10:25-36. [PMID: 27042088 DOI: 10.4137/BCBCR.S32783] [Cited by in Crossref: 41] [Cited by in F6Publishing: 44] [Article Influence: 8.2] [Reference Citation Analysis]
42 Slade D. PARP and PARG inhibitors in cancer treatment. Genes Dev 2020;34:360-94. [PMID: 32029455 DOI: 10.1101/gad.334516.119] [Cited by in Crossref: 83] [Cited by in F6Publishing: 62] [Article Influence: 83.0] [Reference Citation Analysis]
43 Gatti M, Imhof R, Huang Q, Baudis M, Altmeyer M. The Ubiquitin Ligase TRIP12 Limits PARP1 Trapping and Constrains PARP Inhibitor Efficiency. Cell Rep 2020;32:107985. [PMID: 32755579 DOI: 10.1016/j.celrep.2020.107985] [Cited by in Crossref: 14] [Cited by in F6Publishing: 11] [Article Influence: 14.0] [Reference Citation Analysis]
44 Werner TL, Sachdev J, Swisher EM, Gutierrez M, Kittaneh M, Stein MN, Xiong H, Dunbar M, Sullivan D, Komarnitsky P, McKee M, Tan AR. Safety and pharmacokinetics of veliparib extended-release in patients with advanced solid tumors: a phase I study. Cancer Med 2018;7:2360-9. [PMID: 29733524 DOI: 10.1002/cam4.1488] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 2.7] [Reference Citation Analysis]
45 Makvandi M, Pantel A, Schwartz L, Schubert E, Xu K, Hsieh CJ, Hou C, Kim H, Weng CC, Winters H, Doot R, Farwell MD, Pryma DA, Greenberg RA, Mankoff DA, Simpkins F, Mach RH, Lin LL. A PET imaging agent for evaluating PARP-1 expression in ovarian cancer. J Clin Invest 2018;128:2116-26. [PMID: 29509546 DOI: 10.1172/JCI97992] [Cited by in Crossref: 52] [Cited by in F6Publishing: 25] [Article Influence: 17.3] [Reference Citation Analysis]
46 Green AR, Caracappa D, Benhasouna AA, Alshareeda A, Nolan CC, Macmillan RD, Madhusudan S, Ellis IO, Rakha EA. Biological and clinical significance of PARP1 protein expression in breast cancer. Breast Cancer Res Treat 2015;149:353-62. [PMID: 25528020 DOI: 10.1007/s10549-014-3230-1] [Cited by in Crossref: 40] [Cited by in F6Publishing: 32] [Article Influence: 5.7] [Reference Citation Analysis]
47 Gerhards NM, Rottenberg S. New tools for old drugs: Functional genetic screens to optimize current chemotherapy. Drug Resist Updat 2018;36:30-46. [PMID: 29499836 DOI: 10.1016/j.drup.2018.01.001] [Cited by in Crossref: 23] [Cited by in F6Publishing: 16] [Article Influence: 7.7] [Reference Citation Analysis]
48 Wysham WZ, Mhawech-Fauceglia P, Li H, Hays L, Syriac S, Skrepnik T, Wright J, Pande N, Hoatlin M, Pejovic T. BRCAness profile of sporadic ovarian cancer predicts disease recurrence. PLoS One 2012;7:e30042. [PMID: 22253870 DOI: 10.1371/journal.pone.0030042] [Cited by in Crossref: 45] [Cited by in F6Publishing: 39] [Article Influence: 5.0] [Reference Citation Analysis]
49 De P, Sun Y, Carlson JH, Friedman LS, Leyland-Jones BR, Dey N. Doubling down on the PI3K-AKT-mTOR pathway enhances the antitumor efficacy of PARP inhibitor in triple negative breast cancer model beyond BRCA-ness. Neoplasia 2014;16:43-72. [PMID: 24563619 DOI: 10.1593/neo.131694] [Cited by in Crossref: 67] [Cited by in F6Publishing: 62] [Article Influence: 9.6] [Reference Citation Analysis]
50 Bai H, Cao D, Yang J, Li M, Zhang Z, Shen K. Genetic and epigenetic heterogeneity of epithelial ovarian cancer and the clinical implications for molecular targeted therapy. J Cell Mol Med 2016;20:581-93. [PMID: 26800494 DOI: 10.1111/jcmm.12771] [Cited by in Crossref: 27] [Cited by in F6Publishing: 24] [Article Influence: 5.4] [Reference Citation Analysis]
51 Dean M, Boland J, Yeager M, Im KM, Garland L, Rodriguez-Herrera M, Perez M, Mitchell J, Roberson D, Jones K, Lee HJ, Eggebeen R, Sawitzke J, Bass S, Zhang X, Robles V, Hollis C, Barajas C, Rath E, Arentz C, Figueroa JA, Nguyen DD, Nahleh Z. Addressing health disparities in Hispanic breast cancer: accurate and inexpensive sequencing of BRCA1 and BRCA2. Gigascience 2015;4:50. [PMID: 26543556 DOI: 10.1186/s13742-015-0088-z] [Cited by in Crossref: 30] [Cited by in F6Publishing: 25] [Article Influence: 5.0] [Reference Citation Analysis]
52 Brewster AM, Chavez-MacGregor M, Brown P. Epidemiology, biology, and treatment of triple-negative breast cancer in women of African ancestry. Lancet Oncol 2014;15:e625-34. [PMID: 25456381 DOI: 10.1016/S1470-2045(14)70364-X] [Cited by in Crossref: 111] [Cited by in F6Publishing: 69] [Article Influence: 15.9] [Reference Citation Analysis]
53 Lobo M, López-Tarruella S, Luque S, Lizarraga S, Flores-Sánchez C, Bueno O, Solera J, Jerez Y, Del Val RG, Palomero MI, Cebollero M, Echavarría I, Torres G, Martín M, Márquez-Rodas I. Evaluation of Breast Cancer Patients with Genetic Risk in a University Hospital: Before and After the Implementation of a Heredofamilial Cancer Unit. J Genet Couns 2018;27:854-62. [PMID: 29247312 DOI: 10.1007/s10897-017-0187-3] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.8] [Reference Citation Analysis]
54 Heerma van Voss MR, Brilliant JD, Vesuna F, Bol GM, van der Wall E, van Diest PJ, Raman V. Combination treatment using DDX3 and PARP inhibitors induces synthetic lethality in BRCA1-proficient breast cancer. Med Oncol 2017;34:33. [PMID: 28138868 DOI: 10.1007/s12032-017-0889-2] [Cited by in Crossref: 14] [Cited by in F6Publishing: 7] [Article Influence: 3.5] [Reference Citation Analysis]
55 Rehman FL, Lord CJ, Ashworth A. Synthetic lethal approaches to breast cancer therapy. Nat Rev Clin Oncol 2010;7:718-24. [PMID: 20956981 DOI: 10.1038/nrclinonc.2010.172] [Cited by in Crossref: 64] [Cited by in F6Publishing: 61] [Article Influence: 5.8] [Reference Citation Analysis]
56 Jacot W, Lopez-Crapez E, Mollevi C, Boissière-Michot F, Simony-Lafontaine J, Ho-Pun-Cheung A, Chartron E, Theillet C, Lemoine A, Saffroy R, Lamy PJ, Guiu S. BRCA1 Promoter Hypermethylation is Associated with Good Prognosis and Chemosensitivity in Triple-Negative Breast Cancer. Cancers (Basel) 2020;12:E828. [PMID: 32235500 DOI: 10.3390/cancers12040828] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 7.0] [Reference Citation Analysis]
57 Yang C, Arnold AG, Catchings A, Rai V, Stadler ZK, Zhang L. The RAD51D c.82G>A (p.Val28Met) variant disrupts normal splicing and is associated with hereditary ovarian cancer. Breast Cancer Res Treat 2021;185:869-77. [PMID: 33452952 DOI: 10.1007/s10549-020-06066-7] [Reference Citation Analysis]
58 Tacconi EM, Badie S, De Gregoriis G, Reisländer T, Lai X, Porru M, Folio C, Moore J, Kopp A, Baguña Torres J, Sneddon D, Green M, Dedic S, Lee JW, Batra AS, Rueda OM, Bruna A, Leonetti C, Caldas C, Cornelissen B, Brino L, Ryan A, Biroccio A, Tarsounas M. Chlorambucil targets BRCA1/2-deficient tumours and counteracts PARP inhibitor resistance. EMBO Mol Med 2019;11:e9982. [PMID: 31273933 DOI: 10.15252/emmm.201809982] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 5.5] [Reference Citation Analysis]
59 Roberts NJ, Klein AP. Genome-wide sequencing to identify the cause of hereditary cancer syndromes: with examples from familial pancreatic cancer. Cancer Lett 2013;340:227-33. [PMID: 23196058 DOI: 10.1016/j.canlet.2012.11.008] [Cited by in Crossref: 16] [Cited by in F6Publishing: 13] [Article Influence: 1.8] [Reference Citation Analysis]
60 Geenen JJJ, Dackus GMHE, Schouten PC, Pluim D, Marchetti S, Sonke GS, Jóźwiak K, Huitema ADR, Beijnen JH, Schellens JHM, Linn SC. A Phase I dose-escalation study of two cycles carboplatin-olaparib followed by olaparib monotherapy in patients with advanced cancer. Int J Cancer 2021;148:3041-50. [PMID: 33539540 DOI: 10.1002/ijc.33498] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
61 Hodgson DR, Dougherty BA, Lai Z, Fielding A, Grinsted L, Spencer S, O'Connor MJ, Ho TW, Robertson JD, Lanchbury JS, Timms KM, Gutin A, Orr M, Jones H, Gilks B, Womack C, Gourley C, Ledermann J, Barrett JC. Candidate biomarkers of PARP inhibitor sensitivity in ovarian cancer beyond the BRCA genes.Br J Cancer. 2018;119:1401-1409. [PMID: 30353044 DOI: 10.1038/s41416-018-0274-8] [Cited by in Crossref: 67] [Cited by in F6Publishing: 60] [Article Influence: 22.3] [Reference Citation Analysis]
62 Zhou Z, Zhu L, Niu X, Shen S, Zhao Y, Zhang J, Ye J, Han-Zhang H, Liu J, Liu C, Lu S. Comparison of genomic landscapes of large cell neuroendocrine carcinoma, small cell lung carcinoma, and large cell carcinoma. Thorac Cancer 2019;10:839-47. [PMID: 30793508 DOI: 10.1111/1759-7714.13011] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 3.5] [Reference Citation Analysis]
63 Reaz S, Tamkus D, Andrechek ER. Using gene expression data to direct breast cancer therapy: evidence from a preclinical trial. J Mol Med (Berl) 2018;96:111-7. [PMID: 29313063 DOI: 10.1007/s00109-017-1620-7] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 1.7] [Reference Citation Analysis]
64 Li Z, Kang Y. Emerging therapeutic targets in metastatic progression: A focus on breast cancer. Pharmacol Ther 2016;161:79-96. [PMID: 27000769 DOI: 10.1016/j.pharmthera.2016.03.003] [Cited by in Crossref: 31] [Cited by in F6Publishing: 28] [Article Influence: 6.2] [Reference Citation Analysis]
65 Sachdev E, Tabatabai R, Roy V, Rimel BJ, Mita MM. PARP Inhibition in Cancer: An Update on Clinical Development. Target Oncol 2019;14:657-79. [PMID: 31625002 DOI: 10.1007/s11523-019-00680-2] [Cited by in Crossref: 37] [Cited by in F6Publishing: 32] [Article Influence: 37.0] [Reference Citation Analysis]
66 Maric G, Rose AA, Annis MG, Siegel PM. Glycoprotein non-metastatic b (GPNMB): A metastatic mediator and emerging therapeutic target in cancer. Onco Targets Ther 2013;6:839-52. [PMID: 23874106 DOI: 10.2147/OTT.S44906] [Cited by in Crossref: 16] [Cited by in F6Publishing: 50] [Article Influence: 2.0] [Reference Citation Analysis]
67 Forster MD, Dedes KJ, Sandhu S, Frentzas S, Kristeleit R, Ashworth A, Poole CJ, Weigelt B, Kaye SB, Molife LR. Treatment with olaparib in a patient with PTEN-deficient endometrioid endometrial cancer. Nat Rev Clin Oncol 2011;8:302-6. [PMID: 21468130 DOI: 10.1038/nrclinonc.2011.42] [Cited by in Crossref: 81] [Cited by in F6Publishing: 79] [Article Influence: 8.1] [Reference Citation Analysis]
68 Su JM, Thompson P, Adesina A, Li XN, Kilburn L, Onar-Thomas A, Kocak M, Chyla B, McKeegan E, Warren KE, Goldman S, Pollack IF, Fouladi M, Chen A, Giranda V, Boyett J, Kun L, Blaney SM. A phase I trial of veliparib (ABT-888) and temozolomide in children with recurrent CNS tumors: a pediatric brain tumor consortium report. Neuro Oncol 2014;16:1661-8. [PMID: 24908656 DOI: 10.1093/neuonc/nou103] [Cited by in Crossref: 42] [Cited by in F6Publishing: 35] [Article Influence: 6.0] [Reference Citation Analysis]
69 Pan Y, Yang H, Claret FX. Emerging roles of Jab1/CSN5 in DNA damage response, DNA repair, and cancer. Cancer Biol Ther 2014;15:256-62. [PMID: 24495954 DOI: 10.4161/cbt.27823] [Cited by in Crossref: 36] [Cited by in F6Publishing: 35] [Article Influence: 5.1] [Reference Citation Analysis]
70 AlDubayan SH, Giannakis M, Moore ND, Han GC, Reardon B, Hamada T, Mu XJ, Nishihara R, Qian Z, Liu L, Yurgelun MB, Syngal S, Garraway LA, Ogino S, Fuchs CS, Van Allen EM. Inherited DNA-Repair Defects in Colorectal Cancer. Am J Hum Genet 2018;102:401-14. [PMID: 29478780 DOI: 10.1016/j.ajhg.2018.01.018] [Cited by in Crossref: 43] [Cited by in F6Publishing: 43] [Article Influence: 14.3] [Reference Citation Analysis]
71 Flaum N, Crosbie EJ, Edmondson RJ, Smith MJ, Evans DG. Epithelial ovarian cancer risk: A review of the current genetic landscape. Clin Genet 2020;97:54-63. [PMID: 31099061 DOI: 10.1111/cge.13566] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 3.5] [Reference Citation Analysis]
72 Kelloff GJ, Sigman CC. Cancer biomarkers: selecting the right drug for the right patient. Nat Rev Drug Discov 2012;11:201-14. [PMID: 22322254 DOI: 10.1038/nrd3651] [Cited by in Crossref: 186] [Cited by in F6Publishing: 140] [Article Influence: 20.7] [Reference Citation Analysis]
73 Pishvaian MJ, Biankin AV, Bailey P, Chang DK, Laheru D, Wolfgang CL, Brody JR. BRCA2 secondary mutation-mediated resistance to platinum and PARP inhibitor-based therapy in pancreatic cancer. Br J Cancer 2017;116:1021-6. [PMID: 28291774 DOI: 10.1038/bjc.2017.40] [Cited by in Crossref: 35] [Cited by in F6Publishing: 29] [Article Influence: 8.8] [Reference Citation Analysis]
74 Yang SH, Kuo TC, Wu H, Guo JC, Hsu C, Hsu CH, Tien YW, Yeh KH, Cheng AL, Kuo SH. Perspectives on the combination of radiotherapy and targeted therapy with DNA repair inhibitors in the treatment of pancreatic cancer. World J Gastroenterol 2016;22:7275-88. [PMID: 27621574 DOI: 10.3748/wjg.v22.i32.7275] [Cited by in CrossRef: 18] [Cited by in F6Publishing: 16] [Article Influence: 4.5] [Reference Citation Analysis]
75 Stopeck AT, Brown-Glaberman U, Wong HY, Park BH, Barnato SE, Gradishar WJ, Hudis CA, Rugo HS. The role of targeted therapy and biomarkers in breast cancer treatment. Clin Exp Metastasis 2012;29:807-19. [PMID: 22692561 DOI: 10.1007/s10585-012-9496-y] [Cited by in Crossref: 26] [Cited by in F6Publishing: 23] [Article Influence: 2.9] [Reference Citation Analysis]
76 Jiang Q, Greenberg RA. Deciphering the BRCA1 Tumor Suppressor Network. J Biol Chem 2015;290:17724-32. [PMID: 26048987 DOI: 10.1074/jbc.R115.667931] [Cited by in Crossref: 54] [Cited by in F6Publishing: 40] [Article Influence: 9.0] [Reference Citation Analysis]
77 Carey L, Winer E, Viale G, Cameron D, Gianni L. Triple-negative breast cancer: disease entity or title of convenience? Nat Rev Clin Oncol. 2010;7:683-692. [PMID: 20877296 DOI: 10.1038/nrclinonc.2010.154] [Cited by in Crossref: 495] [Cited by in F6Publishing: 463] [Article Influence: 45.0] [Reference Citation Analysis]
78 Burgess JT, Rose M, Boucher D, Plowman J, Molloy C, Fisher M, O'Leary C, Richard DJ, O'Byrne KJ, Bolderson E. The Therapeutic Potential of DNA Damage Repair Pathways and Genomic Stability in Lung Cancer. Front Oncol 2020;10:1256. [PMID: 32850380 DOI: 10.3389/fonc.2020.01256] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 8.0] [Reference Citation Analysis]
79 Davies H, Glodzik D, Morganella S, Yates LR, Staaf J, Zou X, Ramakrishna M, Martin S, Boyault S, Sieuwerts AM, Simpson PT, King TA, Raine K, Eyfjord JE, Kong G, Borg Å, Birney E, Stunnenberg HG, van de Vijver MJ, Børresen-Dale AL, Martens JW, Span PN, Lakhani SR, Vincent-Salomon A, Sotiriou C, Tutt A, Thompson AM, Van Laere S, Richardson AL, Viari A, Campbell PJ, Stratton MR, Nik-Zainal S. HRDetect is a predictor of BRCA1 and BRCA2 deficiency based on mutational signatures. Nat Med 2017;23:517-25. [PMID: 28288110 DOI: 10.1038/nm.4292] [Cited by in Crossref: 365] [Cited by in F6Publishing: 268] [Article Influence: 91.3] [Reference Citation Analysis]
80 Yamashita Y, Nishiumi S, Kono S, Takao S, Azuma T, Yoshida M. Differences in elongation of very long chain fatty acids and fatty acid metabolism between triple-negative and hormone receptor-positive breast cancer. BMC Cancer 2017;17:589. [PMID: 28851309 DOI: 10.1186/s12885-017-3554-4] [Cited by in Crossref: 30] [Cited by in F6Publishing: 19] [Article Influence: 7.5] [Reference Citation Analysis]
81 Senra JM, Telfer BA, Cherry KE, McCrudden CM, Hirst DG, O’Connor MJ, Wedge SR, Stratford IJ. Inhibition of PARP-1 by olaparib (AZD2281) increases the radiosensitivity of a lung tumor xenograft. Mol Cancer Ther. 2011;10:1949-1958. [PMID: 21825006 DOI: 10.1158/1535-7163.mct-11-0278] [Cited by in Crossref: 120] [Cited by in F6Publishing: 64] [Article Influence: 12.0] [Reference Citation Analysis]
82 Pilla Reddy V, Bui K, Scarfe G, Zhou D, Learoyd M. Physiologically Based Pharmacokinetic Modeling for Olaparib Dosing Recommendations: Bridging Formulations, Drug Interactions, and Patient Populations. Clin Pharmacol Ther 2019;105:229-41. [PMID: 29717476 DOI: 10.1002/cpt.1103] [Cited by in Crossref: 22] [Cited by in F6Publishing: 10] [Article Influence: 7.3] [Reference Citation Analysis]
83 Oualla K, El-Zawahry HM, Arun B, Reuben JM, Woodward WA, Gamal El-Din H, Lim B, Mellas N, Ueno NT, Fouad TM. Novel therapeutic strategies in the treatment of triple-negative breast cancer. Ther Adv Med Oncol 2017;9:493-511. [PMID: 28717401 DOI: 10.1177/1758834017711380] [Cited by in Crossref: 37] [Cited by in F6Publishing: 33] [Article Influence: 9.3] [Reference Citation Analysis]
84 Eccleston A, Bentley A, Dyer M, Strydom A, Vereecken W, George A, Rahman N. A Cost-Effectiveness Evaluation of Germline BRCA1 and BRCA2 Testing in UK Women with Ovarian Cancer. Value Health 2017;20:567-76. [PMID: 28407998 DOI: 10.1016/j.jval.2017.01.004] [Cited by in Crossref: 37] [Cited by in F6Publishing: 19] [Article Influence: 9.3] [Reference Citation Analysis]
85 Fisher CS, Ma CX, Gillanders WE, Aft RL, Eberlein TJ, Gao F, Margenthaler JA. Neoadjuvant chemotherapy is associated with improved survival compared with adjuvant chemotherapy in patients with triple-negative breast cancer only after complete pathologic response. Ann Surg Oncol 2012;19:253-8. [PMID: 21725686 DOI: 10.1245/s10434-011-1877-y] [Cited by in Crossref: 35] [Cited by in F6Publishing: 32] [Article Influence: 3.5] [Reference Citation Analysis]
86 Del Conte G, Sessa C, von Moos R, Viganò L, Digena T, Locatelli A, Gallerani E, Fasolo A, Tessari A, Cathomas R, Gianni L. Phase I study of olaparib in combination with liposomal doxorubicin in patients with advanced solid tumours. Br J Cancer 2014;111:651-9. [PMID: 25025963 DOI: 10.1038/bjc.2014.345] [Cited by in Crossref: 66] [Cited by in F6Publishing: 64] [Article Influence: 9.4] [Reference Citation Analysis]
87 Gilabert M, Launay S, Ginestier C, Bertucci F, Audebert S, Pophillat M, Toiron Y, Baudelet E, Finetti P, Noguchi T, Sobol H, Birnbaum D, Borg JP, Charafe-Jauffret E, Gonçalves A. Poly(ADP-ribose) polymerase 1 (PARP1) overexpression in human breast cancer stem cells and resistance to olaparib. PLoS One 2014;9:e104302. [PMID: 25144364 DOI: 10.1371/journal.pone.0104302] [Cited by in Crossref: 27] [Cited by in F6Publishing: 23] [Article Influence: 3.9] [Reference Citation Analysis]
88 Tosti E, Katakowski JA, Schaetzlein S, Kim HS, Ryan CJ, Shales M, Roguev A, Krogan NJ, Palliser D, Keogh MC, Edelmann W. Evolutionarily conserved genetic interactions with budding and fission yeast MutS identify orthologous relationships in mismatch repair-deficient cancer cells. Genome Med 2014;6:68. [PMID: 25302077 DOI: 10.1186/s13073-014-0068-4] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 1.4] [Reference Citation Analysis]
89 Pal T, Vadaparampil ST. Genetic risk assessments in individuals at high risk for inherited breast cancer in the breast oncology care setting. Cancer Control 2012;19:255-66. [PMID: 23037493 DOI: 10.1177/107327481201900402] [Cited by in Crossref: 23] [Cited by in F6Publishing: 18] [Article Influence: 2.9] [Reference Citation Analysis]
90 Crespan E, Garbelli A, Amoroso A, Maga G. Exploiting the nucleotide substrate specificity of repair DNA polymerases to develop novel anticancer agents. Molecules 2011;16:7994-8019. [PMID: 21926946 DOI: 10.3390/molecules16097994] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 1.1] [Reference Citation Analysis]
91 Koppensteiner R, Samartzis EP, Noske A, von Teichman A, Dedes I, Gwerder M, Imesch P, Ikenberg K, Moch H, Fink D, Stucki M, Dedes KJ. Effect of MRE11 loss on PARP-inhibitor sensitivity in endometrial cancer in vitro. PLoS One 2014;9:e100041. [PMID: 24927325 DOI: 10.1371/journal.pone.0100041] [Cited by in Crossref: 43] [Cited by in F6Publishing: 41] [Article Influence: 6.1] [Reference Citation Analysis]
92 Brown JS, O'Carrigan B, Jackson SP, Yap TA. Targeting DNA Repair in Cancer: Beyond PARP Inhibitors. Cancer Discov 2017;7:20-37. [PMID: 28003236 DOI: 10.1158/2159-8290.CD-16-0860] [Cited by in Crossref: 255] [Cited by in F6Publishing: 135] [Article Influence: 51.0] [Reference Citation Analysis]
93 Chiu JW, Wong H, Leung R, Pang R, Cheung TT, Fan ST, Poon R, Yau T. Advanced pancreatic cancer: flourishing novel approaches in the era of biological therapy. Oncologist 2014;19:937-50. [PMID: 25117068 DOI: 10.1634/theoncologist.2012-0131] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.9] [Reference Citation Analysis]
94 Bertucci F, Finetti P, Birnbaum D. Basal breast cancer: a complex and deadly molecular subtype. Curr Mol Med. 2012;12:96-110. [PMID: 22082486 DOI: 10.2174/156652412798376134] [Cited by in Crossref: 120] [Cited by in F6Publishing: 97] [Article Influence: 13.3] [Reference Citation Analysis]
95 Sie AS, Spruijt L, van Zelst-Stams WA, Mensenkamp AR, Ligtenberg MJ, Brunner HG, Prins JB, Hoogerbrugge N. DNA-testing for BRCA1/2 prior to genetic counselling in patients with breast cancer: design of an intervention study, DNA-direct. BMC Womens Health 2012;12:12. [PMID: 22569005 DOI: 10.1186/1472-6874-12-12] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 1.0] [Reference Citation Analysis]
96 Fang B. Development of synthetic lethality anticancer therapeutics. J Med Chem 2014;57:7859-73. [PMID: 24893124 DOI: 10.1021/jm500415t] [Cited by in Crossref: 41] [Cited by in F6Publishing: 32] [Article Influence: 5.9] [Reference Citation Analysis]
97 Rebbeck TR, Friebel TM, Mitra N, Wan F, Chen S, Andrulis IL, Apostolou P, Arnold N, Arun BK, Barrowdale D, Benitez J, Berger R, Berthet P, Borg A, Buys SS, Caldes T, Carter J, Chiquette J, Claes KB, Couch FJ, Cybulski C, Daly MB, de la Hoya M, Diez O, Domchek SM, Nathanson KL, Durda K, Ellis S, Evans DG, Foretova L, Friedman E, Frost D, Ganz PA, Garber J, Glendon G, Godwin AK, Greene MH, Gronwald J, Hahnen E, Hallberg E, Hamann U, Hansen TV, Imyanitov EN, Isaacs C, Jakubowska A, Janavicius R, Jaworska-Bieniek K, John EM, Karlan BY, Kaufman B, Investigators K, Kwong A, Laitman Y, Lasset C, Lazaro C, Lester J, Loman N, Lubinski J, Manoukian S, Mitchell G, Montagna M, Neuhausen SL, Nevanlinna H, Niederacher D, Nussbaum RL, Offit K, Olah E, Olopade OI, Park SK, Piedmonte M, Radice P, Rappaport-Fuerhauser C, Rookus MA, Seynaeve C, Simard J, Singer CF, Soucy P, Southey M, Stoppa-Lyonnet D, Sukiennicki G, Szabo CI, Tancredi M, Teixeira MR, Teo SH, Terry MB, Thomassen M, Tihomirova L, Tischkowitz M, Toland AE, Toloczko-Grabarek A, Tung N, van Rensburg EJ, Villano D, Wang-Gohrke S, Wappenschmidt B, Weitzel JN, Zidan J, Zorn KK, McGuffog L, Easton D, Chenevix-Trench G, Antoniou AC, Ramus SJ; EMBRACE., HEBON. Inheritance of deleterious mutations at both BRCA1 and BRCA2 in an international sample of 32,295 women. Breast Cancer Res 2016;18:112. [PMID: 27836010 DOI: 10.1186/s13058-016-0768-3] [Cited by in Crossref: 23] [Cited by in F6Publishing: 20] [Article Influence: 4.6] [Reference Citation Analysis]
98 Davis SL, Eckhardt SG, Tentler JJ, Diamond JR. Triple-negative breast cancer: bridging the gap from cancer genomics to predictive biomarkers. Ther Adv Med Oncol 2014;6:88-100. [PMID: 24790649 DOI: 10.1177/1758834013519843] [Cited by in Crossref: 25] [Cited by in F6Publishing: 23] [Article Influence: 3.6] [Reference Citation Analysis]
99 Bundred N, Gardovskis J, Jaskiewicz J, Eglitis J, Paramonov V, McCormack P, Swaisland H, Cavallin M, Parry T, Carmichael J, Dixon JM. Evaluation of the pharmacodynamics and pharmacokinetics of the PARP inhibitor olaparib: a phase I multicentre trial in patients scheduled for elective breast cancer surgery. Invest New Drugs 2013;31:949-58. [PMID: 23315029 DOI: 10.1007/s10637-012-9922-7] [Cited by in Crossref: 59] [Cited by in F6Publishing: 52] [Article Influence: 7.4] [Reference Citation Analysis]
100 van der Biessen DAJ, Gietema JA, de Jonge MJA, Desar IME, den Hollander MW, Dudley M, Dunbar M, Hetman R, Serpenti C, Xiong H, Mittapalli RK, Timms KM, Ansell P, Ratajczak CK, Shepherd SP, van Herpen CML. A phase 1 study of PARP-inhibitor ABT-767 in advanced solid tumors with BRCA1/2 mutations and high-grade serous ovarian, fallopian tube, or primary peritoneal cancer. Invest New Drugs 2018;36:828-35. [PMID: 29313279 DOI: 10.1007/s10637-017-0551-z] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
101 Wen J, Hadden MK. Medulloblastoma drugs in development: Current leads, trials and drawbacks. Eur J Med Chem 2021;215:113268. [PMID: 33636537 DOI: 10.1016/j.ejmech.2021.113268] [Reference Citation Analysis]
102 Barnabas N, Cohen D. Phenotypic and Molecular Characterization of MCF10DCIS and SUM Breast Cancer Cell Lines. Int J Breast Cancer 2013;2013:872743. [PMID: 23401782 DOI: 10.1155/2013/872743] [Cited by in Crossref: 38] [Cited by in F6Publishing: 41] [Article Influence: 4.8] [Reference Citation Analysis]
103 Johnson N, Li YC, Walton ZE, Cheng KA, Li D, Rodig SJ, Moreau LA, Unitt C, Bronson RT, Thomas HD, Newell DR, D'Andrea AD, Curtin NJ, Wong KK, Shapiro GI. Compromised CDK1 activity sensitizes BRCA-proficient cancers to PARP inhibition. Nat Med 2011;17:875-82. [PMID: 21706030 DOI: 10.1038/nm.2377] [Cited by in Crossref: 180] [Cited by in F6Publishing: 159] [Article Influence: 18.0] [Reference Citation Analysis]
104 Watts KJ, Meiser B, Mitchell G, Kirk J, Saunders C, Peate M, Duffy J, Kelly PJ, Gleeson M, Barlow-Stewart K, Rahman B, Friedlander M, Tucker K; TFGT Collaborative Group. How should we discuss genetic testing with women newly diagnosed with breast cancer? Design and implementation of a randomized controlled trial of two models of delivering education about treatment-focused genetic testing to younger women newly diagnosed with breast cancer. BMC Cancer 2012;12:320. [PMID: 22838957 DOI: 10.1186/1471-2407-12-320] [Cited by in Crossref: 18] [Cited by in F6Publishing: 18] [Article Influence: 2.0] [Reference Citation Analysis]
105 Clark CC, Weitzel JN, O'Connor TR. Enhancement of synthetic lethality via combinations of ABT-888, a PARP inhibitor, and carboplatin in vitro and in vivo using BRCA1 and BRCA2 isogenic models. Mol Cancer Ther 2012;11:1948-58. [PMID: 22778154 DOI: 10.1158/1535-7163.MCT-11-0597] [Cited by in Crossref: 53] [Cited by in F6Publishing: 21] [Article Influence: 5.9] [Reference Citation Analysis]
106 Cho D, Park H, Park SH, Kim K, Chung M, Moon W, Kang M, Jang K. The expression of DBC1/CCAR2 is associated with poor prognosis of ovarian carcinoma. J Ovarian Res 2015;8:2. [PMID: 25823848 DOI: 10.1186/s13048-015-0129-3] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 2.0] [Reference Citation Analysis]
107 Larsen MJ, Kruse TA, Tan Q, Lænkholm AV, Bak M, Lykkesfeldt AE, Sørensen KP, Hansen TV, Ejlertsen B, Gerdes AM, Thomassen M. Classifications within molecular subtypes enables identification of BRCA1/BRCA2 mutation carriers by RNA tumor profiling. PLoS One 2013;8:e64268. [PMID: 23704984 DOI: 10.1371/journal.pone.0064268] [Cited by in Crossref: 58] [Cited by in F6Publishing: 54] [Article Influence: 7.3] [Reference Citation Analysis]
108 Maksimenko J, Irmejs A, Nakazawa-Miklasevica M, Melbarde-Gorkusa I, Trofimovics G, Gardovskis J, Miklasevics E. Prognostic role of BRCA1 mutation in patients with triple-negative breast cancer. Oncol Lett 2014;7:278-84. [PMID: 24348864 DOI: 10.3892/ol.2013.1684] [Cited by in Crossref: 17] [Cited by in F6Publishing: 15] [Article Influence: 2.1] [Reference Citation Analysis]
109 Omarini C, Guaitoli G, Pipitone S, Moscetti L, Cortesi L, Cascinu S, Piacentini F. Neoadjuvant treatments in triple-negative breast cancer patients: where we are now and where we are going. Cancer Manag Res 2018;10:91-103. [PMID: 29391830 DOI: 10.2147/CMAR.S146658] [Cited by in Crossref: 36] [Cited by in F6Publishing: 24] [Article Influence: 12.0] [Reference Citation Analysis]
110 Weitzel JN, Blazer KR, MacDonald DJ, Culver JO, Offit K. Genetics, genomics, and cancer risk assessment: State of the Art and Future Directions in the Era of Personalized Medicine. CA Cancer J Clin 2011;61:327-59. [PMID: 21858794 DOI: 10.3322/caac.20128] [Cited by in Crossref: 40] [Cited by in F6Publishing: 86] [Article Influence: 4.0] [Reference Citation Analysis]
111 Higgins MJ, Baselga J. Targeted therapies for breast cancer. J Clin Invest. 2011;121:3797-3803. [PMID: 21965336 DOI: 10.1172/jci57152] [Cited by in Crossref: 232] [Cited by in F6Publishing: 126] [Article Influence: 23.2] [Reference Citation Analysis]
112 Lyons TG. Targeted Therapies for Triple-Negative Breast Cancer. Curr Treat Options Oncol 2019;20:82. [PMID: 31754897 DOI: 10.1007/s11864-019-0682-x] [Cited by in Crossref: 51] [Cited by in F6Publishing: 36] [Article Influence: 25.5] [Reference Citation Analysis]
113 Mayer IA, Abramson VG, Lehmann BD, Pietenpol JA. New strategies for triple-negative breast cancer--deciphering the heterogeneity. Clin Cancer Res. 2014;20:782-790. [PMID: 24536073 DOI: 10.1158/1078-0432.ccr-13-0583] [Cited by in Crossref: 186] [Cited by in F6Publishing: 116] [Article Influence: 26.6] [Reference Citation Analysis]
114 To C, Kim EH, Royce DB, Williams CR, Collins RM, Risingsong R, Sporn MB, Liby KT. The PARP inhibitors, veliparib and olaparib, are effective chemopreventive agents for delaying mammary tumor development in BRCA1-deficient mice. Cancer Prev Res (Phila) 2014;7:698-707. [PMID: 24817481 DOI: 10.1158/1940-6207.CAPR-14-0047] [Cited by in Crossref: 46] [Cited by in F6Publishing: 23] [Article Influence: 6.6] [Reference Citation Analysis]
115 Riley BD, Culver JO, Skrzynia C, Senter LA, Peters JA, Costalas JW, Callif-Daley F, Grumet SC, Hunt KS, Nagy RS, McKinnon WC, Petrucelli NM, Bennett RL, Trepanier AM. Essential elements of genetic cancer risk assessment, counseling, and testing: updated recommendations of the National Society of Genetic Counselors. J Genet Couns 2012;21:151-61. [PMID: 22134580 DOI: 10.1007/s10897-011-9462-x] [Cited by in Crossref: 211] [Cited by in F6Publishing: 142] [Article Influence: 21.1] [Reference Citation Analysis]
116 Glénisson M, Vacher S, Callens C, Susini A, Cizeron-Clairac G, Le Scodan R, Meseure D, Lerebours F, Spyratos F, Lidereau R, Bièche I. Identification of new candidate therapeutic target genes in triple-negative breast cancer. Genes Cancer 2012;3:63-70. [PMID: 22893791 DOI: 10.1177/1947601912449832] [Cited by in Crossref: 20] [Cited by in F6Publishing: 17] [Article Influence: 2.2] [Reference Citation Analysis]
117 Luo ML, Zheng F, Chen W, Liang ZM, Chandramouly G, Tan J, Willis NA, Chen CH, Taveira MO, Zhou XZ, Lu KP, Scully R, Wulf GM, Hu H. Inactivation of the Prolyl Isomerase Pin1 Sensitizes BRCA1-Proficient Breast Cancer to PARP Inhibition. Cancer Res 2020;80:3033-45. [PMID: 32193285 DOI: 10.1158/0008-5472.CAN-19-2739] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 6.0] [Reference Citation Analysis]
118 Garmpis N, Damaskos C, Garmpi A, Nikolettos K, Dimitroulis D, Diamantis E, Farmaki P, Patsouras A, Voutyritsa E, Syllaios A, Zografos CG, Antoniou EA, Nikolettos N, Kostakis A, Kontzoglou K, Schizas D, Nonni A. Molecular Classification and Future Therapeutic Challenges of Triple-negative Breast Cancer. In Vivo 2020;34:1715-27. [PMID: 32606140 DOI: 10.21873/invivo.11965] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 6.0] [Reference Citation Analysis]
119 Teo ZL, Park DJ, Provenzano E, Chatfield CA, Odefrey FA, Nguyen-Dumont T, Dowty JG, Hopper JL, Winship I, Goldgar DE, Southey MC; kConFab. Prevalence of PALB2 mutations in Australasian multiple-case breast cancer families. Breast Cancer Res 2013;15:R17. [PMID: 23448497 DOI: 10.1186/bcr3392] [Cited by in Crossref: 35] [Cited by in F6Publishing: 29] [Article Influence: 4.4] [Reference Citation Analysis]
120 Duan W, Gao L, Zhao W, Leon M, Sadee W, Webb A, Resnick K, Wu X, Ramaswamy B, Cohn DE, Shapiro C, Andreassen PR, Otterson GA, Villalona-Calero MA. Assessment of FANCD2 nuclear foci formation in paraffin-embedded tumors: a potential patient-enrichment strategy for treatment with DNA interstrand crosslinking agents. Transl Res 2013;161:156-64. [PMID: 23063585 DOI: 10.1016/j.trsl.2012.09.003] [Cited by in Crossref: 16] [Cited by in F6Publishing: 10] [Article Influence: 1.8] [Reference Citation Analysis]
121 Lord CJ, Ashworth A. BRCAness revisited. Nat Rev Cancer 2016;16:110-20. [PMID: 26775620 DOI: 10.1038/nrc.2015.21] [Cited by in Crossref: 576] [Cited by in F6Publishing: 479] [Article Influence: 115.2] [Reference Citation Analysis]
122 Brosnan EM, Anders CK. Understanding patterns of brain metastasis in breast cancer and designing rational therapeutic strategies. Ann Transl Med 2018;6:163. [PMID: 29911111 DOI: 10.21037/atm.2018.04.35] [Cited by in Crossref: 23] [Cited by in F6Publishing: 20] [Article Influence: 7.7] [Reference Citation Analysis]
123 Lok BH, Powell SN. Molecular pathways: understanding the role of Rad52 in homologous recombination for therapeutic advancement. Clin Cancer Res. 2012;18:6400-6406. [PMID: 23071261 DOI: 10.1158/1078-0432.CCR-11-3150] [Cited by in Crossref: 72] [Cited by in F6Publishing: 52] [Article Influence: 8.0] [Reference Citation Analysis]
124 Kan Z, Zheng H, Liu X, Li S, Barber TD, Gong Z, Gao H, Hao K, Willard MD, Xu J. Whole-genome sequencing identifies recurrent mutations in hepatocellular carcinoma. Genome Res. 2013;23:1422-1433. [PMID: 23788652 DOI: 10.1101/gr.154492.113] [Cited by in Crossref: 314] [Cited by in F6Publishing: 283] [Article Influence: 39.3] [Reference Citation Analysis]
125 Mirman Z, de Lange T. 53BP1: a DSB escort. Genes Dev. 2020;34:7-23. [PMID: 31896689 DOI: 10.1101/gad.333237.119] [Cited by in Crossref: 56] [Cited by in F6Publishing: 40] [Article Influence: 56.0] [Reference Citation Analysis]
126 Watkins JA, Irshad S, Grigoriadis A, Tutt AN. Genomic scars as biomarkers of homologous recombination deficiency and drug response in breast and ovarian cancers. Breast Cancer Res 2014;16:211. [PMID: 25093514 DOI: 10.1186/bcr3670] [Cited by in Crossref: 151] [Cited by in F6Publishing: 121] [Article Influence: 21.6] [Reference Citation Analysis]
127 Kawazu M, Kojima S, Ueno T, Totoki Y, Nakamura H, Kunita A, Qu W, Yoshimura J, Soda M, Yasuda T, Hama N, Saito-Adachi M, Sato K, Kohsaka S, Sai E, Ikemura M, Yamamoto S, Ogawa T, Fukayama M, Tada K, Seto Y, Morishita S, Hazama S, Shibata T, Yamashita Y, Mano H. Integrative analysis of genomic alterations in triple-negative breast cancer in association with homologous recombination deficiency. PLoS Genet 2017;13:e1006853. [PMID: 28636652 DOI: 10.1371/journal.pgen.1006853] [Cited by in Crossref: 28] [Cited by in F6Publishing: 23] [Article Influence: 7.0] [Reference Citation Analysis]
128 Hutchinson L. Targeted therapies: PARP inhibitor olaparib is safe and effective in patients with BRCA1 and BRCA2 mutations. Nat Rev Clin Oncol 2010;7:549. [PMID: 20922827 DOI: 10.1038/nrclinonc.2010.143] [Cited by in Crossref: 17] [Cited by in F6Publishing: 16] [Article Influence: 1.5] [Reference Citation Analysis]
129 Stanley J, Klepczyk L, Keene K, Wei S, Li Y, Forero A, Grizzle W, Wielgos M, Brazelton J, LoBuglio AF, Yang ES. PARP1 and phospho-p65 protein expression is increased in human HER2-positive breast cancers. Breast Cancer Res Treat 2015;150:569-79. [PMID: 25833211 DOI: 10.1007/s10549-015-3359-6] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 2.2] [Reference Citation Analysis]
130 Murata S, Zhang C, Finch N, Zhang K, Campo L, Breuer EK. Predictors and Modulators of Synthetic Lethality: An Update on PARP Inhibitors and Personalized Medicine. Biomed Res Int 2016;2016:2346585. [PMID: 27642590 DOI: 10.1155/2016/2346585] [Cited by in Crossref: 24] [Cited by in F6Publishing: 20] [Article Influence: 4.8] [Reference Citation Analysis]
131 Bian C, Zhang C, Luo T, Vyas A, Chen SH, Liu C, Kassab MA, Yang Y, Kong M, Yu X. NADP+ is an endogenous PARP inhibitor in DNA damage response and tumor suppression. Nat Commun 2019;10:693. [PMID: 30741937 DOI: 10.1038/s41467-019-08530-5] [Cited by in Crossref: 18] [Cited by in F6Publishing: 17] [Article Influence: 9.0] [Reference Citation Analysis]
132 Song Z, Wang Y, Xiao Q, Yu Z, Zhao L, Wu H, Sun M, Chai Z, Hou P, Geng X, Liu W, Wei M. Poly(ADP-ribose) polymerase-3 overexpression is associated with poor prognosis in patients with breast cancer following chemotherapy. Oncol Lett 2018;16:5621-30. [PMID: 30344717 DOI: 10.3892/ol.2018.9398] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
133 Baloch T, López-Ozuna VM, Wang Q, Matanis E, Kessous R, Kogan L, Yasmeen A, Gotlieb WH. Sequential therapeutic targeting of ovarian Cancer harboring dysfunctional BRCA1. BMC Cancer 2019;19:44. [PMID: 30630446 DOI: 10.1186/s12885-018-5250-4] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 4.0] [Reference Citation Analysis]
134 Castro E, Eeles R. The role of BRCA1 and BRCA2 in prostate cancer. Asian J Androl. 2012;14:409-414. [PMID: 22522501 DOI: 10.1038/aja.2011.150] [Cited by in Crossref: 63] [Cited by in F6Publishing: 53] [Article Influence: 7.0] [Reference Citation Analysis]
135 Mancini P, Angeloni A, Risi E, Orsi E, Mezi S. Standard of care and promising new agents for triple negative metastatic breast cancer. Cancers (Basel) 2014;6:2187-223. [PMID: 25347122 DOI: 10.3390/cancers6042187] [Cited by in Crossref: 31] [Cited by in F6Publishing: 26] [Article Influence: 4.4] [Reference Citation Analysis]
136 Tsimberidou AM. Targeted therapy in cancer. Cancer Chemother Pharmacol 2015;76:1113-32. [PMID: 26391154 DOI: 10.1007/s00280-015-2861-1] [Cited by in Crossref: 63] [Cited by in F6Publishing: 52] [Article Influence: 10.5] [Reference Citation Analysis]
137 Staninova-Stojovska M, Matevska-Geskovska N, Panovski M, Angelovska B, Mitrevski N, Ristevski M, Jovanovic R, Dimovski AJ. Molecular Basis of Inherited Colorectal Carcinomas in the Macedonian Population: An Update. Balkan J Med Genet 2019;22:5-16. [PMID: 31942411 DOI: 10.2478/bjmg-2019-0027] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
138 Chuang HC, Kapuriya N, Kulp SK, Chen CS, Shapiro CL. Differential anti-proliferative activities of poly(ADP-ribose) polymerase (PARP) inhibitors in triple-negative breast cancer cells. Breast Cancer Res Treat 2012;134:649-59. [PMID: 22678161 DOI: 10.1007/s10549-012-2106-5] [Cited by in Crossref: 71] [Cited by in F6Publishing: 59] [Article Influence: 7.9] [Reference Citation Analysis]
139 Turdo F, Bianchi F, Gasparini P, Sandri M, Sasso M, De Cecco L, Forte L, Casalini P, Aiello P, Sfondrini L, Agresti R, Carcangiu ML, Plantamura I, Sozzi G, Tagliabue E, Campiglio M. CDCP1 is a novel marker of the most aggressive human triple-negative breast cancers. Oncotarget. 2016;7:69649-69665. [PMID: 27626701 DOI: 10.18632/oncotarget.11935] [Cited by in Crossref: 18] [Cited by in F6Publishing: 17] [Article Influence: 6.0] [Reference Citation Analysis]
140 Yadav BS, Sharma SC, Chanana P, Jhamb S. Systemic treatment strategies for triple-negative breast cancer. World J Clin Oncol 2014;5:125-33. [PMID: 24829859 DOI: 10.5306/wjco.v5.i2.125] [Cited by in CrossRef: 72] [Cited by in F6Publishing: 65] [Article Influence: 10.3] [Reference Citation Analysis]
141 Park SR, Chen A. Poly(Adenosine diphosphate-ribose) polymerase inhibitors in cancer treatment. Hematol Oncol Clin North Am 2012;26:649-70, ix. [PMID: 22520984 DOI: 10.1016/j.hoc.2012.02.012] [Cited by in Crossref: 17] [Cited by in F6Publishing: 17] [Article Influence: 1.9] [Reference Citation Analysis]
142 Mehanna J, Haddad FG, Eid R, Lambertini M, Kourie HR. Triple-negative breast cancer: current perspective on the evolving therapeutic landscape. Int J Womens Health 2019;11:431-7. [PMID: 31447592 DOI: 10.2147/IJWH.S178349] [Cited by in Crossref: 48] [Cited by in F6Publishing: 19] [Article Influence: 24.0] [Reference Citation Analysis]
143 Mukhopadhyay P, Horváth B, Kechrid M, Tanchian G, Rajesh M, Naura AS, Boulares AH, Pacher P. Poly(ADP-ribose) polymerase-1 is a key mediator of cisplatin-induced kidney inflammation and injury. Free Radic Biol Med 2011;51:1774-88. [PMID: 21884784 DOI: 10.1016/j.freeradbiomed.2011.08.006] [Cited by in Crossref: 62] [Cited by in F6Publishing: 59] [Article Influence: 6.2] [Reference Citation Analysis]
144 Grove CS, Vassiliou GS. Acute myeloid leukaemia: a paradigm for the clonal evolution of cancer? Dis Model Mech. 2014;7:941-951. [PMID: 25056697 DOI: 10.1242/dmm.015974] [Cited by in Crossref: 94] [Cited by in F6Publishing: 80] [Article Influence: 15.7] [Reference Citation Analysis]
145 Robertson L, Hanson H, Seal S, Warren-Perry M, Hughes D, Howell I, Turnbull C, Houlston R, Shanley S, Butler S, Evans DG, Ross G, Eccles D, Tutt A, Rahman N; TNT Trial TMG., BCSC (UK). BRCA1 testing should be offered to individuals with triple-negative breast cancer diagnosed below 50 years. Br J Cancer 2012;106:1234-8. [PMID: 22333603 DOI: 10.1038/bjc.2012.31] [Cited by in Crossref: 64] [Cited by in F6Publishing: 58] [Article Influence: 7.1] [Reference Citation Analysis]
146 Chen X, Yang D, Carey JPW, Karakas C, Albarracin C, Sahin AA, Arun BK, Guray Durak M, Li M, Kohansal M, Bui TN, Ha MJ, Hunt KK, Keyomarsi K. Targeting Replicative Stress and DNA Repair by Combining PARP and Wee1 Kinase Inhibitors Is Synergistic in Triple Negative Breast Cancers with Cyclin E or BRCA1 Alteration. Cancers (Basel) 2021;13:1656. [PMID: 33916118 DOI: 10.3390/cancers13071656] [Reference Citation Analysis]
147 Larsen MJ, Thomassen M, Gerdes AM, Kruse TA. Hereditary breast cancer: clinical, pathological and molecular characteristics. Breast Cancer (Auckl) 2014;8:145-55. [PMID: 25368521 DOI: 10.4137/BCBCR.S18715] [Cited by in Crossref: 11] [Cited by in F6Publishing: 19] [Article Influence: 1.6] [Reference Citation Analysis]
148 Williamson SR, Cheng L. Potential for targeted therapy in prostate cancers with ERG abnormalities. Asian J Androl 2011;13:781-2. [PMID: 21785441 DOI: 10.1038/aja.2011.100] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
149 Osoegawa A, Gills JJ, Kawabata S, Dennis PA. Rapamycin sensitizes cancer cells to growth inhibition by the PARP inhibitor olaparib. Oncotarget 2017;8:87044-53. [PMID: 29152062 DOI: 10.18632/oncotarget.19667] [Cited by in Crossref: 13] [Cited by in F6Publishing: 9] [Article Influence: 3.3] [Reference Citation Analysis]
150 Horton JK, Stefanick DF, Prasad R, Gassman NR, Kedar PS, Wilson SH. Base excision repair defects invoke hypersensitivity to PARP inhibition. Mol Cancer Res 2014;12:1128-39. [PMID: 24770870 DOI: 10.1158/1541-7786.MCR-13-0502] [Cited by in Crossref: 52] [Cited by in F6Publishing: 30] [Article Influence: 7.4] [Reference Citation Analysis]
151 Sharma P, Stecklein SR, Kimler BF, Sethi G, Petroff BK, Phillips TA, Tawfik OW, Godwin AK, Jensen RA. The prognostic value of BRCA1 promoter methylation in early stage triple negative breast cancer. J Cancer Ther Res 2014;3:1-11. [PMID: 25177489 DOI: 10.7243/2049-7962-3-2] [Cited by in Crossref: 28] [Cited by in F6Publishing: 29] [Article Influence: 4.0] [Reference Citation Analysis]
152 Wu L, Yang X. Targeting the Hippo Pathway for Breast Cancer Therapy. Cancers (Basel) 2018;10:E422. [PMID: 30400599 DOI: 10.3390/cancers10110422] [Cited by in Crossref: 39] [Cited by in F6Publishing: 31] [Article Influence: 13.0] [Reference Citation Analysis]
153 Feng FY, de Bono JS, Rubin MA, Knudsen KE. Chromatin to Clinic: The Molecular Rationale for PARP1 Inhibitor Function. Mol Cell 2015;58:925-34. [PMID: 26091341 DOI: 10.1016/j.molcel.2015.04.016] [Cited by in Crossref: 93] [Cited by in F6Publishing: 82] [Article Influence: 15.5] [Reference Citation Analysis]
154 Grindedal EM, Heramb C, Karsrud I, Ariansen SL, Mæhle L, Undlien DE, Norum J, Schlichting E. Current guidelines for BRCA testing of breast cancer patients are insufficient to detect all mutation carriers. BMC Cancer 2017;17:438. [PMID: 28637432 DOI: 10.1186/s12885-017-3422-2] [Cited by in Crossref: 33] [Cited by in F6Publishing: 27] [Article Influence: 8.3] [Reference Citation Analysis]
155 Li J, Wang R, Kong Y, Broman MM, Carlock C, Chen L, Li Z, Farah E, Ratliff TL, Liu X. Targeting Plk1 to Enhance Efficacy of Olaparib in Castration-Resistant Prostate Cancer. Mol Cancer Ther 2017;16:469-79. [PMID: 28069876 DOI: 10.1158/1535-7163.MCT-16-0361] [Cited by in Crossref: 24] [Cited by in F6Publishing: 11] [Article Influence: 6.0] [Reference Citation Analysis]
156 Wang J, Aroumougame A, Lobrich M, Li Y, Chen D, Chen J, Gong Z. PTIP associates with Artemis to dictate DNA repair pathway choice. Genes Dev 2014;28:2693-8. [PMID: 25512557 DOI: 10.1101/gad.252478.114] [Cited by in Crossref: 74] [Cited by in F6Publishing: 68] [Article Influence: 12.3] [Reference Citation Analysis]
157 Pihlak R, Valle JW, McNamara MG. Germline mutations in pancreatic cancer and potential new therapeutic options. Oncotarget. 2017;8:73240-73257. [PMID: 29069866 DOI: 10.18632/oncotarget.17291] [Cited by in Crossref: 32] [Cited by in F6Publishing: 22] [Article Influence: 8.0] [Reference Citation Analysis]
158 Carruthers R, Chalmers AJ. The potential of PARP inhibitors in neuro-oncology. CNS Oncol 2012;1:85-97. [PMID: 25054302 DOI: 10.2217/cns.12.13] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 1.2] [Reference Citation Analysis]
159 Rojas-Jiménez E, Mejía-Gómez JC, Díaz-Velásquez C, Quezada-Urban R, Martínez Gregorio H, Vallejo-Lecuona F, de la Cruz-Montoya A, Porras Reyes FI, Pérez-Sánchez VM, Maldonado-Martínez HA, Robles-Estrada M, Bargalló-Rocha E, Cabrera-Galeana P, Ramos-Ramírez M, Chirino YI, Alonso Herrera L, Terrazas LI, Oliver J, Frecha C, Perdomo S, Vaca-Paniagua F. Comprehensive Genomic Profile of Heterogeneous Long Follow-Up Triple-Negative Breast Cancer and Its Clinical Characteristics Shows DNA Repair Deficiency Has Better Prognostic. Genes (Basel) 2020;11:E1367. [PMID: 33227964 DOI: 10.3390/genes11111367] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
160 Zeng X, Jiang S, Ruan S, Guo Z, Guo J, Liu M, Ye C, Dong J. MAPK4 silencing together with a PARP1 inhibitor as a combination therapy in triple‑negative breast cancer cells. Mol Med Rep 2021;24:548. [PMID: 34080025 DOI: 10.3892/mmr.2021.12187] [Reference Citation Analysis]
161 Kim JW, Min A, Im SA, Jang H, Kim YJ, Kim HJ, Lee KH, Kim TY, Lee KW, Oh DY, Kim JH, Bang YJ. TDP1 and TOP1 Modulation in Olaparib-Resistant Cancer Determines the Efficacy of Subsequent Chemotherapy. Cancers (Basel) 2020;12:E334. [PMID: 32028591 DOI: 10.3390/cancers12020334] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 3.0] [Reference Citation Analysis]
162 Kim EK, Shin HC. The Potential Predictors in Chemotherapy Sensitivity. Adv Exp Med Biol 2021;1187:381-9. [PMID: 33983589 DOI: 10.1007/978-981-32-9620-6_19] [Reference Citation Analysis]
163 Sharma P, Barlow WE, Godwin AK, Pathak H, Isakova K, Williams D, Timms KM, Hartman AR, Wenstrup RJ, Linden HM, Tripathy D, Hortobagyi GN, Hayes DF. Impact of homologous recombination deficiency biomarkers on outcomes in patients with triple-negative breast cancer treated with adjuvant doxorubicin and cyclophosphamide (SWOG S9313). Ann Oncol 2018;29:654-60. [PMID: 29293876 DOI: 10.1093/annonc/mdx821] [Cited by in Crossref: 30] [Cited by in F6Publishing: 23] [Article Influence: 15.0] [Reference Citation Analysis]
164 Henneman L, van Miltenburg MH, Michalak EM, Braumuller TM, Jaspers JE, Drenth AP, de Korte-Grimmerink R, Gogola E, Szuhai K, Schlicker A, Bin Ali R, Pritchard C, Huijbers IJ, Berns A, Rottenberg S, Jonkers J. Selective resistance to the PARP inhibitor olaparib in a mouse model for BRCA1-deficient metaplastic breast cancer. Proc Natl Acad Sci U S A 2015;112:8409-14. [PMID: 26100884 DOI: 10.1073/pnas.1500223112] [Cited by in Crossref: 77] [Cited by in F6Publishing: 64] [Article Influence: 12.8] [Reference Citation Analysis]
165 Geng L, Huehls AM, Wagner JM, Huntoon CJ, Karnitz LM. Checkpoint signaling, base excision repair, and PARP promote survival of colon cancer cells treated with 5-fluorodeoxyuridine but not 5-fluorouracil. PLoS One 2011;6:e28862. [PMID: 22194930 DOI: 10.1371/journal.pone.0028862] [Cited by in Crossref: 21] [Cited by in F6Publishing: 20] [Article Influence: 2.1] [Reference Citation Analysis]
166 Booth L, Roberts JL, Samuel P, Avogadri-Connors F, Cutler RE, Lalani AS, Poklepovic A, Dent P. The irreversible ERBB1/2/4 inhibitor neratinib interacts with the PARP1 inhibitor niraparib to kill ovarian cancer cells. Cancer Biol Ther 2018;19:525-33. [PMID: 29405820 DOI: 10.1080/15384047.2018.1436024] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 3.7] [Reference Citation Analysis]
167 Clifton K, Gutierrez-Barrera A, Ma J, Bassett R Jr, Litton J, Kuerer H, Moulder S, Albarracin C, Hortobagyi G, Arun B. Adjuvant versus neoadjuvant chemotherapy in triple-negative breast cancer patients with BRCA mutations. Breast Cancer Res Treat 2018;170:101-9. [PMID: 29470805 DOI: 10.1007/s10549-018-4727-9] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 3.7] [Reference Citation Analysis]
168 Jamdade VS, Sethi N, Mundhe NA, Kumar P, Lahkar M, Sinha N. Therapeutic targets of triple-negative breast cancer: a review. Br J Pharmacol. 2015;172:4228-4237. [PMID: 26040571 DOI: 10.1111/bph.13211] [Cited by in Crossref: 94] [Cited by in F6Publishing: 90] [Article Influence: 15.7] [Reference Citation Analysis]
169 Rhiem K, Schmutzler R. Impact of Prophylactic Mastectomy in BRCA1/2 Mutation Carriers. Breast Care (Basel) 2014;9:385-9. [PMID: 25759620 DOI: 10.1159/000369592] [Cited by in Crossref: 8] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
170 Gabbasov R, Benrubi ID, O'Brien SW, Krais JJ, Johnson N, Litwin S, Connolly DC. Targeted blockade of HSP90 impairs DNA-damage response proteins and increases the sensitivity of ovarian carcinoma cells to PARP inhibition. Cancer Biol Ther 2019;20:1035-45. [PMID: 30929564 DOI: 10.1080/15384047.2019.1595279] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 4.0] [Reference Citation Analysis]
171 Parkes A, Arun BK, Litton JK. Systemic Treatment Strategies for Patients with Hereditary Breast Cancer Syndromes. Oncologist 2017;22:655-66. [PMID: 28469042 DOI: 10.1634/theoncologist.2016-0430] [Cited by in Crossref: 6] [Cited by in F6Publishing: 1] [Article Influence: 1.5] [Reference Citation Analysis]
172 Dean E, Middleton MR, Pwint T, Swaisland H, Carmichael J, Goodege-Kunwar P, Ranson M. Phase I study to assess the safety and tolerability of olaparib in combination with bevacizumab in patients with advanced solid tumours. Br J Cancer. 2012;106:468-474. [PMID: 22223088 DOI: 10.1038/bjc.2011.555] [Cited by in Crossref: 92] [Cited by in F6Publishing: 79] [Article Influence: 10.2] [Reference Citation Analysis]
173 Yin S, Xu L, Bandyopadhyay S, Sethi S, Reddy KB. Cisplatin and TRAIL enhance breast cancer stem cell death. Int J Oncol. 2011;39:891-898. [PMID: 21687939 DOI: 10.3892/ijo.2011.1085] [Cited by in Crossref: 5] [Cited by in F6Publishing: 23] [Article Influence: 0.5] [Reference Citation Analysis]
174 Ito S, Murphy CG, Doubrovina E, Jasin M, Moynahan ME. PARP Inhibitors in Clinical Use Induce Genomic Instability in Normal Human Cells. PLoS One 2016;11:e0159341. [PMID: 27428646 DOI: 10.1371/journal.pone.0159341] [Cited by in Crossref: 27] [Cited by in F6Publishing: 22] [Article Influence: 5.4] [Reference Citation Analysis]
175 Zhou Z, Jing C, Zhang L, Takeo F, Kim H, Huang Y, Liu Z, Wan Y. Regulation of Rad17 protein turnover unveils an impact of Rad17-APC cascade in breast carcinogenesis and treatment. J Biol Chem 2013;288:18134-45. [PMID: 23637229 DOI: 10.1074/jbc.M113.456962] [Cited by in Crossref: 11] [Cited by in F6Publishing: 6] [Article Influence: 1.4] [Reference Citation Analysis]
176 Wang L, Zhai Q, Lu Q, Lee K, Zheng Q, Hong R, Wang S. Clinical genomic profiling to identify actionable alterations for very early relapsed triple-negative breast cancer patients in the Chinese population. Ann Med 2021;53:1358-69. [PMID: 34396843 DOI: 10.1080/07853890.2021.1966086] [Reference Citation Analysis]
177 Ip LR, Poulogiannis G, Viciano FC, Sasaki J, Kofuji S, Spanswick VJ, Hochhauser D, Hartley JA, Sasaki T, Gewinner CA. Loss of INPP4B causes a DNA repair defect through loss of BRCA1, ATM and ATR and can be targeted with PARP inhibitor treatment. Oncotarget 2015;6:10548-62. [PMID: 25868852 DOI: 10.18632/oncotarget.3307] [Cited by in Crossref: 21] [Cited by in F6Publishing: 16] [Article Influence: 4.2] [Reference Citation Analysis]
178 Yang C, Arnold AG, Trottier M, Sonoda Y, Abu-Rustum NR, Zivanovic O, Robson ME, Stadler ZK, Walsh MF, Hyman DM, Offit K, Zhang L. Characterization of a novel germline PALB2 duplication in a hereditary breast and ovarian cancer family. Breast Cancer Res Treat 2016;160:447-56. [PMID: 27757719 DOI: 10.1007/s10549-016-4021-7] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 1.8] [Reference Citation Analysis]
179 Couch FJ, Hart SN, Sharma P, Toland AE, Wang X, Miron P, Olson JE, Godwin AK, Pankratz VS, Olswold C, Slettedahl S, Hallberg E, Guidugli L, Davila JI, Beckmann MW, Janni W, Rack B, Ekici AB, Slamon DJ, Konstantopoulou I, Fostira F, Vratimos A, Fountzilas G, Pelttari LM, Tapper WJ, Durcan L, Cross SS, Pilarski R, Shapiro CL, Klemp J, Yao S, Garber J, Cox A, Brauch H, Ambrosone C, Nevanlinna H, Yannoukakos D, Slager SL, Vachon CM, Eccles DM, Fasching PA. Inherited mutations in 17 breast cancer susceptibility genes among a large triple-negative breast cancer cohort unselected for family history of breast cancer. J Clin Oncol 2015;33:304-11. [PMID: 25452441 DOI: 10.1200/JCO.2014.57.1414] [Cited by in Crossref: 342] [Cited by in F6Publishing: 198] [Article Influence: 48.9] [Reference Citation Analysis]
180 Ha K, Fiskus W, Choi DS, Bhaskara S, Cerchietti L, Devaraj SG, Shah B, Sharma S, Chang JC, Melnick AM, Hiebert S, Bhalla KN. Histone deacetylase inhibitor treatment induces 'BRCAness' and synergistic lethality with PARP inhibitor and cisplatin against human triple negative breast cancer cells. Oncotarget 2014;5:5637-50. [PMID: 25026298 DOI: 10.18632/oncotarget.2154] [Cited by in Crossref: 90] [Cited by in F6Publishing: 79] [Article Influence: 15.0] [Reference Citation Analysis]
181 Arnedos M, Bihan C, Delaloge S, Andre F. Triple-negative breast cancer: are we making headway at least? Ther Adv Med Oncol 2012;4:195-210. [PMID: 22754593 DOI: 10.1177/1758834012444711] [Cited by in Crossref: 52] [Cited by in F6Publishing: 47] [Article Influence: 5.8] [Reference Citation Analysis]
182 Ghiorzo P, Pensotti V, Fornarini G, Sciallero S, Battistuzzi L, Belli F, Bonelli L, Borgonovo G, Bruno W, Gozza A. Contribution of germline mutations in the BRCA and PALB2 genes to pancreatic cancer in Italy. Fam Cancer. 2012;11:41-47. [PMID: 21989927 DOI: 10.1007/s10689-011-9483-5] [Cited by in Crossref: 21] [Cited by in F6Publishing: 23] [Article Influence: 2.3] [Reference Citation Analysis]
183 Vincent AM, Callaghan BC, Smith AL, Feldman EL. Diabetic neuropathy: cellular mechanisms as therapeutic targets. Nat Rev Neurol. 2011;7:573-583. [PMID: 21912405 DOI: 10.1038/nrneurol.2011.137] [Cited by in Crossref: 292] [Cited by in F6Publishing: 243] [Article Influence: 29.2] [Reference Citation Analysis]
184 Sheppard VB, Graves KD, Christopher J, Hurtado-de-Mendoza A, Talley C, Williams KP. African American women's limited knowledge and experiences with genetic counseling for hereditary breast cancer. J Genet Couns 2014;23:311-22. [PMID: 24186304 DOI: 10.1007/s10897-013-9663-6] [Cited by in Crossref: 31] [Cited by in F6Publishing: 19] [Article Influence: 3.9] [Reference Citation Analysis]
185 Turner NC, Tutt AN. Platinum chemotherapy for BRCA1-related breast cancer: do we need more evidence? Breast Cancer Res 2012;14:115. [PMID: 23146216 DOI: 10.1186/bcr3332] [Cited by in Crossref: 42] [Cited by in F6Publishing: 33] [Article Influence: 4.7] [Reference Citation Analysis]
186 Santana-Davila R, Perez EA. Treatment options for patients with triple-negative breast cancer. J Hematol Oncol 2010;3:42. [PMID: 20979652 DOI: 10.1186/1756-8722-3-42] [Cited by in Crossref: 38] [Cited by in F6Publishing: 37] [Article Influence: 3.5] [Reference Citation Analysis]
187 Pop L, Suciu I, Ionescu O, Bacalbasa N, Ionescu P. The role of novel poly (ADP-ribose) inhibitors in the treatment of locally advanced and metastatic Her-2/neu negative breast cancer with inherited germline BRCA1/2 mutations. A review of the literature. J Med Life 2021;14:17-20. [PMID: 33767780 DOI: 10.25122/jml-2020-0132] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
188 Tinoco G, Warsch S, Glück S, Avancha K, Montero AJ. Treating breast cancer in the 21st century: emerging biological therapies. J Cancer. 2013;4:117-132. [PMID: 23386910 DOI: 10.7150/jca.4925] [Cited by in Crossref: 86] [Cited by in F6Publishing: 76] [Article Influence: 10.8] [Reference Citation Analysis]
189 Pouliot GP, Degar J, Hinze L, Kochupurakkal B, Vo CD, Burns MA, Moreau L, Ganesa C, Roderick J, Peirs S, Menten B, Loh ML, Hunger SP, Silverman LB, Harris MH, Stevenson KE, Weinstock DM, Weng AP, Van Vlierberghe P, D'Andrea AD, Gutierrez A. Fanconi-BRCA pathway mutations in childhood T-cell acute lymphoblastic leukemia. PLoS One 2019;14:e0221288. [PMID: 31721781 DOI: 10.1371/journal.pone.0221288] [Cited by in Crossref: 9] [Cited by in F6Publishing: 5] [Article Influence: 4.5] [Reference Citation Analysis]
190 Andreopoulou E, Schweber SJ, Sparano JA, McDaid HM. Therapies for triple negative breast cancer. Expert Opin Pharmacother 2015;16:983-98. [PMID: 25881743 DOI: 10.1517/14656566.2015.1032246] [Cited by in Crossref: 53] [Cited by in F6Publishing: 49] [Article Influence: 8.8] [Reference Citation Analysis]
191 Smith AD, Roda D, Yap TA. Strategies for modern biomarker and drug development in oncology. J Hematol Oncol 2014;7:70. [PMID: 25277503 DOI: 10.1186/s13045-014-0070-8] [Cited by in Crossref: 84] [Cited by in F6Publishing: 76] [Article Influence: 12.0] [Reference Citation Analysis]
192 Michels J, Vitale I, Senovilla L, Enot DP, Garcia P, Lissa D, Olaussen KA, Brenner C, Soria JC, Castedo M, Kroemer G. Synergistic interaction between cisplatin and PARP inhibitors in non-small cell lung cancer. Cell Cycle 2013;12:877-83. [PMID: 23428903 DOI: 10.4161/cc.24034] [Cited by in Crossref: 36] [Cited by in F6Publishing: 32] [Article Influence: 4.5] [Reference Citation Analysis]
193 Min A, Im SA, Kim DK, Song SH, Kim HJ, Lee KH, Kim TY, Han SW, Oh DY, Kim TY, O'Connor MJ, Bang YJ. Histone deacetylase inhibitor, suberoylanilide hydroxamic acid (SAHA), enhances anti-tumor effects of the poly (ADP-ribose) polymerase (PARP) inhibitor olaparib in triple-negative breast cancer cells. Breast Cancer Res 2015;17:33. [PMID: 25888415 DOI: 10.1186/s13058-015-0534-y] [Cited by in Crossref: 87] [Cited by in F6Publishing: 81] [Article Influence: 14.5] [Reference Citation Analysis]
194 Low SK, Zembutsu H, Nakamura Y. Breast cancer: The translation of big genomic data to cancer precision medicine. Cancer Sci 2018;109:497-506. [PMID: 29215763 DOI: 10.1111/cas.13463] [Cited by in Crossref: 53] [Cited by in F6Publishing: 38] [Article Influence: 13.3] [Reference Citation Analysis]
195 de Ruijter TC, Veeck J, de Hoon JP, van Engeland M, Tjan-Heijnen VC. Characteristics of triple-negative breast cancer. J Cancer Res Clin Oncol. 2011;137:183-192. [PMID: 21069385 DOI: 10.1007/s00432-010-0957-x] [Cited by in Crossref: 140] [Cited by in F6Publishing: 124] [Article Influence: 12.7] [Reference Citation Analysis]
196 Leichman L, Groshen S, O’Neil BH, Messersmith W, Berlin J, Chan E, Leichman CG, Cohen SJ, Cohen D, Lenz HJ. Phase II Study of Olaparib (AZD-2281) After Standard Systemic Therapies for Disseminated Colorectal Cancer. Oncologist. 2016;21:172-177. [PMID: 26786262 DOI: 10.1634/theoncologist.2015-0319] [Cited by in Crossref: 31] [Cited by in F6Publishing: 27] [Article Influence: 6.2] [Reference Citation Analysis]
197 Hedström E, Pederiva C, Farnebo J, Nodin B, Jirström K, Brennan DJ, Farnebo M. Downregulation of the cancer susceptibility protein WRAP53β in epithelial ovarian cancer leads to defective DNA repair and poor clinical outcome. Cell Death Dis 2015;6:e1892. [PMID: 26426684 DOI: 10.1038/cddis.2015.250] [Cited by in Crossref: 14] [Cited by in F6Publishing: 15] [Article Influence: 2.3] [Reference Citation Analysis]
198 Wilkerson PM, Dedes KJ, Samartzis EP, Dedes I, Lambros MB, Natrajan R, Gauthier A, Piscuoglio S, Töpfer C, Vukovic V, Daley F, Weigelt B, Reis-Filho JS. Preclinical evaluation of the PARP inhibitor BMN-673 for the treatment of ovarian clear cell cancer. Oncotarget 2017;8:6057-66. [PMID: 28002809 DOI: 10.18632/oncotarget.14011] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 3.0] [Reference Citation Analysis]
199 Mehta AK, Cheney EM, Hartl CA, Pantelidou C, Oliwa M, Castrillon JA, Lin JR, Hurst KE, de Oliveira Taveira M, Johnson NT, Oldham WM, Kalocsay M, Berberich MJ, Boswell SA, Kothari A, Johnson S, Dillon DA, Lipschitz M, Rodig S, Santagata S, Garber JE, Tung N, Yélamos J, Thaxton JE, Mittendorf EA, Sorger PK, Shapiro GI, Guerriero JL. Targeting immunosuppressive macrophages overcomes PARP inhibitor resistance in BRCA1-associated triple-negative breast cancer. Nat Cancer 2021;2:66-82. [PMID: 33738458 DOI: 10.1038/s43018-020-00148-7] [Cited by in Crossref: 13] [Cited by in F6Publishing: 8] [Article Influence: 13.0] [Reference Citation Analysis]
200 Mori H, Kubo M, Nishimura R, Osako T, Arima N, Okumura Y, Okido M, Yamada M, Kai M, Kishimoto J, Miyazaki T, Oda Y, Otsuka T, Nakamura M. BRCAness as a Biomarker for Predicting Prognosis and Response to Anthracycline-Based Adjuvant Chemotherapy for Patients with Triple-Negative Breast Cancer. PLoS One 2016;11:e0167016. [PMID: 27977696 DOI: 10.1371/journal.pone.0167016] [Cited by in Crossref: 18] [Cited by in F6Publishing: 17] [Article Influence: 3.6] [Reference Citation Analysis]
201 Zhou JX, Feng LJ, Zhang X. Risk of severe hematologic toxicities in cancer patients treated with PARP inhibitors: a meta-analysis of randomized controlled trials. Drug Des Devel Ther 2017;11:3009-17. [PMID: 29075104 DOI: 10.2147/DDDT.S147726] [Cited by in Crossref: 32] [Cited by in F6Publishing: 16] [Article Influence: 8.0] [Reference Citation Analysis]
202 Sambandam V, Frederick MJ, Shen L, Tong P, Rao X, Peng S, Singh R, Mazumdar T, Huang C, Li Q, Pickering CR, Myers JN, Wang J, Johnson FM. PDK1 Mediates NOTCH1-Mutated Head and Neck Squamous Carcinoma Vulnerability to Therapeutic PI3K/mTOR Inhibition. Clin Cancer Res 2019;25:3329-40. [PMID: 30770351 DOI: 10.1158/1078-0432.CCR-18-3276] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 4.5] [Reference Citation Analysis]
203 Upreti M, Jyoti A, Johnson SE, Swindell EP, Napier D, Sethi P, Chan R, Feddock JM, Weiss HL, O'Halloran TV, Evers BM. Radiation-enhanced therapeutic targeting of galectin-1 enriched malignant stroma in triple negative breast cancer. Oncotarget 2016;7:41559-74. [PMID: 27223428 DOI: 10.18632/oncotarget.9490] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 2.7] [Reference Citation Analysis]
204 Mateo J, Ong M, Tan DS, Gonzalez MA, de Bono JS. Appraising iniparib, the PARP inhibitor that never was--what must we learn? Nat Rev Clin Oncol 2013;10:688-96. [PMID: 24129347 DOI: 10.1038/nrclinonc.2013.177] [Cited by in Crossref: 55] [Cited by in F6Publishing: 47] [Article Influence: 6.9] [Reference Citation Analysis]
205 Lim JSJ, Tan DSP. Understanding Resistance Mechanisms and Expanding the Therapeutic Utility of PARP Inhibitors. Cancers (Basel) 2017;9:E109. [PMID: 28829366 DOI: 10.3390/cancers9080109] [Cited by in Crossref: 19] [Cited by in F6Publishing: 17] [Article Influence: 4.8] [Reference Citation Analysis]
206 Juvekar A, Burga LN, Hu H, Lunsford EP, Ibrahim YH, Balmañà J, Rajendran A, Papa A, Spencer K, Lyssiotis CA, Nardella C, Pandolfi PP, Baselga J, Scully R, Asara JM, Cantley LC, Wulf GM. Combining a PI3K inhibitor with a PARP inhibitor provides an effective therapy for BRCA1-related breast cancer. Cancer Discov 2012;2:1048-63. [PMID: 22915751 DOI: 10.1158/2159-8290.CD-11-0336] [Cited by in Crossref: 280] [Cited by in F6Publishing: 154] [Article Influence: 31.1] [Reference Citation Analysis]
207 Moskwa P, Buffa FM, Pan Y, Panchakshari R, Gottipati P, Muschel RJ, Beech J, Kulshrestha R, Abdelmohsen K, Weinstock DM. miR-182-mediated downregulation of BRCA1 impacts DNA repair and sensitivity to PARP inhibitors. Mol Cell. 2011;41:210-220. [PMID: 21195000 DOI: 10.1016/j.molcel.2010.12.005] [Cited by in Crossref: 310] [Cited by in F6Publishing: 275] [Article Influence: 28.2] [Reference Citation Analysis]
208 Tung N, Lin NU, Kidd J, Allen BA, Singh N, Wenstrup RJ, Hartman AR, Winer EP, Garber JE. Frequency of Germline Mutations in 25 Cancer Susceptibility Genes in a Sequential Series of Patients With Breast Cancer. J Clin Oncol 2016;34:1460-8. [PMID: 26976419 DOI: 10.1200/JCO.2015.65.0747] [Cited by in Crossref: 247] [Cited by in F6Publishing: 119] [Article Influence: 49.4] [Reference Citation Analysis]
209 Zhou Z, Patel M, Ng N, Hsieh MH, Orth AP, Walker JR, Batalov S, Harris JL, Liu J. Identification of synthetic lethality of PRKDC in MYC-dependent human cancers by pooled shRNA screening. BMC Cancer 2014;14:944. [PMID: 25495526 DOI: 10.1186/1471-2407-14-944] [Cited by in Crossref: 25] [Cited by in F6Publishing: 24] [Article Influence: 3.6] [Reference Citation Analysis]
210 Javle M, Curtin NJ. The role of PARP in DNA repair and its therapeutic exploitation. Br J Cancer 2011;105:1114-22. [PMID: 21989215 DOI: 10.1038/bjc.2011.382] [Cited by in Crossref: 168] [Cited by in F6Publishing: 148] [Article Influence: 16.8] [Reference Citation Analysis]
211 Huang C, Han Z, Wu D. Effects of TPX2 gene on radiotherapy sensitization in breast cancer stem cells. Oncol Lett 2017;14:1531-5. [PMID: 28789376 DOI: 10.3892/ol.2017.6277] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
212 Ocana A, Pandiella A. Targeting oncogenic vulnerabilities in triple negative breast cancer: biological bases and ongoing clinical studies. Oncotarget 2017;8:22218-34. [PMID: 28108739 DOI: 10.18632/oncotarget.14731] [Cited by in Crossref: 29] [Cited by in F6Publishing: 29] [Article Influence: 7.3] [Reference Citation Analysis]
213 Zhang W, Lv S, Liu J, Zang Z, Yin J, An N, Yang H, Song Y. PCI-24781 down-regulates EZH2 expression and then promotes glioma apoptosis by suppressing the PIK3K/Akt/mTOR pathway. Genet Mol Biol 2014;37:716-24. [PMID: 25505847 DOI: 10.1590/S1415-47572014005000011] [Cited by in Crossref: 11] [Cited by in F6Publishing: 3] [Article Influence: 1.6] [Reference Citation Analysis]
214 Carey LA, Sharpless NE. PARP and cancer--if it's broke, don't fix it. N Engl J Med 2011;364:277-9. [PMID: 21208102 DOI: 10.1056/NEJMe1012546] [Cited by in Crossref: 40] [Cited by in F6Publishing: 19] [Article Influence: 4.0] [Reference Citation Analysis]
215 Hahnen E, Lederer B, Hauke J, Loibl S, Kröber S, Schneeweiss A, Denkert C, Fasching PA, Blohmer JU, Jackisch C, Paepke S, Gerber B, Kümmel S, Schem C, Neidhardt G, Huober J, Rhiem K, Costa S, Altmüller J, Hanusch C, Thiele H, Müller V, Nürnberg P, Karn T, Nekljudova V, Untch M, von Minckwitz G, Schmutzler RK. Germline Mutation Status, Pathological Complete Response, and Disease-Free Survival in Triple-Negative Breast Cancer: Secondary Analysis of the GeparSixto Randomized Clinical Trial. JAMA Oncol 2017;3:1378-85. [PMID: 28715532 DOI: 10.1001/jamaoncol.2017.1007] [Cited by in Crossref: 150] [Cited by in F6Publishing: 134] [Article Influence: 37.5] [Reference Citation Analysis]
216 Ledford H. Drug candidates derailed in case of mistaken identity. Nature 2012;483:519. [PMID: 22460874 DOI: 10.1038/483519a] [Cited by in Crossref: 21] [Cited by in F6Publishing: 20] [Article Influence: 2.3] [Reference Citation Analysis]
217 van Vuurden DG, Hulleman E, Meijer OL, Wedekind LE, Kool M, Witt H, Vandertop PW, Würdinger T, Noske DP, Kaspers GJ, Cloos J. PARP inhibition sensitizes childhood high grade glioma, medulloblastoma and ependymoma to radiation. Oncotarget 2011;2:984-96. [PMID: 22184287 DOI: 10.18632/oncotarget.362] [Cited by in Crossref: 59] [Cited by in F6Publishing: 52] [Article Influence: 6.6] [Reference Citation Analysis]
218 Angeli D, Salvi S, Tedaldi G. Genetic Predisposition to Breast and Ovarian Cancers: How Many and Which Genes to Test? Int J Mol Sci 2020;21:E1128. [PMID: 32046255 DOI: 10.3390/ijms21031128] [Cited by in Crossref: 17] [Cited by in F6Publishing: 10] [Article Influence: 17.0] [Reference Citation Analysis]
219 Santarpia L, Iwamoto T, Di Leo A, Hayashi N, Bottai G, Stampfer M, André F, Turner NC, Symmans WF, Hortobágyi GN, Pusztai L, Bianchini G. DNA repair gene patterns as prognostic and predictive factors in molecular breast cancer subtypes. Oncologist 2013;18:1063-73. [PMID: 24072219 DOI: 10.1634/theoncologist.2013-0163] [Cited by in Crossref: 58] [Cited by in F6Publishing: 50] [Article Influence: 7.3] [Reference Citation Analysis]
220 Murphy AK, Fitzgerald M, Ro T, Kim JH, Rabinowitsch AI, Chowdhury D, Schildkraut CL, Borowiec JA. Phosphorylated RPA recruits PALB2 to stalled DNA replication forks to facilitate fork recovery. J Cell Biol 2014;206:493-507. [PMID: 25113031 DOI: 10.1083/jcb.201404111] [Cited by in Crossref: 71] [Cited by in F6Publishing: 62] [Article Influence: 10.1] [Reference Citation Analysis]
221 Wang D, Li C, Zhang Y, Wang M, Jiang N, Xiang L, Li T, Roberts TM, Zhao JJ, Cheng H, Liu P. Combined inhibition of PI3K and PARP is effective in the treatment of ovarian cancer cells with wild-type PIK3CA genes. Gynecol Oncol 2016;142:548-56. [PMID: 27426307 DOI: 10.1016/j.ygyno.2016.07.092] [Cited by in Crossref: 39] [Cited by in F6Publishing: 35] [Article Influence: 7.8] [Reference Citation Analysis]
222 Mestres JA, iMolins AB, Martínez LC, López-Muñiz JI, Gil EC, de Juan Ferré A, Del Barco Berrón S, Pérez YF, Mata JG, Palomo AG, Gregori JG, Pardo PG, Mañas JJ, Hernández AL, de Dueñas EM, Jáñez NM, Murillo SM, Bofill JS, Auñón PZ, Sanchez-Rovira P. Defining the optimal sequence for the systemic treatment of metastatic breast cancer. Clin Transl Oncol 2017;19:149-61. [PMID: 27314861 DOI: 10.1007/s12094-016-1520-2] [Cited by in Crossref: 20] [Cited by in F6Publishing: 17] [Article Influence: 4.0] [Reference Citation Analysis]
223 Lin SH, Zhang J, Giri U, Stephan C, Sobieski M, Zhong L, Mason KA, Molkentine J, Thames HD, Yoo SS, Heymach JV. A high content clonogenic survival drug screen identifies mek inhibitors as potent radiation sensitizers for KRAS mutant non-small-cell lung cancer. J Thorac Oncol 2014;9:965-73. [PMID: 24922006 DOI: 10.1097/JTO.0000000000000199] [Cited by in Crossref: 21] [Cited by in F6Publishing: 10] [Article Influence: 3.5] [Reference Citation Analysis]
224 Davar D, Beumer JH, Hamieh L, Tawbi H. Role of PARP inhibitors in cancer biology and therapy. Curr Med Chem 2012;19:3907-21. [PMID: 22788767 DOI: 10.2174/092986712802002464] [Cited by in Crossref: 78] [Cited by in F6Publishing: 70] [Article Influence: 8.7] [Reference Citation Analysis]
225 Deng L, Lei Q, Wang Y, Wang Z, Xie G, Zhong X, Wang Y, Chen N, Qiu Y, Pu T, Bu H, Zheng H. Downregulation of miR-221-3p and upregulation of its target gene PARP1 are prognostic biomarkers for triple negative breast cancer patients and associated with poor prognosis. Oncotarget 2017;8:108712-25. [PMID: 29312562 DOI: 10.18632/oncotarget.21561] [Cited by in Crossref: 28] [Cited by in F6Publishing: 27] [Article Influence: 7.0] [Reference Citation Analysis]
226 Sonnenblick A, de Azambuja E, Azim HA Jr, Piccart M. An update on PARP inhibitors--moving to the adjuvant setting. Nat Rev Clin Oncol 2015;12:27-41. [PMID: 25286972 DOI: 10.1038/nrclinonc.2014.163] [Cited by in Crossref: 234] [Cited by in F6Publishing: 192] [Article Influence: 33.4] [Reference Citation Analysis]
227 Teo MY, O'Reilly EM. Is it time to split strategies to treat homologous recombinant deficiency in pancreas cancer? J Gastrointest Oncol 2016;7:738-49. [PMID: 27747088 DOI: 10.21037/jgo.2016.05.04] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 1.8] [Reference Citation Analysis]
228 Digan W, Countouris H, Barritault M, Baudoin D, Laurent-Puig P, Blons H, Burgun A, Rance B. An architecture for genomics analysis in a clinical setting using Galaxy and Docker. Gigascience 2017;6:1-9. [PMID: 29048555 DOI: 10.1093/gigascience/gix099] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
229 Arun B, Akar U, Gutierrez-Barrera AM, Hortobagyi GN, Ozpolat B. The PARP inhibitor AZD2281 (Olaparib) induces autophagy/mitophagy in BRCA1 and BRCA2 mutant breast cancer cells. Int J Oncol 2015;47:262-8. [PMID: 25975349 DOI: 10.3892/ijo.2015.3003] [Cited by in Crossref: 30] [Cited by in F6Publishing: 30] [Article Influence: 5.0] [Reference Citation Analysis]
230 Appleman LJ, Beumer JH, Jiang Y, Lin Y, Ding F, Puhalla S, Swartz L, Owonikoko TK, Donald Harvey R, Stoller R, Petro DP, Tawbi HA, Argiris A, Strychor S, Pouquet M, Kiesel B, Chen AP, Gandara D, Belani CP, Chu E, Ramalingam SS. Phase 1 study of veliparib (ABT-888), a poly (ADP-ribose) polymerase inhibitor, with carboplatin and paclitaxel in advanced solid malignancies. Cancer Chemother Pharmacol 2019;84:1289-301. [PMID: 31549216 DOI: 10.1007/s00280-019-03960-w] [Cited by in Crossref: 13] [Cited by in F6Publishing: 10] [Article Influence: 6.5] [Reference Citation Analysis]
231 Scott CL, Swisher EM, Kaufmann SH. Poly (ADP-ribose) polymerase inhibitors: recent advances and future development. J Clin Oncol 2015;33:1397-406. [PMID: 25779564 DOI: 10.1200/JCO.2014.58.8848] [Cited by in Crossref: 223] [Cited by in F6Publishing: 130] [Article Influence: 37.2] [Reference Citation Analysis]
232 Chon HS, Sehovic M, Marchion D, Walko C, Xiong Y, Extermann M. Biologic Mechanisms Linked to Prognosis in Ovarian Cancer that May Be Affected by Aging. J Cancer 2019;10:2604-18. [PMID: 31258768 DOI: 10.7150/jca.29611] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
233 Plummer R, Stephens P, Aissat-Daudigny L, Cambois A, Moachon G, Brown PD, Campone M. Phase 1 dose-escalation study of the PARP inhibitor CEP-9722 as monotherapy or in combination with temozolomide in patients with solid tumors. Cancer Chemother Pharmacol 2014;74:257-65. [PMID: 24880570 DOI: 10.1007/s00280-014-2486-9] [Cited by in Crossref: 23] [Cited by in F6Publishing: 14] [Article Influence: 3.3] [Reference Citation Analysis]
234 Wahlberg E, Karlberg T, Kouznetsova E, Markova N, Macchiarulo A, Thorsell AG, Pol E, Frostell Å, Ekblad T, Öncü D, Kull B, Robertson GM, Pellicciari R, Schüler H, Weigelt J. Family-wide chemical profiling and structural analysis of PARP and tankyrase inhibitors. Nat Biotechnol 2012;30:283-8. [PMID: 22343925 DOI: 10.1038/nbt.2121] [Cited by in Crossref: 313] [Cited by in F6Publishing: 287] [Article Influence: 34.8] [Reference Citation Analysis]
235 Brouckaert O, Wildiers H, Floris G, Neven P. Update on triple-negative breast cancer: prognosis and management strategies. Int J Womens Health 2012;4:511-20. [PMID: 23071421 DOI: 10.2147/IJWH.S18541] [Cited by in Crossref: 17] [Cited by in F6Publishing: 47] [Article Influence: 1.9] [Reference Citation Analysis]
236 Desai A, Yan Y, Gerson SL. Advances in therapeutic targeting of the DNA damage response in cancer. DNA Repair (Amst) 2018;66-67:24-9. [PMID: 29715575 DOI: 10.1016/j.dnarep.2018.04.004] [Cited by in Crossref: 31] [Cited by in F6Publishing: 25] [Article Influence: 10.3] [Reference Citation Analysis]
237 Feng X, Koh DW. Inhibition of poly(ADP-ribose) polymerase-1 or poly(ADP‑ribose) glycohydrolase individually, but not in combination, leads to improved chemotherapeutic efficacy in HeLa cells. Int J Oncol 2013;42:749-56. [PMID: 23254695 DOI: 10.3892/ijo.2012.1740] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 1.3] [Reference Citation Analysis]
238 Vollebergh MA, Jonkers J, Linn SC. Genomic instability in breast and ovarian cancers: translation into clinical predictive biomarkers. Cell Mol Life Sci 2012;69:223-45. [PMID: 21922196 DOI: 10.1007/s00018-011-0809-0] [Cited by in Crossref: 49] [Cited by in F6Publishing: 36] [Article Influence: 4.9] [Reference Citation Analysis]
239 Mateo J, Lord CJ, Serra V, Tutt A, Balmaña J, Castroviejo-Bermejo M, Cruz C, Oaknin A, Kaye SB, de Bono JS. A decade of clinical development of PARP inhibitors in perspective. Ann Oncol 2019;30:1437-47. [PMID: 31218365 DOI: 10.1093/annonc/mdz192] [Cited by in Crossref: 135] [Cited by in F6Publishing: 112] [Article Influence: 135.0] [Reference Citation Analysis]
240 Yazinski SA, Comaills V, Buisson R, Genois MM, Nguyen HD, Ho CK, Todorova Kwan T, Morris R, Lauffer S, Nussenzweig A, Ramaswamy S, Benes CH, Haber DA, Maheswaran S, Birrer MJ, Zou L. ATR inhibition disrupts rewired homologous recombination and fork protection pathways in PARP inhibitor-resistant BRCA-deficient cancer cells. Genes Dev 2017;31:318-32. [PMID: 28242626 DOI: 10.1101/gad.290957.116] [Cited by in Crossref: 167] [Cited by in F6Publishing: 140] [Article Influence: 41.8] [Reference Citation Analysis]
241 De Lorenzo SB, Patel AG, Hurley RM, Kaufmann SH. The Elephant and the Blind Men: Making Sense of PARP Inhibitors in Homologous Recombination Deficient Tumor Cells. Front Oncol 2013;3:228. [PMID: 24062981 DOI: 10.3389/fonc.2013.00228] [Cited by in Crossref: 67] [Cited by in F6Publishing: 70] [Article Influence: 8.4] [Reference Citation Analysis]
242 Siamakpour-Reihani S, Owzar K, Jiang C, Scarbrough PM, Craciunescu OI, Horton JK, Dressman HK, Blackwell KL, Dewhirst MW. Genomic profiling in locally advanced and inflammatory breast cancer and its link to DCE-MRI and overall survival. Int J Hyperthermia 2015;31:386-95. [PMID: 25811737 DOI: 10.3109/02656736.2015.1016557] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 1.8] [Reference Citation Analysis]
243 Baldock RA, Pressimone CA, Baird JM, Khodakov A, Luong TT, Grundy MK, Smith CM, Karpenshif Y, Bratton-Palmer DS, Prakash R, Jasin M, Garcin EB, Gon S, Modesti M, Bernstein KA. RAD51D splice variants and cancer-associated mutations reveal XRCC2 interaction to be critical for homologous recombination. DNA Repair (Amst) 2019;76:99-107. [PMID: 30836272 DOI: 10.1016/j.dnarep.2019.02.008] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 3.5] [Reference Citation Analysis]
244 Ibrahim M, Yadav S, Ogunleye F, Zakalik D. Male BRCA mutation carriers: clinical characteristics and cancer spectrum. BMC Cancer 2018;18:179. [PMID: 29433453 DOI: 10.1186/s12885-018-4098-y] [Cited by in Crossref: 25] [Cited by in F6Publishing: 18] [Article Influence: 8.3] [Reference Citation Analysis]
245 Ebeid K, Meng X, Thiel KW, Do AV, Geary SM, Morris AS, Pham EL, Wongrakpanich A, Chhonker YS, Murry DJ, Leslie KK, Salem AK. Synthetically lethal nanoparticles for treatment of endometrial cancer. Nat Nanotechnol 2018;13:72-81. [PMID: 29203914 DOI: 10.1038/s41565-017-0009-7] [Cited by in Crossref: 29] [Cited by in F6Publishing: 21] [Article Influence: 7.3] [Reference Citation Analysis]
246 Krais JJ, Johnson N. BRCA1 Mutations in Cancer: Coordinating Deficiencies in Homologous Recombination with Tumorigenesis. Cancer Res 2020;80:4601-9. [PMID: 32747362 DOI: 10.1158/0008-5472.CAN-20-1830] [Cited by in Crossref: 6] [Cited by in F6Publishing: 2] [Article Influence: 6.0] [Reference Citation Analysis]
247 Ganguly B, Dolfi SC, Rodriguez-Rodriguez L, Ganesan S, Hirshfield KM. Role of Biomarkers in the Development of PARP Inhibitors. Biomark Cancer 2016;8:15-25. [PMID: 26997874 DOI: 10.4137/BIC.S36679] [Cited by in Crossref: 9] [Cited by in F6Publishing: 17] [Article Influence: 1.8] [Reference Citation Analysis]
248 Ernst C, Hahnen E, Engel C, Nothnagel M, Weber J, Schmutzler RK, Hauke J. Performance of in silico prediction tools for the classification of rare BRCA1/2 missense variants in clinical diagnostics. BMC Med Genomics 2018;11:35. [PMID: 29580235 DOI: 10.1186/s12920-018-0353-y] [Cited by in Crossref: 39] [Cited by in F6Publishing: 28] [Article Influence: 13.0] [Reference Citation Analysis]
249 Poveda A, Oaknin A, Romero I, Guerrero-Zotano A, Fariñas-Madrid L, Rodriguez-Freixinos V, Mallol P, Lopez-Reig R, Lopez-Guerrero JA. A phase I dose-finding, pharmacokinetics and genotyping study of olaparib and lurbinectedin in patients with advanced solid tumors. Sci Rep 2021;11:4433. [PMID: 33627685 DOI: 10.1038/s41598-021-82671-w] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
250 Klattenhoff AW, Thakur M, Chu CS, Ray D, Habib SL, Kidane D. Loss of NEIL3 DNA glycosylase markedly increases replication associated double strand breaks and enhances sensitivity to ATR inhibitor in glioblastoma cells. Oncotarget 2017;8:112942-58. [PMID: 29348879 DOI: 10.18632/oncotarget.22896] [Cited by in Crossref: 13] [Cited by in F6Publishing: 10] [Article Influence: 3.3] [Reference Citation Analysis]
251 Lachapelle J, Foulkes WD. Triple-negative and basal-like breast cancer: implications for oncologists. Curr Oncol 2011;18:161-4. [PMID: 21874112 DOI: 10.3747/co.v18i4.824] [Cited by in Crossref: 19] [Cited by in F6Publishing: 16] [Article Influence: 1.9] [Reference Citation Analysis]
252 Booth L, Cruickshanks N, Ridder T, Dai Y, Grant S, Dent P. PARP and CHK inhibitors interact to cause DNA damage and cell death in mammary carcinoma cells. Cancer Biol Ther 2013;14:458-65. [PMID: 23917378 DOI: 10.4161/cbt.24424] [Cited by in Crossref: 44] [Cited by in F6Publishing: 37] [Article Influence: 6.3] [Reference Citation Analysis]
253 Neophytou C, Boutsikos P, Papageorgis P. Molecular Mechanisms and Emerging Therapeutic Targets of Triple-Negative Breast Cancer Metastasis. Front Oncol 2018;8:31. [PMID: 29520340 DOI: 10.3389/fonc.2018.00031] [Cited by in Crossref: 59] [Cited by in F6Publishing: 54] [Article Influence: 19.7] [Reference Citation Analysis]
254 Yao H, He G, Yan S, Chen C, Song L, Rosol TJ, Deng X. Triple-negative breast cancer: is there a treatment on the horizon? Oncotarget 2017;8:1913-24. [PMID: 27765921 DOI: 10.18632/oncotarget.12284] [Cited by in Crossref: 143] [Cited by in F6Publishing: 127] [Article Influence: 47.7] [Reference Citation Analysis]
255 O'Sullivan Coyne G, Chen AP, Meehan R, Doroshow JH. PARP Inhibitors in Reproductive System Cancers: Current Use and Developments. Drugs 2017;77:113-30. [PMID: 28078645 DOI: 10.1007/s40265-016-0688-7] [Cited by in Crossref: 29] [Cited by in F6Publishing: 21] [Article Influence: 7.3] [Reference Citation Analysis]
256 Rigakos G, Razis E. BRCAness: finding the Achilles heel in ovarian cancer. Oncologist 2012;17:956-62. [PMID: 22673632 DOI: 10.1634/theoncologist.2012-0028] [Cited by in Crossref: 66] [Cited by in F6Publishing: 62] [Article Influence: 7.3] [Reference Citation Analysis]
257 Motea EA, Fattah FJ, Xiao L, Girard L, Rommel A, Morales JC, Patidar P, Zhou Y, Porter A, Xie Y, Minna JD, Boothman DA. Kub5-Hera RPRD1B Deficiency Promotes "BRCAness" and Vulnerability to PARP Inhibition in BRCA-proficient Breast Cancers. Clin Cancer Res 2018;24:6459-70. [PMID: 30108102 DOI: 10.1158/1078-0432.CCR-17-1118] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 2.3] [Reference Citation Analysis]
258 Darici S, Alkhaldi H, Horne G, Jørgensen HG, Marmiroli S, Huang X. Targeting PI3K/Akt/mTOR in AML: Rationale and Clinical Evidence. J Clin Med 2020;9:E2934. [PMID: 32932888 DOI: 10.3390/jcm9092934] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 6.0] [Reference Citation Analysis]
259 Frederick BA, Gupta R, Atilano-Roque A, Su TT, Raben D. Combined EGFR1 and PARP1 Inhibition Enhances the Effect of Radiation in Head and Neck Squamous Cell Carcinoma Models. Radiat Res 2020;194:519-31. [PMID: 32936912 DOI: 10.1667/RR15480.1] [Reference Citation Analysis]
260 Trenner A, Sartori AA. Harnessing DNA Double-Strand Break Repair for Cancer Treatment. Front Oncol 2019;9:1388. [PMID: 31921645 DOI: 10.3389/fonc.2019.01388] [Cited by in Crossref: 41] [Cited by in F6Publishing: 37] [Article Influence: 20.5] [Reference Citation Analysis]
261 Kurian AW, Munoz DF, Rust P, Schackmann EA, Smith M, Clarke L, Mills MA, Plevritis SK. Online tool to guide decisions for BRCA1/2 mutation carriers. J Clin Oncol 2012;30:497-506. [PMID: 22231042 DOI: 10.1200/JCO.2011.38.6060] [Cited by in Crossref: 67] [Cited by in F6Publishing: 25] [Article Influence: 7.4] [Reference Citation Analysis]
262 Yun EJ, Lin CJ, Dang A, Hernandez E, Guo J, Chen WM, Allison J, Kim N, Kapur P, Brugarolas J, Wu K, He D, Lai CH, Lin H, Saha D, Baek ST, Chen BPC, Hsieh JT. Downregulation of Human DAB2IP Gene Expression in Renal Cell Carcinoma Results in Resistance to Ionizing Radiation. Clin Cancer Res 2019;25:4542-51. [PMID: 31000589 DOI: 10.1158/1078-0432.CCR-18-3004] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 3.5] [Reference Citation Analysis]
263 Zhao L, Si CS, Yu Y, Lu JW, Zhuang Y. Depletion of DNA damage binding protein 2 sensitizes triple-negative breast cancer cells to poly ADP-ribose polymerase inhibition by destabilizing Rad51. Cancer Sci 2019;110:3543-52. [PMID: 31541611 DOI: 10.1111/cas.14201] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
264 Alluri P, Newman LA. Basal-like and triple-negative breast cancers: searching for positives among many negatives. Surg Oncol Clin N Am 2014;23:567-77. [PMID: 24882351 DOI: 10.1016/j.soc.2014.03.003] [Cited by in Crossref: 52] [Cited by in F6Publishing: 47] [Article Influence: 8.7] [Reference Citation Analysis]
265 Kedrin D, Gala MK. Genetics of the serrated pathway to colorectal cancer. Clin Transl Gastroenterol 2015;6:e84. [PMID: 25856207 DOI: 10.1038/ctg.2015.12] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 1.5] [Reference Citation Analysis]
266 Santarpia L, Bottai G, Kelly CM, Győrffy B, Székely B, Pusztai L. Deciphering and Targeting Oncogenic Mutations and Pathways in Breast Cancer. Oncologist 2016;21:1063-78. [PMID: 27384237 DOI: 10.1634/theoncologist.2015-0369] [Cited by in Crossref: 30] [Cited by in F6Publishing: 21] [Article Influence: 6.0] [Reference Citation Analysis]
267 Pern F, Bogdanova N, Schürmann P, Lin M, Ay A, Länger F, Hillemanns P, Christiansen H, Park-Simon TW, Dörk T. Mutation analysis of BRCA1, BRCA2, PALB2 and BRD7 in a hospital-based series of German patients with triple-negative breast cancer. PLoS One 2012;7:e47993. [PMID: 23110154 DOI: 10.1371/journal.pone.0047993] [Cited by in Crossref: 34] [Cited by in F6Publishing: 27] [Article Influence: 3.8] [Reference Citation Analysis]
268 Jaspers JE, Kersbergen A, Boon U, Sol W, van Deemter L, Zander SA, Drost R, Wientjens E, Ji J, Aly A. Loss of 53BP1 causes PARP inhibitor resistance in Brca1-mutated mouse mammary tumors. Cancer Discov. 2013;3:68-81. [PMID: 23103855 DOI: 10.1158/2159-8290.cd-12-0049] [Cited by in Crossref: 295] [Cited by in F6Publishing: 187] [Article Influence: 32.8] [Reference Citation Analysis]
269 Gilardini Montani MS, Prodosmo A, Stagni V, Merli D, Monteonofrio L, Gatti V, Gentileschi MP, Barilà D, Soddu S. ATM-depletion in breast cancer cells confers sensitivity to PARP inhibition. J Exp Clin Cancer Res 2013;32:95. [PMID: 24252502 DOI: 10.1186/1756-9966-32-95] [Cited by in Crossref: 61] [Cited by in F6Publishing: 56] [Article Influence: 7.6] [Reference Citation Analysis]
270 Tung N, Garber JE, Hacker MR, Torous V, Freeman GJ, Poles E, Rodig S, Alexander B, Lee L, Collins LC, Schnitt SJ. Prevalence and predictors of androgen receptor and programmed death-ligand 1 in BRCA1-associated and sporadic triple-negative breast cancer. NPJ Breast Cancer 2016;2:16002. [PMID: 28721372 DOI: 10.1038/npjbcancer.2016.2] [Cited by in Crossref: 19] [Cited by in F6Publishing: 17] [Article Influence: 3.8] [Reference Citation Analysis]
271 Jekimovs C, Bolderson E, Suraweera A, Adams M, O'Byrne KJ, Richard DJ. Chemotherapeutic compounds targeting the DNA double-strand break repair pathways: the good, the bad, and the promising. Front Oncol 2014;4:86. [PMID: 24795863 DOI: 10.3389/fonc.2014.00086] [Cited by in Crossref: 69] [Cited by in F6Publishing: 62] [Article Influence: 9.9] [Reference Citation Analysis]
272 Cruz C, Llop-Guevara A, Garber JE, Arun BK, Pérez Fidalgo JA, Lluch A, Telli ML, Fernández C, Kahatt C, Galmarini CM, Soto-Matos A, Alfaro V, Pérez de la Haza A, Domchek SM, Antolin S, Vahdat L, Tung NM, Lopez R, Arribas J, Vivancos A, Baselga J, Serra V, Balmaña J, Isakoff SJ. Multicenter Phase II Study of Lurbinectedin in BRCA-Mutated and Unselected Metastatic Advanced Breast Cancer and Biomarker Assessment Substudy. J Clin Oncol 2018;36:3134-43. [PMID: 30240327 DOI: 10.1200/JCO.2018.78.6558] [Cited by in Crossref: 22] [Cited by in F6Publishing: 9] [Article Influence: 7.3] [Reference Citation Analysis]
273 Maugeri-Saccà M, Zeuner A, De Maria R. Therapeutic targeting of cancer stem cells. Front Oncol. 2011;1:10. [PMID: 22655230 DOI: 10.3389/fonc.2011.00010] [Cited by in Crossref: 17] [Cited by in F6Publishing: 15] [Article Influence: 1.7] [Reference Citation Analysis]
274 Lee JM, Hays JL, Chiou VL, Annunziata CM, Swisher EM, Harrell MI, Yu M, Gordon N, Sissung TM, Ji J, Figg WD, Minasian L, Lipkowitz S, Wood BJ, Doroshow J, Kohn EC. Phase I/Ib study of olaparib and carboplatin in women with triple negative breast cancer. Oncotarget 2017;8:79175-87. [PMID: 29108297 DOI: 10.18632/oncotarget.16577] [Cited by in Crossref: 25] [Cited by in F6Publishing: 20] [Article Influence: 6.3] [Reference Citation Analysis]
275 Davidson D, Wang Y, Aloyz R, Panasci L. The PARP inhibitor ABT-888 synergizes irinotecan treatment of colon cancer cell lines. Invest New Drugs. 2013;31:461-468. [PMID: 23054213 DOI: 10.1007/s10637-012-9886-7] [Cited by in Crossref: 35] [Cited by in F6Publishing: 25] [Article Influence: 3.9] [Reference Citation Analysis]
276 Collignon J, Lousberg L, Schroeder H, Jerusalem G. Triple-negative breast cancer: treatment challenges and solutions. Breast Cancer (Dove Med Press) 2016;8:93-107. [PMID: 27284266 DOI: 10.2147/BCTT.S69488] [Cited by in Crossref: 37] [Cited by in F6Publishing: 89] [Article Influence: 7.4] [Reference Citation Analysis]
277 Basu B, Sandhu SK, de Bono JS. PARP inhibitors: mechanism of action and their potential role in the prevention and treatment of cancer. Drugs 2012;72:1579-90. [PMID: 22834679 DOI: 10.2165/11635510-000000000-00000] [Cited by in Crossref: 21] [Cited by in F6Publishing: 19] [Article Influence: 2.3] [Reference Citation Analysis]
278 Meindl A, Ditsch N, Kast K, Rhiem K, Schmutzler RK. Hereditary breast and ovarian cancer: new genes, new treatments, new concepts. Dtsch Arztebl Int. 2011;108:323-330. [PMID: 21637635 DOI: 10.3238/arztebl.2011.0323] [Cited by in Crossref: 9] [Cited by in F6Publishing: 36] [Article Influence: 0.9] [Reference Citation Analysis]
279 Bettaieb A, Paul C, Plenchette S, Shan J, Chouchane L, Ghiringhelli F. Precision medicine in breast cancer: reality or utopia? J Transl Med 2017;15:139. [PMID: 28623955 DOI: 10.1186/s12967-017-1239-z] [Cited by in Crossref: 33] [Cited by in F6Publishing: 28] [Article Influence: 8.3] [Reference Citation Analysis]
280 McLellan JL, O'Neil NJ, Barrett I, Ferree E, van Pel DM, Ushey K, Sipahimalani P, Bryan J, Rose AM, Hieter P. Synthetic lethality of cohesins with PARPs and replication fork mediators. PLoS Genet 2012;8:e1002574. [PMID: 22412391 DOI: 10.1371/journal.pgen.1002574] [Cited by in Crossref: 47] [Cited by in F6Publishing: 38] [Article Influence: 5.2] [Reference Citation Analysis]
281 Kim KM, Moon YJ, Park SH, Park HJ, Wang SI, Park HS, Lee H, Kwon KS, Moon WS, Lee DG, Kim JR, Jang KY. Individual and Combined Expression of DNA Damage Response Molecules PARP1, γH2AX, BRCA1, and BRCA2 Predict Shorter Survival of Soft Tissue Sarcoma Patients. PLoS One 2016;11:e0163193. [PMID: 27643881 DOI: 10.1371/journal.pone.0163193] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 2.8] [Reference Citation Analysis]
282 Pearson SJ, Roy Sarkar T, McQueen CM, Elswood J, Schmitt EE, Wall SW, Scribner KC, Wyatt G, Barhoumi R, Behbod F, Rijnkels M, Porter WW. ATM-dependent activation of SIM2s regulates homologous recombination and epithelial-mesenchymal transition. Oncogene 2019;38:2611-26. [PMID: 30531838 DOI: 10.1038/s41388-018-0622-4] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 3.0] [Reference Citation Analysis]
283 Pan Z, Xie X. BRCA mutations in the manifestation and treatment of ovarian cancer. Oncotarget 2017;8:97657-70. [PMID: 29228641 DOI: 10.18632/oncotarget.18280] [Cited by in Crossref: 13] [Cited by in F6Publishing: 9] [Article Influence: 3.3] [Reference Citation Analysis]
284 Wielgos ME, Zhang Z, Rajbhandari R, Cooper TS, Zeng L, Forero A, Esteva FJ, Osborne CK, Schiff R, LoBuglio AF, Nozell SE, Yang ES. Trastuzumab-Resistant HER2+ Breast Cancer Cells Retain Sensitivity to Poly (ADP-Ribose) Polymerase (PARP) Inhibition. Mol Cancer Ther 2018;17:921-30. [PMID: 29592880 DOI: 10.1158/1535-7163.MCT-17-0302] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
285 Cerutti R, Pirinen E, Lamperti C, Marchet S, Sauve AA, Li W, Leoni V, Schon EA, Dantzer F, Auwerx J, Viscomi C, Zeviani M. NAD(+)-dependent activation of Sirt1 corrects the phenotype in a mouse model of mitochondrial disease. Cell Metab 2014;19:1042-9. [PMID: 24814483 DOI: 10.1016/j.cmet.2014.04.001] [Cited by in Crossref: 214] [Cited by in F6Publishing: 190] [Article Influence: 30.6] [Reference Citation Analysis]
286 Lee LJ, Alexander B, Schnitt SJ, Comander A, Gallagher B, Garber JE, Tung N. Clinical outcome of triple negative breast cancer in BRCA1 mutation carriers and noncarriers. Cancer 2011;117:3093-100. [PMID: 21264845 DOI: 10.1002/cncr.25911] [Cited by in Crossref: 49] [Cited by in F6Publishing: 43] [Article Influence: 4.9] [Reference Citation Analysis]
287 Ueki A, Hirasawa A. Molecular Features and Clinical Management of Hereditary Gynecological Cancers. Int J Mol Sci 2020;21:E9504. [PMID: 33327492 DOI: 10.3390/ijms21249504] [Reference Citation Analysis]
288 Saha P, Nanda R. Concepts and targets in triple-negative breast cancer: recent results and clinical implications. Ther Adv Med Oncol 2016;8:351-9. [PMID: 27583027 DOI: 10.1177/1758834016657071] [Cited by in Crossref: 17] [Cited by in F6Publishing: 16] [Article Influence: 3.4] [Reference Citation Analysis]
289 Gucalp A, Traina TA. Triple-negative breast cancer: adjuvant therapeutic options. Chemother Res Pract 2011;2011:696208. [PMID: 22312556 DOI: 10.1155/2011/696208] [Cited by in Crossref: 18] [Cited by in F6Publishing: 33] [Article Influence: 1.8] [Reference Citation Analysis]
290 Giacchetti S, Porcher R, Lehmann-Che J, Hamy AS, de Roquancourt A, Cuvier C, Cottu PH, Bertheau P, Albiter M, Bouhidel F, Coussy F, Extra JM, Marty M, de Thé H, Espié M. Long-term survival of advanced triple-negative breast cancers with a dose-intense cyclophosphamide/anthracycline neoadjuvant regimen. Br J Cancer 2014;110:1413-9. [PMID: 24569467 DOI: 10.1038/bjc.2014.81] [Cited by in Crossref: 17] [Cited by in F6Publishing: 12] [Article Influence: 2.4] [Reference Citation Analysis]
291 Exman P, Mallery RM, Lin NU, Parsons HA. Response to Olaparib in a Patient with Germline BRCA2 Mutation and Breast Cancer Leptomeningeal Carcinomatosis. NPJ Breast Cancer 2019;5:46. [PMID: 31815182 DOI: 10.1038/s41523-019-0139-1] [Cited by in Crossref: 6] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
292 Macedo GS, Alemar B, Ashton-Prolla P. Reviewing the characteristics of BRCA and PALB2-related cancers in the precision medicine era. Genet Mol Biol 2019;42:215-31. [PMID: 31067289 DOI: 10.1590/1678-4685-GMB-2018-0104] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 4.5] [Reference Citation Analysis]
293 Panou V, Gadiraju M, Wolin A, Weipert CM, Skarda E, Husain AN, Patel JD, Rose B, Zhang SR, Weatherly M, Nelakuditi V, Knight Johnson A, Helgeson M, Fischer D, Desai A, Sulai N, Ritterhouse L, Røe OD, Turaga KK, Huo D, Segal J, Kadri S, Li Z, Kindler HL, Churpek JE. Frequency of Germline Mutations in Cancer Susceptibility Genes in Malignant Mesothelioma.J Clin Oncol. 2018;36:2863-2871. [PMID: 30113886 DOI: 10.1200/JCO.2018.78.5204] [Cited by in Crossref: 68] [Cited by in F6Publishing: 30] [Article Influence: 22.7] [Reference Citation Analysis]
294 Ellisen LW. PARP inhibitors in cancer therapy: promise, progress, and puzzles. Cancer Cell 2011;19:165-7. [PMID: 21316599 DOI: 10.1016/j.ccr.2011.01.047] [Cited by in Crossref: 43] [Cited by in F6Publishing: 34] [Article Influence: 4.3] [Reference Citation Analysis]
295 Abu-Sanad A, Wang Y, Hasheminasab F, Panasci J, Noë A, Rosca L, Davidson D, Amrein L, Sharif-Askari B, Aloyz R, Panasci L. Simultaneous inhibition of ATR and PARP sensitizes colon cancer cell lines to irinotecan. Front Pharmacol 2015;6:147. [PMID: 26257651 DOI: 10.3389/fphar.2015.00147] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 2.2] [Reference Citation Analysis]
296 Churpek JE, Walsh T, Zheng Y, Moton Z, Thornton AM, Lee MK, Casadei S, Watts A, Neistadt B, Churpek MM, Huo D, Zvosec C, Liu F, Niu Q, Marquez R, Zhang J, Fackenthal J, King MC, Olopade OI. Inherited predisposition to breast cancer among African American women. Breast Cancer Res Treat 2015;149:31-9. [PMID: 25428789 DOI: 10.1007/s10549-014-3195-0] [Cited by in Crossref: 81] [Cited by in F6Publishing: 67] [Article Influence: 11.6] [Reference Citation Analysis]
297 Kandula M, Ch KK, Ys AR. Molecular Mechanism and Targeted Therapy Options of Triple-Negative (ER, PgR, HER-2/neu) Breast Cancer: Review. World J Oncol 2013;4:137-41. [PMID: 29147345 DOI: 10.4021/wjon681e] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 0.1] [Reference Citation Analysis]
298 Siddharth S, Sharma D. Racial Disparity and Triple-Negative Breast Cancer in African-American Women: A Multifaceted Affair between Obesity, Biology, and Socioeconomic Determinants. Cancers (Basel) 2018;10:E514. [PMID: 30558195 DOI: 10.3390/cancers10120514] [Cited by in Crossref: 49] [Cited by in F6Publishing: 33] [Article Influence: 16.3] [Reference Citation Analysis]
299 Schoonen PM, Kok YP, Wierenga E, Bakker B, Foijer F, Spierings DCJ, van Vugt MATM. Premature mitotic entry induced by ATR inhibition potentiates olaparib inhibition-mediated genomic instability, inflammatory signaling, and cytotoxicity in BRCA2-deficient cancer cells. Mol Oncol 2019;13:2422-40. [PMID: 31529615 DOI: 10.1002/1878-0261.12573] [Cited by in Crossref: 24] [Cited by in F6Publishing: 20] [Article Influence: 12.0] [Reference Citation Analysis]
300 Gonzalez-Angulo AM, Timms KM, Liu S, Chen H, Litton JK, Potter J, Lanchbury JS, Stemke-Hale K, Hennessy BT, Arun BK. Incidence and outcome of BRCA mutations in unselected patients with triple receptor-negative breast cancer. Clin Cancer Res. 2011;17:1082-1089. [PMID: 21233401 DOI: 10.1158/1078-0432.ccr-10-2560] [Cited by in Crossref: 345] [Cited by in F6Publishing: 196] [Article Influence: 34.5] [Reference Citation Analysis]
301 Abramson VG, Mayer IA. Molecular Heterogeneity of Triple Negative Breast Cancer. Curr Breast Cancer Rep 2014;6:154-8. [PMID: 25419441 DOI: 10.1007/s12609-014-0152-1] [Cited by in Crossref: 34] [Cited by in F6Publishing: 32] [Article Influence: 4.9] [Reference Citation Analysis]
302 Quist J, Mirza H, Cheang MCU, Telli ML, O'Shaughnessy JA, Lord CJ, Tutt ANJ, Grigoriadis A. A Four-gene Decision Tree Signature Classification of Triple-negative Breast Cancer: Implications for Targeted Therapeutics. Mol Cancer Ther 2019;18:204-12. [PMID: 30305342 DOI: 10.1158/1535-7163.MCT-18-0243] [Cited by in Crossref: 10] [Cited by in F6Publishing: 7] [Article Influence: 3.3] [Reference Citation Analysis]
303 Wolf DM, Yau C, Sanil A, Glas A, Petricoin E, Wulfkuhle J, Severson TM, Linn S, Brown-Swigart L, Hirst G, Buxton M, DeMichele A, Hylton N, Symmans F, Yee D, Paoloni M, Esserman L, Berry D, Rugo H, Olopade O, van 't Veer L. DNA repair deficiency biomarkers and the 70-gene ultra-high risk signature as predictors of veliparib/carboplatin response in the I-SPY 2 breast cancer trial. NPJ Breast Cancer 2017;3:31. [PMID: 28948212 DOI: 10.1038/s41523-017-0025-7] [Cited by in Crossref: 38] [Cited by in F6Publishing: 32] [Article Influence: 9.5] [Reference Citation Analysis]
304 Minchom A, Aversa C, Lopez J. Dancing with the DNA damage response: next-generation anti-cancer therapeutic strategies. Ther Adv Med Oncol 2018;10:1758835918786658. [PMID: 30023007 DOI: 10.1177/1758835918786658] [Cited by in Crossref: 65] [Cited by in F6Publishing: 54] [Article Influence: 21.7] [Reference Citation Analysis]
305 Yarchoan M, Myzak MC, Johnson BA 3rd, De Jesus-Acosta A, Le DT, Jaffee EM, Azad NS, Donehower RC, Zheng L, Oberstein PE, Fine RL, Laheru DA, Goggins M. Olaparib in combination with irinotecan, cisplatin, and mitomycin C in patients with advanced pancreatic cancer. Oncotarget 2017;8:44073-81. [PMID: 28454122 DOI: 10.18632/oncotarget.17237] [Cited by in Crossref: 34] [Cited by in F6Publishing: 33] [Article Influence: 11.3] [Reference Citation Analysis]
306 Buchtel KM, Vogel Postula KJ, Weiss S, Williams C, Pineda M, Weissman SM. FDA Approval of PARP Inhibitors and the Impact on Genetic Counseling and Genetic Testing Practices. J Genet Couns 2018;27:131-9. [PMID: 28780754 DOI: 10.1007/s10897-017-0130-7] [Cited by in Crossref: 15] [Cited by in F6Publishing: 10] [Article Influence: 3.8] [Reference Citation Analysis]
307 Stordal B, Timms K, Farrelly A, Gallagher D, Busschots S, Renaud M, Thery J, Williams D, Potter J, Tran T, Korpanty G, Cremona M, Carey M, Li J, Li Y, Aslan O, O'Leary JJ, Mills GB, Hennessy BT. BRCA1/2 mutation analysis in 41 ovarian cell lines reveals only one functionally deleterious BRCA1 mutation. Mol Oncol 2013;7:567-79. [PMID: 23415752 DOI: 10.1016/j.molonc.2012.12.007] [Cited by in Crossref: 84] [Cited by in F6Publishing: 79] [Article Influence: 10.5] [Reference Citation Analysis]
308 Zhong X, Dong Z, Dong H, Li J, Peng Z, Deng L, Zhu X, Sun Y, Lu X, Shen F, Su X, Zhang L, Gu Y, Zheng H. Prevalence and Prognostic Role of BRCA1/2 Variants in Unselected Chinese Breast Cancer Patients. PLoS One 2016;11:e0156789. [PMID: 27257965 DOI: 10.1371/journal.pone.0156789] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 2.6] [Reference Citation Analysis]
309 Wang J, Zhang Y, Yuan L, Ren L, Zhang Y, Qi X. Comparative efficacy, safety, and acceptability of single-agent poly (ADP-ribose) polymerase (PARP) inhibitors in BRCA-mutated HER2-negative metastatic or advanced breast cancer: a network meta-analysis. Aging (Albany NY) 2020;13:450-9. [PMID: 33257598 DOI: 10.18632/aging.202152] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
310 Shuen AY, Foulkes WD. Inherited mutations in breast cancer genes--risk and response. J Mammary Gland Biol Neoplasia. 2011;16:3-15. [PMID: 21461995 DOI: 10.1007/s10911-011-9213-5] [Cited by in Crossref: 48] [Cited by in F6Publishing: 31] [Article Influence: 4.8] [Reference Citation Analysis]
311 Abramson VG, Lehmann BD, Ballinger TJ, Pietenpol JA. Subtyping of triple-negative breast cancer: implications for therapy. Cancer. 2015;121:8-16. [PMID: 25043972 DOI: 10.1002/cncr.28914] [Cited by in Crossref: 169] [Cited by in F6Publishing: 165] [Article Influence: 24.1] [Reference Citation Analysis]
312 Dréan A, Williamson CT, Brough R, Brandsma I, Menon M, Konde A, Garcia-Murillas I, Pemberton HN, Frankum J, Rafiq R, Badham N, Campbell J, Gulati A, Turner NC, Pettitt SJ, Ashworth A, Lord CJ. Modeling Therapy Resistance in BRCA1/2-Mutant Cancers. Mol Cancer Ther 2017;16:2022-34. [PMID: 28619759 DOI: 10.1158/1535-7163.MCT-17-0098] [Cited by in Crossref: 39] [Cited by in F6Publishing: 21] [Article Influence: 9.8] [Reference Citation Analysis]
313 Lee JM, Peer CJ, Yu M, Amable L, Gordon N, Annunziata CM, Houston N, Goey AK, Sissung TM, Parker B, Minasian L, Chiou VL, Murphy RF, Widemann BC, Figg WD, Kohn EC. Sequence-Specific Pharmacokinetic and Pharmacodynamic Phase I/Ib Study of Olaparib Tablets and Carboplatin in Women's Cancer. Clin Cancer Res 2017;23:1397-406. [PMID: 27663600 DOI: 10.1158/1078-0432.CCR-16-1546] [Cited by in Crossref: 25] [Cited by in F6Publishing: 15] [Article Influence: 5.0] [Reference Citation Analysis]
314 Dale Rein I, Solberg Landsverk K, Micci F, Patzke S, Stokke T. Replication-induced DNA damage after PARP inhibition causes G2 delay, and cell line-dependent apoptosis, necrosis and multinucleation. Cell Cycle. 2015;14:3248-3260. [PMID: 26312527 DOI: 10.1080/15384101.2015.1085137] [Cited by in Crossref: 30] [Cited by in F6Publishing: 26] [Article Influence: 6.0] [Reference Citation Analysis]
315 Ullal AV, Reiner T, Yang KS, Gorbatov R, Min C, Issadore D, Lee H, Weissleder R. Nanoparticle-mediated measurement of target-drug binding in cancer cells. ACS Nano 2011;5:9216-24. [PMID: 21962084 DOI: 10.1021/nn203450p] [Cited by in Crossref: 17] [Cited by in F6Publishing: 13] [Article Influence: 1.7] [Reference Citation Analysis]
316 Evans DGR, van Veen EM, Byers HJ, Wallace AJ, Ellingford JM, Beaman G, Santoyo-Lopez J, Aitman TJ, Eccles DM, Lalloo FI, Smith MJ, Newman WG. A Dominantly Inherited 5' UTR Variant Causing Methylation-Associated Silencing of BRCA1 as a Cause of Breast and Ovarian Cancer. Am J Hum Genet 2018;103:213-20. [PMID: 30075112 DOI: 10.1016/j.ajhg.2018.07.002] [Cited by in Crossref: 35] [Cited by in F6Publishing: 27] [Article Influence: 17.5] [Reference Citation Analysis]
317 Dedes KJ, Wilkerson PM, Wetterskog D, Weigelt B, Ashworth A, Reis-Filho JS. Synthetic lethality of PARP inhibition in cancers lacking BRCA1 and BRCA2 mutations. Cell Cycle. 2011;10:1192-1199. [PMID: 21487248 DOI: 10.4161/cc.10.8.15273] [Cited by in Crossref: 107] [Cited by in F6Publishing: 93] [Article Influence: 10.7] [Reference Citation Analysis]
318 Capoluongo E. BRCA to the future: towards best testing practice in the era of personalised healthcare. Eur J Hum Genet 2016;24 Suppl 1:S1-2. [PMID: 27514838 DOI: 10.1038/ejhg.2016.92] [Cited by in Crossref: 10] [Cited by in F6Publishing: 7] [Article Influence: 3.3] [Reference Citation Analysis]
319 Hirshfield KM, Tolkunov D, Zhong H, Ali SM, Stein MN, Murphy S, Vig H, Vazquez A, Glod J, Moss RA, Belyi V, Chan CS, Chen S, Goodell L, Foran D, Yelensky R, Palma NA, Sun JX, Miller VA, Stephens PJ, Ross JS, Kaufman H, Poplin E, Mehnert J, Tan AR, Bertino JR, Aisner J, DiPaola RS, Rodriguez-Rodriguez L, Ganesan S. Clinical Actionability of Comprehensive Genomic Profiling for Management of Rare or Refractory Cancers. Oncologist 2016;21:1315-25. [PMID: 27566247 DOI: 10.1634/theoncologist.2016-0049] [Cited by in Crossref: 34] [Cited by in F6Publishing: 30] [Article Influence: 6.8] [Reference Citation Analysis]
320 Fujii T, Kogawa T, Dong W, Sahin AA, Moulder S, Litton JK, Tripathy D, Iwamoto T, Hunt KK, Pusztai L, Lim B, Shen Y, Ueno NT. Revisiting the definition of estrogen receptor positivity in HER2-negative primary breast cancer. Ann Oncol 2017;28:2420-8. [PMID: 28961844 DOI: 10.1093/annonc/mdx397] [Cited by in Crossref: 44] [Cited by in F6Publishing: 37] [Article Influence: 14.7] [Reference Citation Analysis]
321 Pölsler L, Fiegl H, Wimmer K, Oberaigner W, Amberger A, Traunfellner P, Morscher RJ, Weber I, Fauth C, Wernstedt A, Sperner-Unterweger B, Oberguggenberger A, Hubalek M, Marth C, Zschocke J. High prevalence of BRCA1 stop mutation c.4183C>T in the Tyrolean population: implications for genetic testing. Eur J Hum Genet 2016;24:258-62. [PMID: 26014432 DOI: 10.1038/ejhg.2015.108] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
322 Sariyar M, Suhr S, Schlünder I. How Sensitive Is Genetic Data? Biopreserv Biobank 2017;15:494-501. [PMID: 28880588 DOI: 10.1089/bio.2017.0033] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.8] [Reference Citation Analysis]
323 Li J, Wen WX, Eklund M, Kvist A, Eriksson M, Christensen HN, Torstensson A, Bajalica-Lagercrantz S, Dunning AM, Decker B, Allen J, Luccarini C, Pooley K, Simard J, Dorling L, Easton DF, Teo SH, Hall P, Borg Å, Grönberg H, Czene K. Prevalence of BRCA1 and BRCA2 pathogenic variants in a large, unselected breast cancer cohort. Int J Cancer 2019;144:1195-204. [PMID: 30175445 DOI: 10.1002/ijc.31841] [Cited by in Crossref: 15] [Cited by in F6Publishing: 11] [Article Influence: 5.0] [Reference Citation Analysis]
324 Higgins MJ, Baselga J. Breast cancer in 2010: Novel targets and therapies for a personalized approach. Nat Rev Clin Oncol. 2011;8:65-66. [PMID: 21278769 DOI: 10.1038/nrclinonc.2010.217] [Cited by in Crossref: 17] [Cited by in F6Publishing: 16] [Article Influence: 1.7] [Reference Citation Analysis]
325 Liu Q, Xiao Q, Sun Z, Wang B, Wang L, Wang N, Wang K, Song C, Yang Q. Exosome component 1 cleaves single-stranded DNA and sensitizes human kidney renal clear cell carcinoma cells to poly(ADP-ribose) polymerase inhibitor. Elife 2021;10:e69454. [PMID: 34159897 DOI: 10.7554/eLife.69454] [Reference Citation Analysis]
326 Wan Q, Hu L, Ouyang T, Li J, Wang T, Fan Z, Fan T, Lin B, Xu Y, Xie Y. Clinical phenotypes combined with saturation genome editing identifying the pathogenicity of BRCA1 variants of uncertain significance in breast cancer. Fam Cancer 2021;20:85-95. [PMID: 32803532 DOI: 10.1007/s10689-020-00202-4] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
327 Basu NN, Barr L, Ross GL, Evans DG. Contralateral risk-reducing mastectomy: review of risk factors and risk-reducing strategies. Int J Surg Oncol 2015;2015:901046. [PMID: 25692038 DOI: 10.1155/2015/901046] [Cited by in Crossref: 6] [Cited by in F6Publishing: 10] [Article Influence: 1.0] [Reference Citation Analysis]
328 Song H, Luo Q, Deng X, Ji C, Li D, Munankarmy A, Jian W, Zhao J, Fang L. VGLL4 interacts with STAT3 to function as a tumor suppressor in triple-negative breast cancer. Exp Mol Med 2019;51:1-13. [PMID: 31748508 DOI: 10.1038/s12276-019-0338-8] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
329 Thumser-Henner P, Nytko KJ, Rohrer Bley C. Mutations of BRCA2 in canine mammary tumors and their targeting potential in clinical therapy. BMC Vet Res 2020;16:30. [PMID: 32005245 DOI: 10.1186/s12917-020-2247-4] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 6.0] [Reference Citation Analysis]
330 OʼSullivan Coyne G, Chen A, Kummar S. Delivering on the promise: poly ADP ribose polymerase inhibition as targeted anticancer therapy. Curr Opin Oncol 2015;27:475-81. [PMID: 26447876 DOI: 10.1097/CCO.0000000000000238] [Cited by in Crossref: 15] [Cited by in F6Publishing: 7] [Article Influence: 3.0] [Reference Citation Analysis]
331 Mukai T, Fujita S, Morita Y. Tankyrase (PARP5) Inhibition Induces Bone Loss through Accumulation of Its Substrate SH3BP2. Cells 2019;8:E195. [PMID: 30813388 DOI: 10.3390/cells8020195] [Cited by in Crossref: 10] [Cited by in F6Publishing: 7] [Article Influence: 5.0] [Reference Citation Analysis]
332 Mateo J, Porta N, Bianchini D, McGovern U, Elliott T, Jones R, Syndikus I, Ralph C, Jain S, Varughese M, Parikh O, Crabb S, Robinson A, McLaren D, Birtle A, Tanguay J, Miranda S, Figueiredo I, Seed G, Bertan C, Flohr P, Ebbs B, Rescigno P, Fowler G, Ferreira A, Riisnaes R, Pereira R, Curcean A, Chandler R, Clarke M, Gurel B, Crespo M, Nava Rodrigues D, Sandhu S, Espinasse A, Chatfield P, Tunariu N, Yuan W, Hall E, Carreira S, de Bono JS. Olaparib in patients with metastatic castration-resistant prostate cancer with DNA repair gene aberrations (TOPARP-B): a multicentre, open-label, randomised, phase 2 trial. Lancet Oncol 2020;21:162-74. [PMID: 31806540 DOI: 10.1016/S1470-2045(19)30684-9] [Cited by in Crossref: 178] [Cited by in F6Publishing: 76] [Article Influence: 89.0] [Reference Citation Analysis]
333 Stoppa-Lyonnet D. The biological effects and clinical implications of BRCA mutations: where do we go from here? Eur J Hum Genet 2016;24 Suppl 1:S3-9. [PMID: 27514841 DOI: 10.1038/ejhg.2016.93] [Cited by in Crossref: 38] [Cited by in F6Publishing: 32] [Article Influence: 9.5] [Reference Citation Analysis]
334 Bodily WR, Shirts BH, Walsh T, Gulsuner S, King MC, Parker A, Roosan M, Piccolo SR. Effects of germline and somatic events in candidate BRCA-like genes on breast-tumor signatures. PLoS One 2020;15:e0239197. [PMID: 32997669 DOI: 10.1371/journal.pone.0239197] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 4.0] [Reference Citation Analysis]
335 Horiuchi D, Kusdra L, Huskey NE, Chandriani S, Lenburg ME, Gonzalez-Angulo AM, Creasman KJ, Bazarov AV, Smyth JW, Davis SE, Yaswen P, Mills GB, Esserman LJ, Goga A. MYC pathway activation in triple-negative breast cancer is synthetic lethal with CDK inhibition. J Exp Med 2012;209:679-96. [PMID: 22430491 DOI: 10.1084/jem.20111512] [Cited by in Crossref: 222] [Cited by in F6Publishing: 196] [Article Influence: 24.7] [Reference Citation Analysis]
336 Christenson ES, Antonarakis ES. PARP inhibitors for homologous recombination-deficient prostate cancer. Expert Opin Emerg Drugs 2018;23:123-33. [PMID: 29595348 DOI: 10.1080/14728214.2018.1459563] [Cited by in Crossref: 16] [Cited by in F6Publishing: 15] [Article Influence: 5.3] [Reference Citation Analysis]
337 Ben Ayed-Guerfali D, Ben Kridis-Rejab W, Ammous-Boukhris N, Ayadi W, Charfi S, Khanfir A, Sellami-Boudawara T, Frikha M, Daoud J, Mokdad-Gargouri R. Novel and recurrent BRCA1/BRCA2 germline mutations in patients with breast/ovarian cancer: a series from the south of Tunisia. J Transl Med 2021;19:108. [PMID: 33726785 DOI: 10.1186/s12967-021-02772-y] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
338 Stecklein SR, Sharma P. Tumor homologous recombination deficiency assays: another step closer to clinical application? Breast Cancer Res 2014;16:409. [PMID: 25928813 DOI: 10.1186/s13058-014-0409-7] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 0.9] [Reference Citation Analysis]
339 Athie A, Arce-Gallego S, Gonzalez M, Morales-Barrera R, Suarez C, Casals Galobart T, Hernandez Viedma G, Carles J, Mateo J. Targeting DNA Repair Defects for Precision Medicine in Prostate Cancer. Curr Oncol Rep 2019;21:42. [PMID: 30919167 DOI: 10.1007/s11912-019-0790-6] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 5.5] [Reference Citation Analysis]
340 Yip K, Alonzi R. Carbogen gas and radiotherapy outcomes in prostate cancer. Ther Adv Urol 2013;5:25-34. [PMID: 23372608 DOI: 10.1177/1756287212452195] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 0.6] [Reference Citation Analysis]
341 Deshpande R, Asiedu MK, Klebig M, Sutor S, Kuzmin E, Nelson J, Piotrowski J, Shin SH, Yoshida M, Costanzo M, Boone C, Wigle DA, Myers CL. A comparative genomic approach for identifying synthetic lethal interactions in human cancer. Cancer Res 2013;73:6128-36. [PMID: 23980094 DOI: 10.1158/0008-5472.CAN-12-3956] [Cited by in Crossref: 42] [Cited by in F6Publishing: 26] [Article Influence: 5.3] [Reference Citation Analysis]
342 Klauke ML, Hoogerbrugge N, Budczies J, Bult P, Prinzler J, Radke C, van Krieken JH, Dietel M, Denkert C, Müller BM. Higher cytoplasmic and nuclear poly(ADP-ribose) polymerase expression in familial than in sporadic breast cancer. Virchows Arch 2012;461:425-31. [PMID: 22968923 DOI: 10.1007/s00428-012-1311-2] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.3] [Reference Citation Analysis]
343 Wang F, Li YC, Liu LP, Zhang HM, Tong S. Circulating Tumor Cells and Tumor Stem Cells Detection in the Peripheral Blood Mononuclear Cells of Breast Cancer. J Clin Lab Anal 2016;30:616-22. [PMID: 26892105 DOI: 10.1002/jcla.21911] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 1.2] [Reference Citation Analysis]
344 Vaklavas C, Forero-Torres A. How do I treat "triple-negative" disease. Curr Treat Options Oncol 2011;12:369-88. [PMID: 22048876 DOI: 10.1007/s11864-011-0168-y] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 0.9] [Reference Citation Analysis]
345 Boonen RACM, Vreeswijk MPG, van Attikum H. Functional Characterization of PALB2 Variants of Uncertain Significance: Toward Cancer Risk and Therapy Response Prediction. Front Mol Biosci 2020;7:169. [PMID: 33195396 DOI: 10.3389/fmolb.2020.00169] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
346 Cheng H, Zhang Z, Borczuk A, Powell CA, Balajee AS, Lieberman HB, Halmos B. PARP inhibition selectively increases sensitivity to cisplatin in ERCC1-low non-small cell lung cancer cells. Carcinogenesis 2013;34:739-49. [PMID: 23275151 DOI: 10.1093/carcin/bgs393] [Cited by in Crossref: 60] [Cited by in F6Publishing: 55] [Article Influence: 6.7] [Reference Citation Analysis]
347 Knittel G, Rehkämper T, Korovkina D, Liedgens P, Fritz C, Torgovnick A, Al-Baldawi Y, Al-Maarri M, Cun Y, Fedorchenko O, Riabinska A, Beleggia F, Nguyen PH, Wunderlich FT, Ortmann M, Montesinos-Rongen M, Tausch E, Stilgenbauer S, P Frenzel L, Herling M, Herling C, Bahlo J, Hallek M, Peifer M, Buettner R, Persigehl T, Reinhardt HC. Two mouse models reveal an actionable PARP1 dependence in aggressive chronic lymphocytic leukemia. Nat Commun 2017;8:153. [PMID: 28751718 DOI: 10.1038/s41467-017-00210-6] [Cited by in Crossref: 20] [Cited by in F6Publishing: 17] [Article Influence: 5.0] [Reference Citation Analysis]
348 Bouwman P, Jonkers J. The effects of deregulated DNA damage signalling on cancer chemotherapy response and resistance. Nat Rev Cancer 2012;12:587-98. [PMID: 22918414 DOI: 10.1038/nrc3342] [Cited by in Crossref: 352] [Cited by in F6Publishing: 320] [Article Influence: 39.1] [Reference Citation Analysis]
349 Tung N, Miron A, Schnitt SJ, Gautam S, Fetten K, Kaplan J, Yassin Y, Buraimoh A, Kim JY, Szász AM, Tian R, Wang ZC, Collins LC, Brock J, Krag K, Legare RD, Sgroi D, Ryan PD, Silver DP, Garber JE, Richardson AL. Prevalence and predictors of loss of wild type BRCA1 in estrogen receptor positive and negative BRCA1-associated breast cancers. Breast Cancer Res 2010;12:R95. [PMID: 21080930 DOI: 10.1186/bcr2776] [Cited by in Crossref: 27] [Cited by in F6Publishing: 23] [Article Influence: 2.5] [Reference Citation Analysis]
350 Ma W, Halweg CJ, Menendez D, Resnick MA. Differential effects of poly(ADP-ribose) polymerase inhibition on DNA break repair in human cells are revealed with Epstein-Barr virus. Proc Natl Acad Sci U S A 2012;109:6590-5. [PMID: 22493268 DOI: 10.1073/pnas.1118078109] [Cited by in Crossref: 28] [Cited by in F6Publishing: 26] [Article Influence: 3.1] [Reference Citation Analysis]
351 Curtin NJ. DNA repair dysregulation from cancer driver to therapeutic target. Nat Rev Cancer 2012;12:801-17. [PMID: 23175119 DOI: 10.1038/nrc3399] [Cited by in Crossref: 593] [Cited by in F6Publishing: 516] [Article Influence: 74.1] [Reference Citation Analysis]
352 Gonzalo S. Novel roles of 1α,25(OH)2D3 on DNA repair provide new strategies for breast cancer treatment. J Steroid Biochem Mol Biol 2014;144 Pt A:59-64. [PMID: 24080249 DOI: 10.1016/j.jsbmb.2013.09.009] [Cited by in Crossref: 16] [Cited by in F6Publishing: 12] [Article Influence: 2.0] [Reference Citation Analysis]
353 Sistigu A, Manic G, Obrist F, Vitale I. Trial watch - inhibiting PARP enzymes for anticancer therapy. Mol Cell Oncol 2016;3:e1053594. [PMID: 27308587 DOI: 10.1080/23723556.2015.1053594] [Cited by in Crossref: 17] [Cited by in F6Publishing: 16] [Article Influence: 2.8] [Reference Citation Analysis]
354 Li CJ, Tzeng YT, Chiu YH, Lin HY, Hou MF, Chu PY. Pathogenesis and Potential Therapeutic Targets for Triple-Negative Breast Cancer. Cancers (Basel) 2021;13:2978. [PMID: 34198652 DOI: 10.3390/cancers13122978] [Reference Citation Analysis]
355 Livraghi L, Garber JE. PARP inhibitors in the management of breast cancer: current data and future prospects. BMC Med 2015;13:188. [PMID: 26268938 DOI: 10.1186/s12916-015-0425-1] [Cited by in Crossref: 160] [Cited by in F6Publishing: 137] [Article Influence: 26.7] [Reference Citation Analysis]
356 Abugattas J, Llacuachaqui M, Allende YS, Velásquez AA, Velarde R, Cotrina J, Garcés M, León M, Calderón G, de la Cruz M, Mora P, Royer R, Herzog J, Weitzel JN, Narod SA. Prevalence of BRCA1 and BRCA2 mutations in unselected breast cancer patients from Peru. Clin Genet 2015;88:371-5. [PMID: 25256238 DOI: 10.1111/cge.12505] [Cited by in Crossref: 33] [Cited by in F6Publishing: 31] [Article Influence: 4.7] [Reference Citation Analysis]
357 Eccles DM, Mitchell G, Monteiro AN, Schmutzler R, Couch FJ, Spurdle AB, Gómez-García EB; ENIGMA Clinical Working Group. BRCA1 and BRCA2 genetic testing-pitfalls and recommendations for managing variants of uncertain clinical significance. Ann Oncol 2015;26:2057-65. [PMID: 26153499 DOI: 10.1093/annonc/mdv278] [Cited by in Crossref: 119] [Cited by in F6Publishing: 95] [Article Influence: 19.8] [Reference Citation Analysis]
358 Mintz RL, Lao YH, Chi CW, He S, Li M, Quek CH, Shao D, Chen B, Han J, Wang S, Leong KW. CRISPR/Cas9-mediated mutagenesis to validate the synergy between PARP1 inhibition and chemotherapy in BRCA1-mutated breast cancer cells. Bioeng Transl Med 2020;5:e10152. [PMID: 31989039 DOI: 10.1002/btm2.10152] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 8.0] [Reference Citation Analysis]
359 Song WH, Kim SH, Joung JY, Park WS, Seo HK, Chung J, Lee KH. Prostate Cancer in a Patient with a Family History of BRCA Mutation: a Case Report and Literature Review. J Korean Med Sci 2017;32:377-81. [PMID: 28049253 DOI: 10.3346/jkms.2017.32.2.377] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 1.8] [Reference Citation Analysis]
360 Turk AA, Wisinski KB. PARP inhibitors in breast cancer: Bringing synthetic lethality to the bedside. Cancer 2018;124:2498-506. [PMID: 29660759 DOI: 10.1002/cncr.31307] [Cited by in Crossref: 34] [Cited by in F6Publishing: 26] [Article Influence: 11.3] [Reference Citation Analysis]
361 Severson TM, Wolf DM, Yau C, Peeters J, Wehkam D, Schouten PC, Chin SF, Majewski IJ, Michaut M, Bosma A, Pereira B, Bismeijer T, Wessels L, Caldas C, Bernards R, Simon IM, Glas AM, Linn S, van 't Veer L. The BRCA1ness signature is associated significantly with response to PARP inhibitor treatment versus control in the I-SPY 2 randomized neoadjuvant setting. Breast Cancer Res 2017;19:99. [PMID: 28851423 DOI: 10.1186/s13058-017-0861-2] [Cited by in Crossref: 29] [Cited by in F6Publishing: 26] [Article Influence: 7.3] [Reference Citation Analysis]
362 Velagapudi UK, Langelier MF, Delgado-Martin C, Diolaiti ME, Bakker S, Ashworth A, Patel BA, Shao X, Pascal JM, Talele TT. Design and Synthesis of Poly(ADP-ribose) Polymerase Inhibitors: Impact of Adenosine Pocket-Binding Motif Appendage to the 3-Oxo-2,3-dihydrobenzofuran-7-carboxamide on Potency and Selectivity. J Med Chem 2019;62:5330-57. [PMID: 31042381 DOI: 10.1021/acs.jmedchem.8b01709] [Cited by in Crossref: 11] [Cited by in F6Publishing: 7] [Article Influence: 5.5] [Reference Citation Analysis]
363 Jacob SL, Kiedrowski LA, Chae YK. The dynamic landscape of BRCA1 reversion mutations from indel to SNV in a patient with ovarian cancer treated with PARP-inhibitors and immunotherapy. Heliyon 2020;6:e03841. [PMID: 32420470 DOI: 10.1016/j.heliyon.2020.e03841] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
364 Salem ME, Battaglin F, Goldberg RM, Puccini A, Shields AF, Arguello D, Korn WM, Marshall JL, Grothey A, Lenz HJ. Molecular Analyses of Left- and Right-Sided Tumors in Adolescents and Young Adults with Colorectal Cancer. Oncologist 2020;25:404-13. [PMID: 31848314 DOI: 10.1634/theoncologist.2019-0552] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 4.5] [Reference Citation Analysis]
365 Schiewer MJ, Goodwin JF, Han S, Brenner JC, Augello MA, Dean JL, Liu F, Planck JL, Ravindranathan P, Chinnaiyan AM, McCue P, Gomella LG, Raj GV, Dicker AP, Brody JR, Pascal JM, Centenera MM, Butler LM, Tilley WD, Feng FY, Knudsen KE. Dual roles of PARP-1 promote cancer growth and progression. Cancer Discov 2012;2:1134-49. [PMID: 22993403 DOI: 10.1158/2159-8290.CD-12-0120] [Cited by in Crossref: 204] [Cited by in F6Publishing: 139] [Article Influence: 22.7] [Reference Citation Analysis]
366 Shao N, Shi Y, Yu L, Ye R, Shan Z, Zhang Z, Zhang Y, Lin Y. Prospect for Application of PARP Inhibitor in Patients with HER2 Negative Breast Cancer. Int J Biol Sci 2019;15:962-72. [PMID: 31182917 DOI: 10.7150/ijbs.30721] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 3.5] [Reference Citation Analysis]
367 Steenbruggen TG, van Ramshorst MS, Kok M, Linn SC, Smorenburg CH, Sonke GS. Neoadjuvant Therapy for Breast Cancer: Established Concepts and Emerging Strategies. Drugs 2017;77:1313-36. [PMID: 28616845 DOI: 10.1007/s40265-017-0774-5] [Cited by in Crossref: 22] [Cited by in F6Publishing: 20] [Article Influence: 7.3] [Reference Citation Analysis]
368 Marquard AM, Eklund AC, Joshi T, Krzystanek M, Favero F, Wang ZC, Richardson AL, Silver DP, Szallasi Z, Birkbak NJ. Pan-cancer analysis of genomic scar signatures associated with homologous recombination deficiency suggests novel indications for existing cancer drugs. Biomark Res 2015;3:9. [PMID: 26015868 DOI: 10.1186/s40364-015-0033-4] [Cited by in Crossref: 100] [Cited by in F6Publishing: 81] [Article Influence: 16.7] [Reference Citation Analysis]
369 Adams DJ. The Valley of Death in anticancer drug development: a reassessment. Trends Pharmacol Sci 2012;33:173-80. [PMID: 22410081 DOI: 10.1016/j.tips.2012.02.001] [Cited by in Crossref: 47] [Cited by in F6Publishing: 37] [Article Influence: 5.2] [Reference Citation Analysis]
370 Takaoka M, Miki Y. BRCA1 gene: function and deficiency. Int J Clin Oncol 2018;23:36-44. [PMID: 28884397 DOI: 10.1007/s10147-017-1182-2] [Cited by in Crossref: 42] [Cited by in F6Publishing: 37] [Article Influence: 10.5] [Reference Citation Analysis]
371 Vaidyanathan A, Sawers L, Gannon AL, Chakravarty P, Scott AL, Bray SE, Ferguson MJ, Smith G. ABCB1 (MDR1) induction defines a common resistance mechanism in paclitaxel- and olaparib-resistant ovarian cancer cells. Br J Cancer 2016;115:431-41. [PMID: 27415012 DOI: 10.1038/bjc.2016.203] [Cited by in Crossref: 120] [Cited by in F6Publishing: 111] [Article Influence: 24.0] [Reference Citation Analysis]
372 Jang NY, Kim DH, Cho BJ, Choi EJ, Lee JS, Wu HG, Chie EK, Kim IA. Radiosensitization with combined use of olaparib and PI-103 in triple-negative breast cancer. BMC Cancer 2015;15:89. [PMID: 25884663 DOI: 10.1186/s12885-015-1090-7] [Cited by in Crossref: 34] [Cited by in F6Publishing: 29] [Article Influence: 5.7] [Reference Citation Analysis]
373 Teyssonneau D, Margot H, Cabart M, Anonnay M, Sargos P, Vuong NS, Soubeyran I, Sevenet N, Roubaud G. Prostate cancer and PARP inhibitors: progress and challenges. J Hematol Oncol 2021;14:51. [PMID: 33781305 DOI: 10.1186/s13045-021-01061-x] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 3.0] [Reference Citation Analysis]
374 Visvader JE. Cells of origin in cancer. Nature. 2011;469:314-322. [PMID: 21248838 DOI: 10.1038/nature09781] [Cited by in Crossref: 923] [Cited by in F6Publishing: 807] [Article Influence: 92.3] [Reference Citation Analysis]
375 Owonikoko TK, Zhang G, Deng X, Rossi MR, Switchenko JM, Doho GH, Chen Z, Kim S, Strychor S, Christner SM, Beumer J, Li C, Yue P, Chen A, Sica GL, Ramalingam SS, Kowalski J, Khuri FR, Sun SY. Poly (ADP) ribose polymerase enzyme inhibitor, veliparib, potentiates chemotherapy and radiation in vitro and in vivo in small cell lung cancer. Cancer Med 2014;3:1579-94. [PMID: 25124282 DOI: 10.1002/cam4.317] [Cited by in Crossref: 48] [Cited by in F6Publishing: 43] [Article Influence: 6.9] [Reference Citation Analysis]
376 Cerrato A, Morra F, Di Domenico I, Celetti A. NSCLC Mutated Isoforms of CCDC6 Affect the Intracellular Distribution of the Wild Type Protein Promoting Cisplatinum Resistance and PARP Inhibitors Sensitivity in Lung Cancer Cells. Cancers (Basel) 2019;12:E44. [PMID: 31877762 DOI: 10.3390/cancers12010044] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
377 Park SH, Noh SJ, Kim KM, Bae JS, Kwon KS, Jung SH, Kim JR, Lee H, Chung MJ, Moon WS, Kang MJ, Jang KY. Expression of DNA Damage Response Molecules PARP1, γH2AX, BRCA1, and BRCA2 Predicts Poor Survival of Breast Carcinoma Patients. Transl Oncol 2015;8:239-49. [PMID: 26310369 DOI: 10.1016/j.tranon.2015.04.004] [Cited by in Crossref: 14] [Cited by in F6Publishing: 16] [Article Influence: 2.3] [Reference Citation Analysis]
378 Weil MK, Chen AP. PARP inhibitor treatment in ovarian and breast cancer. Curr Probl Cancer. 2011;35:7-50. [PMID: 21300207 DOI: 10.1016/j.currproblcancer.2010.12.002] [Cited by in Crossref: 79] [Cited by in F6Publishing: 70] [Article Influence: 7.9] [Reference Citation Analysis]
379 Chaudhary LN. Early stage triple negative breast cancer: Management and future directions. Semin Oncol 2020;47:201-8. [PMID: 32507668 DOI: 10.1053/j.seminoncol.2020.05.006] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
380 Helena JM, Joubert AM, Grobbelaar S, Nolte EM, Nel M, Pepper MS, Coetzee M, Mercier AE. Deoxyribonucleic Acid Damage and Repair: Capitalizing on Our Understanding of the Mechanisms of Maintaining Genomic Integrity for Therapeutic Purposes. Int J Mol Sci 2018;19:E1148. [PMID: 29641431 DOI: 10.3390/ijms19041148] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 3.7] [Reference Citation Analysis]
381 Nightingale H, Pfeffer G, Bargiela D, Horvath R, Chinnery PF. Emerging therapies for mitochondrial disorders. Brain 2016;139:1633-48. [PMID: 27190030 DOI: 10.1093/brain/aww081] [Cited by in Crossref: 38] [Cited by in F6Publishing: 32] [Article Influence: 7.6] [Reference Citation Analysis]
382 Pierce A, McGowan PM, Cotter M, Mullooly M, O'Donovan N, Rani S, O'Driscoll L, Crown J, Duffy MJ. Comparative antiproliferative effects of iniparib and olaparib on a panel of triple-negative and non-triple-negative breast cancer cell lines. Cancer Biol Ther 2013;14:537-45. [PMID: 23760496 DOI: 10.4161/cbt.24349] [Cited by in Crossref: 28] [Cited by in F6Publishing: 24] [Article Influence: 4.0] [Reference Citation Analysis]
383 Hurvitz SA, Gonçalves A, Rugo HS, Lee KH, Fehrenbacher L, Mina LA, Diab S, Blum JL, Chakrabarti J, Elmeliegy M, DeAnnuntis L, Gauthier E, Czibere A, Tudor IC, Quek RGW, Litton JK, Ettl J. Talazoparib in Patients with a Germline BRCA-Mutated Advanced Breast Cancer: Detailed Safety Analyses from the Phase III EMBRACA Trial. Oncologist 2020;25:e439-50. [PMID: 32162822 DOI: 10.1634/theoncologist.2019-0493] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 7.0] [Reference Citation Analysis]
384 Eke I, Makinde AY, Aryankalayil MJ, Ahmed MM, Coleman CN. Comprehensive molecular tumor profiling in radiation oncology: How it could be used for precision medicine. Cancer Lett 2016;382:118-26. [PMID: 26828133 DOI: 10.1016/j.canlet.2016.01.041] [Cited by in Crossref: 10] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
385 Minami CA, Chung DU, Chang HR. Management options in triple-negative breast cancer. Breast Cancer (Auckl) 2011;5:175-99. [PMID: 21863131 DOI: 10.4137/BCBCR.S6562] [Cited by in Crossref: 8] [Cited by in F6Publishing: 16] [Article Influence: 0.8] [Reference Citation Analysis]
386 Beggs AD, Dilworth MP. Surgery in the era of the 'omics revolution. Br J Surg 2015;102:e29-40. [PMID: 25627134 DOI: 10.1002/bjs.9722] [Cited by in Crossref: 7] [Cited by in F6Publishing: 2] [Article Influence: 1.2] [Reference Citation Analysis]
387 Nowsheen S, Cooper T, Bonner JA, LoBuglio AF, Yang ES. HER2 overexpression renders human breast cancers sensitive to PARP inhibition independently of any defect in homologous recombination DNA repair. Cancer Res 2012;72:4796-806. [PMID: 22987487 DOI: 10.1158/0008-5472.CAN-12-1287] [Cited by in Crossref: 40] [Cited by in F6Publishing: 19] [Article Influence: 4.4] [Reference Citation Analysis]
388 Jiang J, Lu Y, Li Z, Li L, Niu D, Xu W, Liu J, Fu L, Zhou Z, Gu Y, Xia F. Ganetespib overcomes resistance to PARP inhibitors in breast cancer by targeting core proteins in the DNA repair machinery. Invest New Drugs 2017;35:251-9. [PMID: 28111726 DOI: 10.1007/s10637-016-0424-x] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 3.0] [Reference Citation Analysis]
389 Wilson RH, Evans TJ, Middleton MR, Molife LR, Spicer J, Dieras V, Roxburgh P, Giordano H, Jaw-Tsai S, Goble S, Plummer R. A phase I study of intravenous and oral rucaparib in combination with chemotherapy in patients with advanced solid tumours. Br J Cancer 2017;116:884-92. [PMID: 28222073 DOI: 10.1038/bjc.2017.36] [Cited by in Crossref: 38] [Cited by in F6Publishing: 33] [Article Influence: 9.5] [Reference Citation Analysis]
390 Kummar S, Chen A, Parchment RE, Kinders RJ, Ji J, Tomaszewski JE, Doroshow JH. Advances in using PARP inhibitors to treat cancer. BMC Med 2012;10:25. [PMID: 22401667 DOI: 10.1186/1741-7015-10-25] [Cited by in Crossref: 95] [Cited by in F6Publishing: 82] [Article Influence: 10.6] [Reference Citation Analysis]
391 Swindall AF, Stanley JA, Yang ES. PARP-1: Friend or Foe of DNA Damage and Repair in Tumorigenesis? Cancers (Basel) 2013;5:943-58. [PMID: 24202328 DOI: 10.3390/cancers5030943] [Cited by in Crossref: 63] [Cited by in F6Publishing: 51] [Article Influence: 7.9] [Reference Citation Analysis]
392 Aronson SJ, Rehm HL. Building the foundation for genomics in precision medicine. Nature 2015;526:336-42. [PMID: 26469044 DOI: 10.1038/nature15816] [Cited by in Crossref: 261] [Cited by in F6Publishing: 178] [Article Influence: 52.2] [Reference Citation Analysis]
393 Dhillon KK, Swisher EM, Taniguchi T. Secondary mutations of BRCA1/2 and drug resistance. Cancer Sci 2011;102:663-9. [PMID: 21205087 DOI: 10.1111/j.1349-7006.2010.01840.x] [Cited by in Crossref: 82] [Cited by in F6Publishing: 72] [Article Influence: 8.2] [Reference Citation Analysis]
394 Chan DA, Giaccia AJ. Harnessing synthetic lethal interactions in anticancer drug discovery. Nat Rev Drug Discov 2011;10:351-64. [PMID: 21532565 DOI: 10.1038/nrd3374] [Cited by in Crossref: 194] [Cited by in F6Publishing: 162] [Article Influence: 19.4] [Reference Citation Analysis]
395 Wu SY, Wang H, Shao ZM, Jiang YZ. Triple-negative breast cancer: new treatment strategies in the era of precision medicine. Sci China Life Sci 2021;64:372-88. [PMID: 32803712 DOI: 10.1007/s11427-020-1714-8] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
396 Zeng Y, Rucki AA, Che X, Zheng L. Shifting paradigm of developing biologics for the treatment of pancreatic adenocarcinoma. J Gastrointest Oncol 2017;8:441-8. [PMID: 28736631 DOI: 10.21037/jgo.2016.10.02] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
397 Sipos O, Tovey H, Quist J, Haider S, Nowinski S, Gazinska P, Kernaghan S, Toms C, Maguire S, Orr N, Linn SC, Owen J, Gillett C, Pinder SE, Bliss JM, Tutt A, Cheang MCU, Grigoriadis A. Assessment of structural chromosomal instability phenotypes as biomarkers of carboplatin response in triple negative breast cancer: the TNT trial. Ann Oncol 2021;32:58-65. [PMID: 33098992 DOI: 10.1016/j.annonc.2020.10.475] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
398 Maeda J, Roybal EJ, Brents CA, Uesaka M, Aizawa Y, Kato TA. Natural and glucosyl flavonoids inhibit poly(ADP-ribose) polymerase activity and induce synthetic lethality in BRCA mutant cells. Oncol Rep 2014;31:551-6. [PMID: 24317580 DOI: 10.3892/or.2013.2902] [Cited by in Crossref: 38] [Cited by in F6Publishing: 28] [Article Influence: 4.8] [Reference Citation Analysis]
399 van Altena AM, van Aarle S, Kiemeney LA, Hoogerbrugge N, Massuger LF, de Hullu JA. Adequacy of family history taking in ovarian cancer patients: a population-based study. Fam Cancer 2012;11:343-9. [PMID: 22388872 DOI: 10.1007/s10689-012-9518-6] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 1.4] [Reference Citation Analysis]
400 O'Reilly EA, Gubbins L, Sharma S, Tully R, Guang MH, Weiner-Gorzel K, McCaffrey J, Harrison M, Furlong F, Kell M, McCann A. The fate of chemoresistance in triple negative breast cancer (TNBC). BBA Clin 2015;3:257-75. [PMID: 26676166 DOI: 10.1016/j.bbacli.2015.03.003] [Cited by in Crossref: 184] [Cited by in F6Publishing: 173] [Article Influence: 30.7] [Reference Citation Analysis]
401 Patel AG, De Lorenzo SB, Flatten KS, Poirier GG, Kaufmann SH. Failure of iniparib to inhibit poly(ADP-Ribose) polymerase in vitro. Clin Cancer Res. 2012;18:1655-1662. [PMID: 22291137 DOI: 10.1158/1078-0432.ccr-11-2890] [Cited by in Crossref: 159] [Cited by in F6Publishing: 76] [Article Influence: 17.7] [Reference Citation Analysis]
402 Peer CJ, Lee JM, Roth J, Rodgers L, Nguyen J, Annunziata CM, Minasian L, Kohn EC, Figg WD. Population pharmacokinetic analyses of the effect of carboplatin pretreatment on olaparib in recurrent or refractory women's cancers. Cancer Chemother Pharmacol 2017;80:165-75. [PMID: 28577239 DOI: 10.1007/s00280-017-3346-1] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
403 Mohan A, Ponnusankar S. Newer therapies for the treatment of metastatic breast cancer: a clinical update. Indian J Pharm Sci 2013;75:251-61. [PMID: 24082340 DOI: 10.4103/0250-474X.117396] [Cited by in Crossref: 13] [Cited by in F6Publishing: 2] [Article Influence: 1.9] [Reference Citation Analysis]
404 Casadei S, Norquist BM, Walsh T, Stray S, Mandell JB, Lee MK, Stamatoyannopoulos JA, King MC. Contribution of inherited mutations in the BRCA2-interacting protein PALB2 to familial breast cancer. Cancer Res. 2011;71:2222-2229. [PMID: 21285249 DOI: 10.1158/0008-5472.can-10-3958] [Cited by in Crossref: 164] [Cited by in F6Publishing: 85] [Article Influence: 16.4] [Reference Citation Analysis]
405 Chalasani P, Livingston R. Differential chemotherapeutic sensitivity for breast tumors with "BRCAness": a review. Oncologist 2013;18:909-16. [PMID: 23881989 DOI: 10.1634/theoncologist.2013-0039] [Cited by in Crossref: 38] [Cited by in F6Publishing: 34] [Article Influence: 4.8] [Reference Citation Analysis]
406 Mehrgou A, Akouchekian M, Hemati S. Investigating of variations in BRCA1 gene in Iranian families with breast cancer. Med J Islam Repub Iran 2018;32:87. [PMID: 30788324 DOI: 10.14196/mjiri.32.87] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
407 Zhu X, Tian T, Ruan M, Rao J, Yang W, Cai X, Sun M, Qin G, Zhao Z, Wu J, Shao Z, Shui R, Hu Z. Expression of DNA Damage Response Proteins and Associations with Clinicopathologic Characteristics in Chinese Familial Breast Cancer Patients with BRCA1/2 Mutations. J Breast Cancer 2018;21:297-305. [PMID: 30275858 DOI: 10.4048/jbc.2018.21.e38] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
408 Caffo O, Veccia A, Kinspergher S, Rizzo M, Maines F. Aberrations of DNA Repair Pathways in Prostate Cancer: Future Implications for Clinical Practice? Front Cell Dev Biol 2018;6:71. [PMID: 30234108 DOI: 10.3389/fcell.2018.00071] [Cited by in Crossref: 7] [Cited by in F6Publishing: 3] [Article Influence: 2.3] [Reference Citation Analysis]
409 Lattimore V, Parsons MT, Spurdle AB, Pearson J, Lehnert K, Sullivan J, Lintott C, Bawden S, Morrin H, Robinson B, Walker L. Under-ascertainment of breast cancer susceptibility gene carriers in a cohort of New Zealand female breast cancer patients. Breast Cancer Res Treat 2021;185:583-90. [PMID: 33113089 DOI: 10.1007/s10549-020-05986-8] [Reference Citation Analysis]
410 Byrski T, Dent R, Blecharz P, Foszczynska-Kloda M, Gronwald J, Huzarski T, Cybulski C, Marczyk E, Chrzan R, Eisen A, Lubinski J, Narod SA. Results of a phase II open-label, non-randomized trial of cisplatin chemotherapy in patients with BRCA1-positive metastatic breast cancer. Breast Cancer Res 2012;14:R110. [PMID: 22817698 DOI: 10.1186/bcr3231] [Cited by in Crossref: 129] [Cited by in F6Publishing: 111] [Article Influence: 14.3] [Reference Citation Analysis]
411 Ivy SP, de Bono J, Kohn EC. The 'Pushmi-Pullyu' of DNA REPAIR: Clinical Synthetic Lethality. Trends Cancer 2016;2:646-56. [PMID: 28741503 DOI: 10.1016/j.trecan.2016.10.014] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 2.2] [Reference Citation Analysis]
412 Williamson CT, Kubota E, Hamill JD, Klimowicz A, Ye R, Muzik H, Dean M, Tu L, Gilley D, Magliocco AM, McKay BC, Bebb DG, Lees-Miller SP. Enhanced cytotoxicity of PARP inhibition in mantle cell lymphoma harbouring mutations in both ATM and p53. EMBO Mol Med 2012;4:515-27. [PMID: 22416035 DOI: 10.1002/emmm.201200229] [Cited by in Crossref: 91] [Cited by in F6Publishing: 79] [Article Influence: 10.1] [Reference Citation Analysis]
413 Rowland LK, Campbell PS, Mavingire N, Wooten JV, McLean L, Zylstra D, Thorne G, Daly D, Boyle K, Whang S, Unternaehrer J, Brantley EJ. Putative tumor suppressor cytoglobin promotes aryl hydrocarbon receptor ligand-mediated triple negative breast cancer cell death. J Cell Biochem 2019;120:6004-14. [PMID: 30450577 DOI: 10.1002/jcb.27887] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 2.7] [Reference Citation Analysis]
414 Hu X, Huang W, Fan M. Emerging therapies for breast cancer. J Hematol Oncol 2017;10:98. [PMID: 28454587 DOI: 10.1186/s13045-017-0466-3] [Cited by in Crossref: 29] [Cited by in F6Publishing: 28] [Article Influence: 7.3] [Reference Citation Analysis]
415 Sand-Dejmek J, Adelmant G, Sobhian B, Calkins AS, Marto J, Iglehart DJ, Lazaro JB. Concordant and opposite roles of DNA-PK and the "facilitator of chromatin transcription" (FACT) in DNA repair, apoptosis and necrosis after cisplatin. Mol Cancer 2011;10:74. [PMID: 21679440 DOI: 10.1186/1476-4598-10-74] [Cited by in Crossref: 16] [Cited by in F6Publishing: 15] [Article Influence: 1.6] [Reference Citation Analysis]
416 Drost R, Dhillon KK, van der Gulden H, van der Heijden I, Brandsma I, Cruz C, Chondronasiou D, Castroviejo-Bermejo M, Boon U, Schut E, van der Burg E, Wientjens E, Pieterse M, Klijn C, Klarenbeek S, Loayza-Puch F, Elkon R, van Deemter L, Rottenberg S, van de Ven M, Dekkers DH, Demmers JA, van Gent DC, Agami R, Balmaña J, Serra V, Taniguchi T, Bouwman P, Jonkers J. BRCA1185delAG tumors may acquire therapy resistance through expression of RING-less BRCA1. J Clin Invest 2016;126:2903-18. [PMID: 27454287 DOI: 10.1172/JCI70196] [Cited by in Crossref: 66] [Cited by in F6Publishing: 39] [Article Influence: 13.2] [Reference Citation Analysis]
417 He X, Folkman L, Borgwardt K. Kernelized rank learning for personalized drug recommendation. Bioinformatics 2018;34:2808-16. [PMID: 29528376 DOI: 10.1093/bioinformatics/bty132] [Cited by in Crossref: 21] [Cited by in F6Publishing: 9] [Article Influence: 10.5] [Reference Citation Analysis]
418 Vollebergh MA, Lips EH, Nederlof PM, Wessels LF, Wesseling J, Vd Vijver MJ, de Vries EG, van Tinteren H, Jonkers J, Hauptmann M. Genomic patterns resembling BRCA1- and BRCA2-mutated breast cancers predict benefit of intensified carboplatin-based chemotherapy. Breast Cancer Res. 2014;16:R47. [PMID: 24887359 DOI: 10.1186/bcr3655] [Cited by in Crossref: 61] [Cited by in F6Publishing: 54] [Article Influence: 8.7] [Reference Citation Analysis]
419 Lee JM, Ledermann JA, Kohn EC. PARP Inhibitors for BRCA1/2 mutation-associated and BRCA-like malignancies. Ann Oncol. 2014;25:32-40. [PMID: 24225019 DOI: 10.1093/annonc/mdt384] [Cited by in Crossref: 206] [Cited by in F6Publishing: 172] [Article Influence: 25.8] [Reference Citation Analysis]
420 Jerez Y, Márquez-Rodas I, Aparicio I, Alva M, Martín M, López-Tarruella S. Poly (ADP-ribose) Polymerase Inhibition in Patients with Breast Cancer and BRCA 1 and 2 Mutations. Drugs 2020;80:131-46. [PMID: 31823331 DOI: 10.1007/s40265-019-01235-5] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 7.0] [Reference Citation Analysis]
421 Ratanaphan A. A DNA repair BRCA1 estrogen receptor and targeted therapy in breast cancer. Int J Mol Sci 2012;13:14898-916. [PMID: 23203101 DOI: 10.3390/ijms131114898] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 1.0] [Reference Citation Analysis]
422 Afghahi A, Timms KM, Vinayak S, Jensen KC, Kurian AW, Carlson RW, Chang PJ, Schackmann E, Hartman AR, Ford JM, Telli ML. Tumor BRCA1 Reversion Mutation Arising during Neoadjuvant Platinum-Based Chemotherapy in Triple-Negative Breast Cancer Is Associated with Therapy Resistance. Clin Cancer Res 2017;23:3365-70. [PMID: 28087643 DOI: 10.1158/1078-0432.CCR-16-2174] [Cited by in Crossref: 33] [Cited by in F6Publishing: 18] [Article Influence: 8.3] [Reference Citation Analysis]
423 Milletti G, Strocchio L, Pagliara D, Girardi K, Carta R, Mastronuzzi A, Locatelli F, Nazio F. Canonical and Noncanonical Roles of Fanconi Anemia Proteins: Implications in Cancer Predisposition. Cancers (Basel) 2020;12:E2684. [PMID: 32962238 DOI: 10.3390/cancers12092684] [Cited by in Crossref: 11] [Cited by in F6Publishing: 7] [Article Influence: 11.0] [Reference Citation Analysis]
424 Previs RA, Sood AK, Mills GB, Westin SN. The rise of genomic profiling in ovarian cancer. Expert Rev Mol Diagn 2016;16:1337-51. [PMID: 27828713 DOI: 10.1080/14737159.2016.1259069] [Cited by in Crossref: 13] [Cited by in F6Publishing: 10] [Article Influence: 3.3] [Reference Citation Analysis]
425 Rizvi W, Truong P, Truong Q. Metastatic Breast Cancer with BRCA Mutation Discovered By Next-Generation Sequencing Responding to Olaparib. Cureus 2017;9:e1337. [PMID: 28706762 DOI: 10.7759/cureus.1337] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 0.5] [Reference Citation Analysis]
426 Nowsheen S, Cooper T, Stanley JA, Yang ES. Synthetic lethal interactions between EGFR and PARP inhibition in human triple negative breast cancer cells. PLoS One 2012;7:e46614. [PMID: 23071597 DOI: 10.1371/journal.pone.0046614] [Cited by in Crossref: 69] [Cited by in F6Publishing: 66] [Article Influence: 7.7] [Reference Citation Analysis]
427 Shi Y, Zhou F, Jiang F, Lu H, Wang J, Cheng C. PARP inhibitor reduces proliferation and increases apoptosis in breast cancer cells. Chin J Cancer Res 2014;26:142-7. [PMID: 24826054 DOI: 10.3978/j.issn.1000-9604.2014.02.13] [Cited by in F6Publishing: 5] [Reference Citation Analysis]
428 O'Sullivan CC, Moon DH, Kohn EC, Lee JM. Beyond Breast and Ovarian Cancers: PARP Inhibitors for BRCA Mutation-Associated and BRCA-Like Solid Tumors. Front Oncol. 2014;4:42. [PMID: 24616882 DOI: 10.3389/fonc.2014.00042] [Cited by in Crossref: 35] [Cited by in F6Publishing: 51] [Article Influence: 5.0] [Reference Citation Analysis]
429 Shen Y, Rehman FL, Feng Y, Boshuizen J, Bajrami I, Elliott R, Wang B, Lord CJ, Post LE, Ashworth A. BMN 673, a novel and highly potent PARP1/2 inhibitor for the treatment of human cancers with DNA repair deficiency. Clin Cancer Res. 2013;19:5003-5015. [PMID: 23881923 DOI: 10.1158/1078-0432.ccr-13-1391] [Cited by in Crossref: 281] [Cited by in F6Publishing: 156] [Article Influence: 35.1] [Reference Citation Analysis]
430 Zhu Y, Liu J, Park J, Rai P, Zhai RG. Subcellular compartmentalization of NAD+ and its role in cancer: A sereNADe of metabolic melodies. Pharmacol Ther 2019;200:27-41. [PMID: 30974124 DOI: 10.1016/j.pharmthera.2019.04.002] [Cited by in Crossref: 22] [Cited by in F6Publishing: 18] [Article Influence: 11.0] [Reference Citation Analysis]
431 Smith KL, Isaacs C. BRCA mutation testing in determining breast cancer therapy. Cancer J 2011;17:492-9. [PMID: 22157293 DOI: 10.1097/PPO.0b013e318238f579] [Cited by in Crossref: 34] [Cited by in F6Publishing: 13] [Article Influence: 3.8] [Reference Citation Analysis]
432 Park JH, Ahn JH, Kim SB. How shall we treat early triple-negative breast cancer (TNBC): from the current standard to upcoming immuno-molecular strategies. ESMO Open 2018;3:e000357. [PMID: 29765774 DOI: 10.1136/esmoopen-2018-000357] [Cited by in Crossref: 53] [Cited by in F6Publishing: 47] [Article Influence: 17.7] [Reference Citation Analysis]
433 Donley N, Jaruga P, Coskun E, Dizdaroglu M, McCullough AK, Lloyd RS. Small Molecule Inhibitors of 8-Oxoguanine DNA Glycosylase-1 (OGG1). ACS Chem Biol 2015;10:2334-43. [PMID: 26218629 DOI: 10.1021/acschembio.5b00452] [Cited by in Crossref: 41] [Cited by in F6Publishing: 38] [Article Influence: 6.8] [Reference Citation Analysis]
434 Sharma P. Biology and Management of Patients With Triple-Negative Breast Cancer. Oncologist 2016;21:1050-62. [PMID: 27401886 DOI: 10.1634/theoncologist.2016-0067] [Cited by in Crossref: 87] [Cited by in F6Publishing: 81] [Article Influence: 17.4] [Reference Citation Analysis]
435 Lipkowitz S, Weissman AM. RINGs of good and evil: RING finger ubiquitin ligases at the crossroads of tumour suppression and oncogenesis. Nat Rev Cancer. 2011;11:629-643. [PMID: 21863050 DOI: 10.1038/nrc3120] [Cited by in Crossref: 242] [Cited by in F6Publishing: 218] [Article Influence: 24.2] [Reference Citation Analysis]
436 Iyevleva AG, Imyanitov EN. Cytotoxic and targeted therapy for hereditary cancers. Hered Cancer Clin Pract. 2016;14:17. [PMID: 27555886 DOI: 10.1186/s13053-016-0057-2] [Cited by in Crossref: 26] [Cited by in F6Publishing: 22] [Article Influence: 5.2] [Reference Citation Analysis]
437 Gadzicki D, Evans DG, Harris H, Julian-Reynier C, Nippert I, Schmidtke J, Tibben A, van Asperen CJ, Schlegelberger B. Genetic testing for familial/hereditary breast cancer-comparison of guidelines and recommendations from the UK, France, the Netherlands and Germany. J Community Genet 2011;2:53-69. [PMID: 22109790 DOI: 10.1007/s12687-011-0042-4] [Cited by in Crossref: 49] [Cited by in F6Publishing: 44] [Article Influence: 4.9] [Reference Citation Analysis]
438 Bougie O, Weberpals JI. Clinical Considerations of BRCA1- and BRCA2-Mutation Carriers: A Review. Int J Surg Oncol 2011;2011:374012. [PMID: 22312502 DOI: 10.1155/2011/374012] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 0.9] [Reference Citation Analysis]
439 Vaca-Paniagua F, Alvarez-Gomez RM, Fragoso-Ontiveros V, Vidal-Millan S, Herrera LA, Cantú D, Bargallo-Rocha E, Mohar A, López-Camarillo C, Pérez-Plasencia C. Full-exon pyrosequencing screening of BRCA germline mutations in Mexican women with inherited breast and ovarian cancer. PLoS One 2012;7:e37432. [PMID: 22655046 DOI: 10.1371/journal.pone.0037432] [Cited by in Crossref: 27] [Cited by in F6Publishing: 26] [Article Influence: 3.0] [Reference Citation Analysis]
440 Grotsky DA, Gonzalez-Suarez I, Novell A, Neumann MA, Yaddanapudi SC, Croke M, Martinez-Alonso M, Redwood AB, Ortega-Martinez S, Feng Z, Lerma E, Ramon y Cajal T, Zhang J, Matias-Guiu X, Dusso A, Gonzalo S. BRCA1 loss activates cathepsin L-mediated degradation of 53BP1 in breast cancer cells. J Cell Biol 2013;200:187-202. [PMID: 23337117 DOI: 10.1083/jcb.201204053] [Cited by in Crossref: 54] [Cited by in F6Publishing: 48] [Article Influence: 6.8] [Reference Citation Analysis]
441 de Groot JS, van Diest PJ, van Amersfoort M, Vlug EJ, Pan X, Ter Hoeve ND, Rosing H, Beijnen JH, Youssef SA, de Bruin A, Jonkers J, van der Wall E, Derksen PWB. Intraductal cisplatin treatment in a BRCA-associated breast cancer mouse model attenuates tumor development but leads to systemic tumors in aged female mice. Oncotarget 2017;8:60750-63. [PMID: 28977823 DOI: 10.18632/oncotarget.18490] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
442 Lenglet A, Liabeuf S, Bodeau S, Louvet L, Mary A, Boullier A, Lemaire-Hurtel AS, Jonet A, Sonnet P, Kamel S, Massy ZA. N-methyl-2-pyridone-5-carboxamide (2PY)-Major Metabolite of Nicotinamide: An Update on an Old Uremic Toxin. Toxins (Basel) 2016;8:E339. [PMID: 27854278 DOI: 10.3390/toxins8110339] [Cited by in Crossref: 25] [Cited by in F6Publishing: 24] [Article Influence: 5.0] [Reference Citation Analysis]
443 Kieffer Y, Bonneau C, Popova T, Rouzier R, Stern MH, Mechta-Grigoriou F. Clinical Interest of Combining Transcriptomic and Genomic Signatures in High-Grade Serous Ovarian Cancer. Front Genet 2020;11:219. [PMID: 32256521 DOI: 10.3389/fgene.2020.00219] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
444 Mutter RW, Riaz N, Ng CK, Delsite R, Piscuoglio S, Edelweiss M, Martelotto LG, Sakr RA, King TA, Giri DD, Drobnjak M, Brogi E, Bindra R, Bernheim G, Lim RS, Blecua P, Desrichard A, Higginson D, Towers R, Jiang R, Lee W, Weigelt B, Reis-Filho JS, Powell SN. Bi-allelic alterations in DNA repair genes underpin homologous recombination DNA repair defects in breast cancer. J Pathol 2017;242:165-77. [PMID: 28299801 DOI: 10.1002/path.4890] [Cited by in Crossref: 28] [Cited by in F6Publishing: 27] [Article Influence: 7.0] [Reference Citation Analysis]
445 Akter H, Sultana N, Martuza N, Siddiqua A, Dity NJ, Rahaman MA, Samara B, Sayeed A, Basiruzzaman M, Rahman MM, Rashidul Hoq M, Amin MR, Baqui MA, Woodbury-Smith M, Uddin KMF, Islam SS, Awwal R, Berdiev BK, Uddin M. Novel mutations in actionable breast cancer genes by targeted sequencing in an ethnically homogenous cohort. BMC Med Genet 2019;20:150. [PMID: 31477031 DOI: 10.1186/s12881-019-0881-0] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
446 Shi Y, Jin J, Ji W, Guan X. Therapeutic landscape in mutational triple negative breast cancer. Mol Cancer 2018;17:99. [PMID: 30007403 DOI: 10.1186/s12943-018-0850-9] [Cited by in Crossref: 32] [Cited by in F6Publishing: 29] [Article Influence: 10.7] [Reference Citation Analysis]
447 Hernández JE, Llacuachaqui M, Palacio GV, Figueroa JD, Madrid J, Lema M, Royer R, Li S, Larson G, Weitzel JN, Narod SA. Prevalence of BRCA1 and BRCA2 mutations in unselected breast cancer patients from medellín, Colombia. Hered Cancer Clin Pract 2014;12:11. [PMID: 24742220 DOI: 10.1186/1897-4287-12-11] [Cited by in Crossref: 29] [Cited by in F6Publishing: 26] [Article Influence: 4.1] [Reference Citation Analysis]
448 Krajewska M, Fehrmann RS, de Vries EG, van Vugt MA. Regulators of homologous recombination repair as novel targets for cancer treatment. Front Genet 2015;6:96. [PMID: 25852742 DOI: 10.3389/fgene.2015.00096] [Cited by in Crossref: 31] [Cited by in F6Publishing: 26] [Article Influence: 5.2] [Reference Citation Analysis]
449 Kriege M, Jager A, Hollestelle A, Berns EM, Blom J, Meijer-van Gelder ME, Sieuwerts AM, van den Ouweland A, Collée JM, Kroep JR, Martens JW, Hooning MJ, Seynaeve C. Sensitivity to systemic therapy for metastatic breast cancer in CHEK2 1100delC mutation carriers. J Cancer Res Clin Oncol 2015;141:1879-87. [PMID: 25958056 DOI: 10.1007/s00432-015-1981-7] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 0.7] [Reference Citation Analysis]
450 Alli E, Sharma VB, Hartman AR, Lin PS, McPherson L, Ford JM. Enhanced sensitivity to cisplatin and gemcitabine in Brca1-deficient murine mammary epithelial cells. BMC Pharmacol 2011;11:7. [PMID: 21771338 DOI: 10.1186/1471-2210-11-7] [Cited by in Crossref: 29] [Cited by in F6Publishing: 21] [Article Influence: 2.9] [Reference Citation Analysis]
451 Mazzucchelli S, Truffi M, Baccarini F, Beretta M, Sorrentino L, Bellini M, Rizzuto MA, Ottria R, Ravelli A, Ciuffreda P, Prosperi D, Corsi F. H-Ferritin-nanocaged olaparib: a promising choice for both BRCA-mutated and sporadic triple negative breast cancer. Sci Rep 2017;7:7505. [PMID: 28790402 DOI: 10.1038/s41598-017-07617-7] [Cited by in Crossref: 29] [Cited by in F6Publishing: 23] [Article Influence: 7.3] [Reference Citation Analysis]
452 Topatana W, Juengpanich S, Li S, Cao J, Hu J, Lee J, Suliyanto K, Ma D, Zhang B, Chen M, Cai X. Advances in synthetic lethality for cancer therapy: cellular mechanism and clinical translation. J Hematol Oncol. 2020;13:118. [PMID: 32883316 DOI: 10.1186/s13045-020-00956-5] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 12.0] [Reference Citation Analysis]
453 Severson TM, Peeters J, Majewski I, Michaut M, Bosma A, Schouten PC, Chin SF, Pereira B, Goldgraben MA, Bismeijer T, Kluin RJ, Muris JJ, Jirström K, Kerkhoven RM, Wessels L, Caldas C, Bernards R, Simon IM, Linn S. BRCA1-like signature in triple negative breast cancer: Molecular and clinical characterization reveals subgroups with therapeutic potential. Mol Oncol 2015;9:1528-38. [PMID: 26004083 DOI: 10.1016/j.molonc.2015.04.011] [Cited by in Crossref: 35] [Cited by in F6Publishing: 34] [Article Influence: 5.8] [Reference Citation Analysis]
454 Park SH, Jang KY, Kim MJ, Yoon S, Jo Y, Kwon SM, Kim KM, Kwon KS, Kim CY, Woo HG. Tumor suppressive effect of PARP1 and FOXO3A in gastric cancers and its clinical implications. Oncotarget 2015;6:44819-31. [PMID: 26540566 DOI: 10.18632/oncotarget.6264] [Cited by in Crossref: 25] [Cited by in F6Publishing: 25] [Article Influence: 5.0] [Reference Citation Analysis]
455 Zhao L, So CWE. PARPi potentiates with current conventional therapy in MLL leukemia. Cell Cycle 2017;16:1861-9. [PMID: 28886273 DOI: 10.1080/15384101.2017.1288325] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
456 Incorvaia L, Passiglia F, Rizzo S, Galvano A, Listì A, Barraco N, Maragliano R, Calò V, Natoli C, Ciaccio M, Bazan V, Russo A. "Back to a false normality": new intriguing mechanisms of resistance to PARP inhibitors. Oncotarget 2017;8:23891-904. [PMID: 28055979 DOI: 10.18632/oncotarget.14409] [Cited by in Crossref: 16] [Cited by in F6Publishing: 9] [Article Influence: 4.0] [Reference Citation Analysis]
457 Jhan JR, Andrechek ER. Triple-negative breast cancer and the potential for targeted therapy. Pharmacogenomics 2017;18:1595-609. [PMID: 29095114 DOI: 10.2217/pgs-2017-0117] [Cited by in Crossref: 69] [Cited by in F6Publishing: 65] [Article Influence: 17.3] [Reference Citation Analysis]
458 Hubalek M, Czech T, Müller H. Biological Subtypes of Triple-Negative Breast Cancer. Breast Care (Basel) 2017;12:8-14. [PMID: 28611535 DOI: 10.1159/000455820] [Cited by in Crossref: 37] [Cited by in F6Publishing: 34] [Article Influence: 9.3] [Reference Citation Analysis]
459 Javle M, Curtin NJ. The potential for poly (ADP-ribose) polymerase inhibitors in cancer therapy. Ther Adv Med Oncol 2011;3:257-67. [PMID: 22084640 DOI: 10.1177/1758834011417039] [Cited by in Crossref: 57] [Cited by in F6Publishing: 46] [Article Influence: 5.7] [Reference Citation Analysis]
460 Li H, Liu R, Shao B, Ran R, Song G, Wang K, Shi Y, Liu J, Hu W, Chen F, Liu X, Zhang G, Zhao C, Jia R, Wang Q, Rugo HS, Zhang Y, Li G, Xu J. Phase I dose-escalation and expansion study of PARP inhibitor, fluzoparib (SHR3162), in patients with advanced solid tumors. Chin J Cancer Res 2020;32:370-82. [PMID: 32694901 DOI: 10.21147/j.issn.1000-9604.2020.03.08] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 4.0] [Reference Citation Analysis]
461 Gogineni K, DeMichele A. Current approaches to the management of Her2-negative metastatic breast cancer. Breast Cancer Res 2012;14:205. [PMID: 22429313 DOI: 10.1186/bcr3064] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 1.7] [Reference Citation Analysis]
462 Tutt A. Inhibited, trapped or adducted: the optimal selective synthetic lethal mix for BRCAness. Ann Oncol 2018;29:18-21. [PMID: 29300815 DOI: 10.1093/annonc/mdx775] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
463 Jacot W, Thezenas S, Senal R, Viglianti C, Laberenne AC, Lopez-Crapez E, Bibeau F, Bleuse JP, Romieu G, Lamy PJ. BRCA1 promoter hypermethylation, 53BP1 protein expression and PARP-1 activity as biomarkers of DNA repair deficit in breast cancer. BMC Cancer 2013;13:523. [PMID: 24191908 DOI: 10.1186/1471-2407-13-523] [Cited by in Crossref: 34] [Cited by in F6Publishing: 30] [Article Influence: 4.3] [Reference Citation Analysis]
464 Le Du F, Eckhardt BL, Lim B, Litton JK, Moulder S, Meric-Bernstam F, Gonzalez-Angulo AM, Ueno NT. Is the future of personalized therapy in triple-negative breast cancer based on molecular subtype? Oncotarget 2015;6:12890-908. [PMID: 25973541 DOI: 10.18632/oncotarget.3849] [Cited by in Crossref: 67] [Cited by in F6Publishing: 57] [Article Influence: 13.4] [Reference Citation Analysis]
465 Park E. Data on cell cycle in breast cancer cell line, MDA-MB-231 with ferulic acid treatment. Data Brief 2016;7:107-10. [PMID: 26958638 DOI: 10.1016/j.dib.2016.02.001] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 2.0] [Reference Citation Analysis]
466 Garcia-Casado Z, Romero I, Fernandez-Serra A, Rubio L, Llopis F, Garcia A, Llombart P, Lopez-Guerrero JA. A de novo complete BRCA1 gene deletion identified in a Spanish woman with early bilateral breast cancer. BMC Med Genet 2011;12:134. [PMID: 21989022 DOI: 10.1186/1471-2350-12-134] [Cited by in Crossref: 19] [Cited by in F6Publishing: 15] [Article Influence: 1.9] [Reference Citation Analysis]
467 Bonanno L, Favaretto A, Rugge M, Taron M, Rosell R. Role of genotyping in non-small cell lung cancer treatment: current status. Drugs 2011;71:2231-46. [PMID: 22085382 DOI: 10.2165/11597700-000000000-00000] [Cited by in Crossref: 15] [Cited by in F6Publishing: 12] [Article Influence: 1.7] [Reference Citation Analysis]
468 Leung M, Rosen D, Fields S, Cesano A, Budman DR. Poly(ADP-ribose) polymerase-1 inhibition: preclinical and clinical development of synthetic lethality. Mol Med. 2011;17:854-862. [PMID: 21424107 DOI: 10.2119/molmed.2010.00240] [Cited by in Crossref: 38] [Cited by in F6Publishing: 33] [Article Influence: 3.8] [Reference Citation Analysis]
469 Fang CB, Wu HT, Zhang ML, Liu J, Zhang GJ. Fanconi Anemia Pathway: Mechanisms of Breast Cancer Predisposition Development and Potential Therapeutic Targets. Front Cell Dev Biol 2020;8:160. [PMID: 32300589 DOI: 10.3389/fcell.2020.00160] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 7.0] [Reference Citation Analysis]
470 Aly A, Ganesan S. BRCA1, PARP, and 53BP1: conditional synthetic lethality and synthetic viability. J Mol Cell Biol 2011;3:66-74. [PMID: 21278454 DOI: 10.1093/jmcb/mjq055] [Cited by in Crossref: 74] [Cited by in F6Publishing: 63] [Article Influence: 7.4] [Reference Citation Analysis]
471 Liang Y, Yang X, Li H, Zhu A, Guo Z, Li M. Prevalence and Spectrum of BRCA1/2 Germline Mutations in Women with Breast Cancer in China Based on Next-Generation Sequencing. Med Sci Monit 2018;24:2465-75. [PMID: 29681614 DOI: 10.12659/msm.905812] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
472 Li C, Li X, Li G, Sun L, Zhang W, Jiang J, Ge Q. Identification of a prognosis‑associated signature associated with energy metabolism in triple‑negative breast cancer. Oncol Rep 2020;44:819-37. [PMID: 32582991 DOI: 10.3892/or.2020.7657] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
473 Gross E, Meul C, Raab S, Propping C, Avril S, Aubele M, Gkazepis A, Schuster T, Grebenchtchikov N, Schmitt M, Kiechle M, Meijer J, Vijzelaar R, Meindl A, van Kuilenburg AB. Somatic copy number changes in DPYD are associated with lower risk of recurrence in triple-negative breast cancers. Br J Cancer 2013;109:2347-55. [PMID: 24104963 DOI: 10.1038/bjc.2013.621] [Cited by in Crossref: 10] [Cited by in F6Publishing: 6] [Article Influence: 1.3] [Reference Citation Analysis]
474 Wu M, Wang X, McGregor N, Pienta KJ, Zhang J. Dynamic regulation of Rad51 by E2F1 and p53 in prostate cancer cells upon drug-induced DNA damage under hypoxia. Mol Pharmacol 2014;85:866-76. [PMID: 24627085 DOI: 10.1124/mol.113.090688] [Cited by in Crossref: 21] [Cited by in F6Publishing: 20] [Article Influence: 3.0] [Reference Citation Analysis]
475 Plummer R. Poly(ADP-ribose) polymerase inhibition: a new direction for BRCA and triple-negative breast cancer? Breast Cancer Res 2011;13:218. [PMID: 21884642 DOI: 10.1186/bcr2877] [Cited by in Crossref: 32] [Cited by in F6Publishing: 30] [Article Influence: 3.2] [Reference Citation Analysis]
476 Ohmoto A, Yachida S. Current status of poly(ADP-ribose) polymerase inhibitors and future directions. Onco Targets Ther 2017;10:5195-208. [PMID: 29138572 DOI: 10.2147/OTT.S139336] [Cited by in Crossref: 71] [Cited by in F6Publishing: 38] [Article Influence: 17.8] [Reference Citation Analysis]
477 Du Y, Yamaguchi H, Wei Y, Hsu JL, Wang HL, Hsu YH, Lin WC, Yu WH, Leonard PG, Lee GR 4th, Chen MK, Nakai K, Hsu MC, Chen CT, Sun Y, Wu Y, Chang WC, Huang WC, Liu CL, Chang YC, Chen CH, Park M, Jones P, Hortobagyi GN, Hung MC. Blocking c-Met-mediated PARP1 phosphorylation enhances anti-tumor effects of PARP inhibitors. Nat Med 2016;22:194-201. [PMID: 26779812 DOI: 10.1038/nm.4032] [Cited by in Crossref: 106] [Cited by in F6Publishing: 100] [Article Influence: 21.2] [Reference Citation Analysis]
478 O'Reilly D, Sendi MA, Kelly CM. Overview of recent advances in metastatic triple negative breast cancer. World J Clin Oncol 2021;12:164-82. [PMID: 33767972 DOI: 10.5306/wjco.v12.i3.164] [Cited by in CrossRef: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
479 Lucas AL, Frado LE, Hwang C, Kumar S, Khanna LG, Levinson EJ, Chabot JA, Chung WK, Frucht H. BRCA1 and BRCA2 germline mutations are frequently demonstrated in both high-risk pancreatic cancer screening and pancreatic cancer cohorts. Cancer. 2014;120:1960-1967. [PMID: 24737347 DOI: 10.1002/cncr.28662] [Cited by in Crossref: 37] [Cited by in F6Publishing: 31] [Article Influence: 5.3] [Reference Citation Analysis]
480 Grindedal EM, Jørgensen K, Olsson P, Gravdehaug B, Lurås H, Schlichting E, Vamre T, Wangensteen T, Heramb C, Mæhle L. Mainstreamed genetic testing of breast cancer patients in two hospitals in South Eastern Norway. Fam Cancer 2020;19:133-42. [PMID: 32002722 DOI: 10.1007/s10689-020-00160-x] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 5.0] [Reference Citation Analysis]
481 Arbini AA, Guerra F, Greco M, Marra E, Gandee L, Xiao G, Lotan Y, Gasparre G, Hsieh JT, Moro L. Mitochondrial DNA depletion sensitizes cancer cells to PARP inhibitors by translational and post-translational repression of BRCA2. Oncogenesis 2013;2:e82. [PMID: 24336406 DOI: 10.1038/oncsis.2013.45] [Cited by in Crossref: 22] [Cited by in F6Publishing: 20] [Article Influence: 2.8] [Reference Citation Analysis]
482 Brenner JC, Ateeq B, Li Y, Yocum AK, Cao Q, Asangani IA, Patel S, Wang X, Liang H, Yu J, Palanisamy N, Siddiqui J, Yan W, Cao X, Mehra R, Sabolch A, Basrur V, Lonigro RJ, Yang J, Tomlins SA, Maher CA, Elenitoba-Johnson KS, Hussain M, Navone NM, Pienta KJ, Varambally S, Feng FY, Chinnaiyan AM. Mechanistic rationale for inhibition of poly(ADP-ribose) polymerase in ETS gene fusion-positive prostate cancer. Cancer Cell 2011;19:664-78. [PMID: 21575865 DOI: 10.1016/j.ccr.2011.04.010] [Cited by in Crossref: 297] [Cited by in F6Publishing: 269] [Article Influence: 29.7] [Reference Citation Analysis]
483 Chowdhury P, Ghosh U, Samanta K, Jaggi M, Chauhan SC, Yallapu MM. Bioactive nanotherapeutic trends to combat triple negative breast cancer. Bioact Mater 2021;6:3269-87. [PMID: 33778204 DOI: 10.1016/j.bioactmat.2021.02.037] [Reference Citation Analysis]
484 Kast K, Rhiem K. Familial breast cancer - targeted therapy in secondary and tertiary prevention. Breast Care (Basel) 2015;10:27-31. [PMID: 25960722 DOI: 10.1159/000380756] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
485 Vidula N, Dubash T, Lawrence MS, Simoneau A, Niemierko A, Blouch E, Nagy B, Roh W, Chirn B, Reeves BA, Malvarosa G, Lennerz J, Isakoff SJ, Juric D, Micalizzi D, Wander S, Spring L, Moy B, Shannon K, Younger J, Lanman R, Toner M, Iafrate AJ, Getz G, Zou L, Ellisen LW, Maheswaran S, Haber DA, Bardia A. Identification of Somatically Acquired BRCA1/2 Mutations by cfDNA Analysis in Patients with Metastatic Breast Cancer. Clin Cancer Res 2020;26:4852-62. [PMID: 32571788 DOI: 10.1158/1078-0432.CCR-20-0638] [Cited by in Crossref: 6] [Article Influence: 6.0] [Reference Citation Analysis]
486 Meric-Bernstam F, Brusco L, Daniels M, Wathoo C, Bailey AM, Strong L, Shaw K, Lu K, Qi Y, Zhao H, Lara-Guerra H, Litton J, Arun B, Eterovic AK, Aytac U, Routbort M, Subbiah V, Janku F, Davies MA, Kopetz S, Mendelsohn J, Mills GB, Chen K. Incidental germline variants in 1000 advanced cancers on a prospective somatic genomic profiling protocol. Ann Oncol 2016;27:795-800. [PMID: 26787237 DOI: 10.1093/annonc/mdw018] [Cited by in Crossref: 93] [Cited by in F6Publishing: 66] [Article Influence: 18.6] [Reference Citation Analysis]
487 Solzak JP, Atale RV, Hancock BA, Sinn AL, Pollok KE, Jones DR, Radovich M. Dual PI3K and Wnt pathway inhibition is a synergistic combination against triple negative breast cancer. NPJ Breast Cancer 2017;3:17. [PMID: 28649657 DOI: 10.1038/s41523-017-0016-8] [Cited by in Crossref: 23] [Cited by in F6Publishing: 19] [Article Influence: 5.8] [Reference Citation Analysis]
488 Castéra L, Krieger S, Rousselin A, Legros A, Baumann JJ, Bruet O, Brault B, Fouillet R, Goardon N, Letac O. Next-generation sequencing for the diagnosis of hereditary breast and ovarian cancer using genomic capture targeting multiple candidate genes. Eur J Hum Genet. 2014;22:1305-1313. [PMID: 24549055 DOI: 10.1038/ejhg.2014.16] [Cited by in Crossref: 157] [Cited by in F6Publishing: 140] [Article Influence: 22.4] [Reference Citation Analysis]
489 Li S, Topatana W, Juengpanich S, Cao J, Hu J, Zhang B, Ma D, Cai X, Chen M. Development of synthetic lethality in cancer: molecular and cellular classification. Signal Transduct Target Ther. 2020;5:241. [PMID: 33077733 DOI: 10.1038/s41392-020-00358-6] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 6.0] [Reference Citation Analysis]
490 Kosaka Y, Yamamoto Y, Tanino H, Nishimiya H, Yamamoto-Ibusuki M, Hirota Y, Iwase H, Nakamura S, Akashi-Tanaka S. BRCAness as an Important Prognostic Marker in Patients with Triple-Negative Breast Cancer Treated with Neoadjuvant Chemotherapy: A Multicenter Retrospective Study. Diagnostics (Basel) 2020;10:E119. [PMID: 32098267 DOI: 10.3390/diagnostics10020119] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
491 Palleschi M, Tedaldi G, Sirico M, Virga A, Ulivi P, De Giorgi U. Moving beyond PARP Inhibition: Current State and Future Perspectives in Breast Cancer. Int J Mol Sci 2021;22:7884. [PMID: 34360649 DOI: 10.3390/ijms22157884] [Reference Citation Analysis]
492 Rafii S, Gourley C, Kumar R, Geuna E, Ern Ang J, Rye T, Chen LM, Shapira-Frommer R, Friedlander M, Matulonis U, De Greve J, Oza AM, Banerjee S, Molife LR, Gore ME, Kaye SB, Yap TA. Baseline clinical predictors of antitumor response to the PARP inhibitor olaparib in germline BRCA1/2 mutated patients with advanced ovarian cancer. Oncotarget 2017;8:47154-60. [PMID: 28454085 DOI: 10.18632/oncotarget.17005] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 4.7] [Reference Citation Analysis]
493 Liu J, Adhav R, Miao K, Su SM, Mo L, Chan UI, Zhang X, Xu J, Li J, Shu X, Zeng J, Zhang X, Lyu X, Pardeshi L, Tan K, Sun H, Wong KH, Deng C, Xu X. Characterization of BRCA1-deficient premalignant tissues and cancers identifies Plekha5 as a tumor metastasis suppressor. Nat Commun 2020;11:4875. [PMID: 32978388 DOI: 10.1038/s41467-020-18637-9] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 8.0] [Reference Citation Analysis]
494 Murai J, Thomas A, Miettinen M, Pommier Y. Schlafen 11 (SLFN11), a restriction factor for replicative stress induced by DNA-targeting anti-cancer therapies. Pharmacol Ther 2019;201:94-102. [PMID: 31128155 DOI: 10.1016/j.pharmthera.2019.05.009] [Cited by in Crossref: 50] [Cited by in F6Publishing: 38] [Article Influence: 25.0] [Reference Citation Analysis]
495 Young A, Berry R, Holloway AF, Blackburn NB, Dickinson JL, Skala M, Phillips JL, Brettingham-Moore KH. RNA-seq profiling of a radiation resistant and radiation sensitive prostate cancer cell line highlights opposing regulation of DNA repair and targets for radiosensitization. BMC Cancer 2014;14:808. [PMID: 25369795 DOI: 10.1186/1471-2407-14-808] [Cited by in Crossref: 21] [Cited by in F6Publishing: 14] [Article Influence: 3.0] [Reference Citation Analysis]
496 Massihnia D, Galvano A, Fanale D, Perez A, Castiglia M, Incorvaia L, Listì A, Rizzo S, Cicero G, Bazan V, Castorina S, Russo A. Triple negative breast cancer: shedding light onto the role of pi3k/akt/mtor pathway. Oncotarget 2016;7:60712-22. [PMID: 27474173 DOI: 10.18632/oncotarget.10858] [Cited by in Crossref: 58] [Cited by in F6Publishing: 54] [Article Influence: 19.3] [Reference Citation Analysis]
497 Tomao F, Papa A, Zaccarelli E, Rossi L, Caruso D, Minozzi M, Vici P, Frati L, Tomao S. Triple-negative breast cancer: new perspectives for targeted therapies. Onco Targets Ther 2015;8:177-93. [PMID: 25653541 DOI: 10.2147/OTT.S67673] [Cited by in Crossref: 85] [Cited by in F6Publishing: 53] [Article Influence: 14.2] [Reference Citation Analysis]
498 Zhang J, Dai Q, Park D, Deng X. Targeting DNA Replication Stress for Cancer Therapy. Genes (Basel) 2016;7:E51. [PMID: 27548226 DOI: 10.3390/genes7080051] [Cited by in Crossref: 47] [Cited by in F6Publishing: 34] [Article Influence: 9.4] [Reference Citation Analysis]
499 Castro E, Goh C, Olmos D, Saunders E, Leongamornlert D, Tymrakiewicz M, Mahmud N, Dadaev T, Govindasami K, Guy M, Sawyer E, Wilkinson R, Ardern-Jones A, Ellis S, Frost D, Peock S, Evans DG, Tischkowitz M, Cole T, Davidson R, Eccles D, Brewer C, Douglas F, Porteous ME, Donaldson A, Dorkins H, Izatt L, Cook J, Hodgson S, Kennedy MJ, Side LE, Eason J, Murray A, Antoniou AC, Easton DF, Kote-Jarai Z, Eeles R. Germline BRCA mutations are associated with higher risk of nodal involvement, distant metastasis, and poor survival outcomes in prostate cancer. J Clin Oncol 2013;31:1748-57. [PMID: 23569316 DOI: 10.1200/JCO.2012.43.1882] [Cited by in Crossref: 393] [Cited by in F6Publishing: 159] [Article Influence: 49.1] [Reference Citation Analysis]
500 Emens LA, Adams S, Cimino-Mathews A, Disis ML, Gatti-Mays ME, Ho AY, Kalinsky K, McArthur HL, Mittendorf EA, Nanda R, Page DB, Rugo HS, Rubin KM, Soliman H, Spears PA, Tolaney SM, Litton JK. Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of breast cancer. J Immunother Cancer 2021;9:e002597. [PMID: 34389617 DOI: 10.1136/jitc-2021-002597] [Reference Citation Analysis]
501 Benafif S, Hall M. An update on PARP inhibitors for the treatment of cancer. Onco Targets Ther 2015;8:519-28. [PMID: 25750544 DOI: 10.2147/OTT.S30793] [Cited by in Crossref: 17] [Cited by in F6Publishing: 40] [Article Influence: 2.8] [Reference Citation Analysis]
502 Liu JF, Barry WT, Birrer M, Lee JM, Buckanovich RJ, Fleming GF, Rimel B, Buss MK, Nattam S, Hurteau J, Luo W, Quy P, Whalen C, Obermayer L, Lee H, Winer EP, Kohn EC, Ivy SP, Matulonis UA. Combination cediranib and olaparib versus olaparib alone for women with recurrent platinum-sensitive ovarian cancer: a randomised phase 2 study. Lancet Oncol 2014;15:1207-14. [PMID: 25218906 DOI: 10.1016/S1470-2045(14)70391-2] [Cited by in Crossref: 362] [Cited by in F6Publishing: 168] [Article Influence: 51.7] [Reference Citation Analysis]
503 Castroviejo-Bermejo M, Cruz C, Llop-Guevara A, Gutiérrez-Enríquez S, Ducy M, Ibrahim YH, Gris-Oliver A, Pellegrino B, Bruna A, Guzmán M, Rodríguez O, Grueso J, Bonache S, Moles-Fernández A, Villacampa G, Viaplana C, Gómez P, Vidal M, Peg V, Serres-Créixams X, Dellaire G, Simard J, Nuciforo P, Rubio IT, Dienstmann R, Barrett JC, Caldas C, Baselga J, Saura C, Cortés J, Déas O, Jonkers J, Masson JY, Cairo S, Judde JG, O'Connor MJ, Díez O, Balmaña J, Serra V. A RAD51 assay feasible in routine tumor samples calls PARP inhibitor response beyond BRCA mutation. EMBO Mol Med 2018;10:e9172. [PMID: 30377213 DOI: 10.15252/emmm.201809172] [Cited by in Crossref: 64] [Cited by in F6Publishing: 50] [Article Influence: 32.0] [Reference Citation Analysis]
504 Parsons HA, Beaver JA, Cimino-Mathews A, Ali SM, Axilbund J, Chu D, Connolly RM, Cochran RL, Croessmann S, Clark TA, Gocke CD, Jeter SC, Kennedy MR, Lauring J, Lee J, Lipson D, Miller VA, Otto GA, Rosner GL, Ross JS, Slater S, Stephens PJ, VanDenBerg DA, Wolff AC, Young LE, Zabransky DJ, Zhang Z, Zorzi J, Stearns V, Park BH. Individualized Molecular Analyses Guide Efforts (IMAGE): A Prospective Study of Molecular Profiling of Tissue and Blood in Metastatic Triple-Negative Breast Cancer. Clin Cancer Res 2017;23:379-86. [PMID: 27489289 DOI: 10.1158/1078-0432.CCR-16-1543] [Cited by in Crossref: 29] [Cited by in F6Publishing: 15] [Article Influence: 5.8] [Reference Citation Analysis]
505 Lai E, Ziranu P, Spanu D, Dubois M, Pretta A, Tolu S, Camera S, Liscia N, Mariani S, Persano M, Migliari M, Donisi C, Demurtas L, Pusceddu V, Puzzoni M, Scartozzi M. BRCA-mutant pancreatic ductal adenocarcinoma. Br J Cancer 2021. [PMID: 34262146 DOI: 10.1038/s41416-021-01469-9] [Reference Citation Analysis]
506 Geenen JJJ, Linn SC, Beijnen JH, Schellens JHM. PARP Inhibitors in the Treatment of Triple-Negative Breast Cancer. Clin Pharmacokinet 2018;57:427-37. [PMID: 29063517 DOI: 10.1007/s40262-017-0587-4] [Cited by in Crossref: 37] [Cited by in F6Publishing: 27] [Article Influence: 18.5] [Reference Citation Analysis]
507 Yonemori K, Tamura K, Kodaira M, Fujikawa K, Sagawa T, Esaki T, Shirakawa T, Hirai F, Yokoi Y, Kawata T, Hatano B, Takahashi Y. Safety and tolerability of the olaparib tablet formulation in Japanese patients with advanced solid tumours. Cancer Chemother Pharmacol 2016;78:525-31. [PMID: 27422301 DOI: 10.1007/s00280-016-3106-7] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 2.2] [Reference Citation Analysis]
508 Liu JF, Tolaney SM, Birrer M, Fleming GF, Buss MK, Dahlberg SE, Lee H, Whalen C, Tyburski K, Winer E, Ivy P, Matulonis UA. A Phase 1 trial of the poly(ADP-ribose) polymerase inhibitor olaparib (AZD2281) in combination with the anti-angiogenic cediranib (AZD2171) in recurrent epithelial ovarian or triple-negative breast cancer. Eur J Cancer. 2013;49:2972-2978. [PMID: 23810467 DOI: 10.1016/j.ejca.2013.05.020] [Cited by in Crossref: 116] [Cited by in F6Publishing: 94] [Article Influence: 14.5] [Reference Citation Analysis]
509 Ademuyiwa FO, Ellis MJ, Ma CX. Neoadjuvant therapy in operable breast cancer: application to triple negative breast cancer. J Oncol 2013;2013:219869. [PMID: 23983689 DOI: 10.1155/2013/219869] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 1.1] [Reference Citation Analysis]
510 Wang C, Mbalaviele G. Role of APD-Ribosylation in Bone Health and Disease. Cells 2019;8:E1201. [PMID: 31590342 DOI: 10.3390/cells8101201] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
511 Lee JM, Hays JL, Annunziata CM, Noonan AM, Minasian L, Zujewski JA, Yu M, Gordon N, Ji J, Sissung TM. Phase I/Ib study of olaparib and carboplatin in BRCA1 or BRCA2 mutation-associated breast or ovarian cancer with biomarker analyses. J Natl Cancer Inst. 2014;106:dju089. [PMID: 24842883 DOI: 10.1093/jnci/dju089] [Cited by in Crossref: 96] [Cited by in F6Publishing: 110] [Article Influence: 13.7] [Reference Citation Analysis]
512 Sharma P, Klemp JR, Kimler BF, Mahnken JD, Geier LJ, Khan QJ, Elia M, Connor CS, McGinness MK, Mammen JM, Wagner JL, Ward C, Ranallo L, Knight CJ, Stecklein SR, Jensen RA, Fabian CJ, Godwin AK. Germline BRCA mutation evaluation in a prospective triple-negative breast cancer registry: implications for hereditary breast and/or ovarian cancer syndrome testing. Breast Cancer Res Treat 2014;145:707-14. [PMID: 24807107 DOI: 10.1007/s10549-014-2980-0] [Cited by in Crossref: 91] [Cited by in F6Publishing: 78] [Article Influence: 13.0] [Reference Citation Analysis]
513 Nicolas E, Bertucci F, Sabatier R, Gonçalves A. Targeting BRCA Deficiency in Breast Cancer: What are the Clinical Evidences and the Next Perspectives? Cancers (Basel) 2018;10:E506. [PMID: 30544963 DOI: 10.3390/cancers10120506] [Cited by in Crossref: 28] [Cited by in F6Publishing: 23] [Article Influence: 9.3] [Reference Citation Analysis]
514 Kaushik P, Molinelli EJ, Miller ML, Wang W, Korkut A, Liu W, Ju Z, Lu Y, Mills G, Sander C. Spatial normalization of reverse phase protein array data. PLoS One 2014;9:e97213. [PMID: 25501559 DOI: 10.1371/journal.pone.0097213] [Cited by in Crossref: 16] [Cited by in F6Publishing: 13] [Article Influence: 2.3] [Reference Citation Analysis]
515 Campelo RG, Massuti B, Mosquera J, Rosell R. 10(th) Congress on Lung Cancer-updates on clinical trials: goal. Transl Lung Cancer Res 2014;3:66-9. [PMID: 25806282 DOI: 10.3978/j.issn.2218-6751.2014.02.05] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
516 Madubata CJ, Roshan-Ghias A, Chu T, Resnick S, Zhao J, Arnes L, Wang J, Rabadan R. Identification of potentially oncogenic alterations from tumor-only samples reveals Fanconi anemia pathway mutations in bladder carcinomas. NPJ Genom Med 2017;2:29. [PMID: 29263839 DOI: 10.1038/s41525-017-0032-5] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
517 Théry JC, Krieger S, Gaildrat P, Révillion F, Buisine MP, Killian A, Duponchel C, Rousselin A, Vaur D, Peyrat JP, Berthet P, Frébourg T, Martins A, Hardouin A, Tosi M. Contribution of bioinformatics predictions and functional splicing assays to the interpretation of unclassified variants of the BRCA genes. Eur J Hum Genet 2011;19:1052-8. [PMID: 21673748 DOI: 10.1038/ejhg.2011.100] [Cited by in Crossref: 75] [Cited by in F6Publishing: 68] [Article Influence: 7.5] [Reference Citation Analysis]
518 Mann M, Kumar S, Sharma A, Chauhan SS, Bhatla N, Kumar S, Bakhshi S, Gupta R, Kumar L. PARP-1 inhibitor modulate β-catenin signaling to enhance cisplatin sensitivity in cancer cervix. Oncotarget 2019;10:4262-75. [PMID: 31303961 DOI: 10.18632/oncotarget.27008] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 3.5] [Reference Citation Analysis]
519 Norris RE, Adamson PC, Nguyen VT, Fox E. Preclinical evaluation of the PARP inhibitor, olaparib, in combination with cytotoxic chemotherapy in pediatric solid tumors. Pediatr Blood Cancer 2014;61:145-50. [PMID: 24038812 DOI: 10.1002/pbc.24697] [Cited by in Crossref: 45] [Cited by in F6Publishing: 35] [Article Influence: 5.6] [Reference Citation Analysis]
520 Wong W, Raufi AG, Safyan RA, Bates SE, Manji GA. BRCA Mutations in Pancreas Cancer: Spectrum, Current Management, Challenges and Future Prospects. Cancer Manag Res. 2020;12:2731-2742. [PMID: 32368150 DOI: 10.2147/cmar.s211151] [Cited by in Crossref: 11] [Cited by in F6Publishing: 7] [Article Influence: 11.0] [Reference Citation Analysis]
521 McCann KE, Hurvitz SA. Advances in the use of PARP inhibitor therapy for breast cancer. Drugs Context 2018;7:212540. [PMID: 30116283 DOI: 10.7573/dic.212540] [Cited by in Crossref: 57] [Cited by in F6Publishing: 43] [Article Influence: 19.0] [Reference Citation Analysis]
522 Ellis MJ, Perou CM. The genomic landscape of breast cancer as a therapeutic roadmap. Cancer Discov 2013;3:27-34. [PMID: 23319768 DOI: 10.1158/2159-8290.CD-12-0462] [Cited by in Crossref: 144] [Cited by in F6Publishing: 80] [Article Influence: 18.0] [Reference Citation Analysis]
523 Peshkin BN, Alabek ML, Isaacs C. BRCA1/2 mutations and triple negative breast cancers. Breast Dis. 2010;32:25-33. [PMID: 21778580 DOI: 10.3233/bd-2010-0306] [Cited by in Crossref: 68] [Cited by in F6Publishing: 46] [Article Influence: 7.6] [Reference Citation Analysis]
524 Kummar S, Oza AM, Fleming GF, Sullivan DM, Gandara DR, Naughton MJ, Villalona-Calero MA, Morgan RJ Jr, Szabo PM, Youn A, Chen AP, Ji J, Allen DE, Lih CJ, Mehaffey MG, Walsh WD, McGregor PM 3rd, Steinberg SM, Williams PM, Kinders RJ, Conley BA, Simon RM, Doroshow JH. Randomized Trial of Oral Cyclophosphamide and Veliparib in High-Grade Serous Ovarian, Primary Peritoneal, or Fallopian Tube Cancers, or BRCA-Mutant Ovarian Cancer. Clin Cancer Res 2015;21:1574-82. [PMID: 25589624 DOI: 10.1158/1078-0432.CCR-14-2565] [Cited by in Crossref: 80] [Cited by in F6Publishing: 43] [Article Influence: 13.3] [Reference Citation Analysis]
525 Chen G, Chen J, Qiao Y, Shi Y, Liu W, Zeng Q, Xie H, Shi X, Sun Y, Liu X, Li T, Zhou L, Wan J, Xie T, Wang H, Wang F. ZNF830 mediates cancer chemoresistance through promoting homologous-recombination repair. Nucleic Acids Res 2018;46:1266-79. [PMID: 29244158 DOI: 10.1093/nar/gkx1258] [Cited by in Crossref: 20] [Cited by in F6Publishing: 15] [Article Influence: 10.0] [Reference Citation Analysis]
526 Somlo G, Frankel PH, Arun BK, Ma CX, Garcia AA, Cigler T, Cream LV, Harvey HA, Sparano JA, Nanda R, Chew HK, Moynihan TJ, Vahdat LT, Goetz MP, Beumer JH, Hurria A, Mortimer J, Piekarz R, Sand S, Herzog J, Van Tongeren LR, Ferry-Galow KV, Chen AP, Ruel C, Newman EM, Gandara DR, Weitzel JN. Efficacy of the PARP Inhibitor Veliparib with Carboplatin or as a Single Agent in Patients with Germline BRCA1- or BRCA2-Associated Metastatic Breast Cancer: California Cancer Consortium Trial NCT01149083. Clin Cancer Res 2017;23:4066-76. [PMID: 28356425 DOI: 10.1158/1078-0432.CCR-16-2714] [Cited by in Crossref: 55] [Cited by in F6Publishing: 26] [Article Influence: 13.8] [Reference Citation Analysis]
527 Schouten PC, Dackus GM, Marchetti S, van Tinteren H, Sonke GS, Schellens JH, Linn SC. A phase I followed by a randomized phase II trial of two cycles carboplatin-olaparib followed by olaparib monotherapy versus capecitabine in BRCA1- or BRCA2-mutated HER2-negative advanced breast cancer as first line treatment (REVIVAL): study protocol for a randomized controlled trial. Trials 2016;17:293. [PMID: 27323902 DOI: 10.1186/s13063-016-1423-0] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 2.0] [Reference Citation Analysis]
528 Nilsson MP, Hartman L, Idvall I, Kristoffersson U, Johannsson OT, Loman N. Long-term prognosis of early-onset breast cancer in a population-based cohort with a known BRCA1/2 mutation status. Breast Cancer Res Treat 2014;144:133-42. [PMID: 24477976 DOI: 10.1007/s10549-014-2842-9] [Cited by in Crossref: 16] [Cited by in F6Publishing: 13] [Article Influence: 2.3] [Reference Citation Analysis]
529 Göttgens EL, Ansems M, Leenders WPJ, Bussink J, Span PN. Genotyping and Characterization of HPV Status, Hypoxia, and Radiosensitivity in 22 Head and Neck Cancer Cell Lines. Cancers (Basel) 2021;13:1069. [PMID: 33802339 DOI: 10.3390/cancers13051069] [Reference Citation Analysis]
530 Ibrahim YH, García-García C, Serra V, He L, Torres-Lockhart K, Prat A, Anton P, Cozar P, Guzmán M, Grueso J, Rodríguez O, Calvo MT, Aura C, Díez O, Rubio IT, Pérez J, Rodón J, Cortés J, Ellisen LW, Scaltriti M, Baselga J. PI3K inhibition impairs BRCA1/2 expression and sensitizes BRCA-proficient triple-negative breast cancer to PARP inhibition. Cancer Discov 2012;2:1036-47. [PMID: 22915752 DOI: 10.1158/2159-8290.CD-11-0348] [Cited by in Crossref: 346] [Cited by in F6Publishing: 201] [Article Influence: 38.4] [Reference Citation Analysis]
531 Ribnikar D, Ribeiro JM, Pinto D, Sousa B, Pinto AC, Gomes E, Moser EC, Cardoso MJ, Cardoso F. Breast cancer under age 40: a different approach. Curr Treat Options Oncol. 2015;16:16. [PMID: 25796377 DOI: 10.1007/s11864-015-0334-8] [Cited by in Crossref: 34] [Cited by in F6Publishing: 34] [Article Influence: 5.7] [Reference Citation Analysis]
532 Wang Y, Bernhardy AJ, Nacson J, Krais JJ, Tan YF, Nicolas E, Radke MR, Handorf E, Llop-Guevara A, Balmaña J, Swisher EM, Serra V, Peri S, Johnson N. BRCA1 intronic Alu elements drive gene rearrangements and PARP inhibitor resistance. Nat Commun 2019;10:5661. [PMID: 31827092 DOI: 10.1038/s41467-019-13530-6] [Cited by in Crossref: 22] [Cited by in F6Publishing: 16] [Article Influence: 11.0] [Reference Citation Analysis]
533 Cruz C, Castroviejo-Bermejo M, Gutiérrez-Enríquez S, Llop-Guevara A, Ibrahim YH, Gris-Oliver A, Bonache S, Morancho B, Bruna A, Rueda OM, Lai Z, Polanska UM, Jones GN, Kristel P, de Bustos L, Guzman M, Rodríguez O, Grueso J, Montalban G, Caratú G, Mancuso F, Fasani R, Jiménez J, Howat WJ, Dougherty B, Vivancos A, Nuciforo P, Serres-Créixams X, Rubio IT, Oaknin A, Cadogan E, Barrett JC, Caldas C, Baselga J, Saura C, Cortés J, Arribas J, Jonkers J, Díez O, O'Connor MJ, Balmaña J, Serra V. RAD51 foci as a functional biomarker of homologous recombination repair and PARP inhibitor resistance in germline BRCA-mutated breast cancer. Ann Oncol 2018;29:1203-10. [PMID: 29635390 DOI: 10.1093/annonc/mdy099] [Cited by in Crossref: 123] [Cited by in F6Publishing: 90] [Article Influence: 61.5] [Reference Citation Analysis]
534 Smith SJ, Long A, Barrow JH, Macarthur DC, Coyle B, Grundy RG; Children's Cancer and Leukaemia Group Biological Studies Committee. Pediatric high-grade glioma: identification of poly(ADP-ribose) polymerase as a potential therapeutic target. Neuro Oncol 2011;13:1171-7. [PMID: 21849329 DOI: 10.1093/neuonc/nor115] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 1.4] [Reference Citation Analysis]
535 Fojo T, Bates S. Mechanisms of resistance to PARP inhibitors--three and counting. Cancer Discov 2013;3:20-3. [PMID: 23319766 DOI: 10.1158/2159-8290.CD-12-0514] [Cited by in Crossref: 48] [Cited by in F6Publishing: 26] [Article Influence: 6.0] [Reference Citation Analysis]
536 Spencer AV, Harbron C, Mander A, Wason J, Peers I. An adaptive design for updating the threshold value of a continuous biomarker. Stat Med 2016;35:4909-23. [PMID: 27417407 DOI: 10.1002/sim.7042] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 1.6] [Reference Citation Analysis]
537 Nile DL, Rae C, Hyndman IJ, Gaze MN, Mairs RJ. An evaluation in vitro of PARP-1 inhibitors, rucaparib and olaparib, as radiosensitisers for the treatment of neuroblastoma. BMC Cancer 2016;16:621. [PMID: 27515310 DOI: 10.1186/s12885-016-2656-8] [Cited by in Crossref: 30] [Cited by in F6Publishing: 23] [Article Influence: 6.0] [Reference Citation Analysis]
538 Audeh MW. Novel treatment strategies in triple-negative breast cancer: specific role of poly(adenosine diphosphate-ribose) polymerase inhibition. Pharmgenomics Pers Med 2014;7:307-16. [PMID: 25342917 DOI: 10.2147/PGPM.S39765] [Cited by in Crossref: 9] [Cited by in F6Publishing: 13] [Article Influence: 1.3] [Reference Citation Analysis]
539 McGonigle S, Chen Z, Wu J, Chang P, Kolber-Simonds D, Ackermann K, Twine NC, Shie JL, Miu JT, Huang KC, Moniz GA, Nomoto K. E7449: A dual inhibitor of PARP1/2 and tankyrase1/2 inhibits growth of DNA repair deficient tumors and antagonizes Wnt signaling. Oncotarget 2015;6:41307-23. [PMID: 26513298 DOI: 10.18632/oncotarget.5846] [Cited by in Crossref: 34] [Cited by in F6Publishing: 27] [Article Influence: 6.8] [Reference Citation Analysis]
540 Pal SK, Childs BH, Pegram M. Triple negative breast cancer: unmet medical needs. Breast Cancer Res Treat. 2011;125:627-636. [PMID: 21161370 DOI: 10.1007/s10549-010-1293-1] [Cited by in Crossref: 194] [Cited by in F6Publishing: 180] [Article Influence: 17.6] [Reference Citation Analysis]
541 Boysen G, Barbieri CE, Prandi D, Blattner M, Chae SS, Dahija A, Nataraj S, Huang D, Marotz C, Xu L, Huang J, Lecca P, Chhangawala S, Liu D, Zhou P, Sboner A, de Bono JS, Demichelis F, Houvras Y, Rubin MA. SPOP mutation leads to genomic instability in prostate cancer. Elife 2015;4:e09207. [PMID: 26374986 DOI: 10.7554/eLife.09207] [Cited by in Crossref: 83] [Cited by in F6Publishing: 61] [Article Influence: 13.8] [Reference Citation Analysis]
542 Luo J, Jin J, Yang F, Sun Z, Zhang W, Shi Y, Xu J, Guan X. The Correlation Between PARP1 and BRCA1 in AR Positive Triple-negative Breast Cancer. Int J Biol Sci 2016;12:1500-10. [PMID: 27994514 DOI: 10.7150/ijbs.16176] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 2.4] [Reference Citation Analysis]
543 Lee YH, Liu X, Qiu F, O'Connor TR, Yen Y, Ann DK. HP1β is a biomarker for breast cancer prognosis and PARP inhibitor therapy. PLoS One 2015;10:e0121207. [PMID: 25769025 DOI: 10.1371/journal.pone.0121207] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 2.7] [Reference Citation Analysis]
544 von Stechow L, Olsen JV. Proteomics insights into DNA damage response and translating this knowledge to clinical strategies. Proteomics 2017;17. [PMID: 27682984 DOI: 10.1002/pmic.201600018] [Cited by in Crossref: 10] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
545 Hyslop T, Michael Y, Avery T, Rui H. Population and target considerations for triple-negative breast cancer clinical trials. Biomark Med 2013;7:11-21. [PMID: 23387481 DOI: 10.2217/bmm.12.114] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 0.9] [Reference Citation Analysis]
546 Balko JM, Stricker TP, Arteaga CL. The genomic map of breast cancer: which roads lead to better targeted therapies? Breast Cancer Res 2013;15:209. [PMID: 23905624 DOI: 10.1186/bcr3435] [Cited by in Crossref: 10] [Cited by in F6Publishing: 6] [Article Influence: 1.4] [Reference Citation Analysis]
547 Zhou D, Li J, Bui K, Learoyd M, Berges A, Milenkova T, Al-Huniti N, Tomkinson H, Xu H. Bridging Olaparib Capsule and Tablet Formulations Using Population Pharmacokinetic Meta-analysis in Oncology Patients. Clin Pharmacokinet 2019;58:615-25. [PMID: 30357650 DOI: 10.1007/s40262-018-0714-x] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 11.0] [Reference Citation Analysis]
548 Goyal G, Fan T, Silberstein PT. Hereditary cancer syndromes: utilizing DNA repair deficiency as therapeutic target. Fam Cancer. 2016;15:359-366. [PMID: 26873719 DOI: 10.1007/s10689-016-9883-7] [Cited by in Crossref: 14] [Cited by in F6Publishing: 10] [Article Influence: 3.5] [Reference Citation Analysis]
549 Kaufman B, Shapira-Frommer R, Schmutzler RK, Audeh MW, Friedlander M, Balmaña J, Mitchell G, Fried G, Stemmer SM, Hubert A, Rosengarten O, Steiner M, Loman N, Bowen K, Fielding A, Domchek SM. Olaparib monotherapy in patients with advanced cancer and a germline BRCA1/2 mutation. J Clin Oncol 2015;33:244-50. [PMID: 25366685 DOI: 10.1200/JCO.2014.56.2728] [Cited by in Crossref: 1000] [Cited by in F6Publishing: 498] [Article Influence: 142.9] [Reference Citation Analysis]
550 Drew Y, Ledermann J, Hall G, Rea D, Glasspool R, Highley M, Jayson G, Sludden J, Murray J, Jamieson D, Halford S, Acton G, Backholer Z, Mangano R, Boddy A, Curtin N, Plummer R. Phase 2 multicentre trial investigating intermittent and continuous dosing schedules of the poly(ADP-ribose) polymerase inhibitor rucaparib in germline BRCA mutation carriers with advanced ovarian and breast cancer. Br J Cancer 2016;114:723-30. [PMID: 27002934 DOI: 10.1038/bjc.2016.41] [Cited by in Crossref: 91] [Cited by in F6Publishing: 63] [Article Influence: 18.2] [Reference Citation Analysis]
551 Ledermann JA, Harter P, Gourley C, Friedlander M, Vergote I, Rustin G, Scott C, Meier W, Shapira-Frommer R, Safra T, Matei D, Fielding A, Bennett B, Parry D, Spencer S, Mann H, Matulonis U. Quality of life during olaparib maintenance therapy in platinum-sensitive relapsed serous ovarian cancer. Br J Cancer 2016;115:1313-20. [PMID: 27824811 DOI: 10.1038/bjc.2016.348] [Cited by in Crossref: 34] [Cited by in F6Publishing: 28] [Article Influence: 6.8] [Reference Citation Analysis]
552 Makohon-Moore A, Brosnan JA, Iacobuzio-Donahue CA. Pancreatic cancer genomics: insights and opportunities for clinical translation. Genome Med 2013;5:26. [PMID: 23673020 DOI: 10.1186/gm430] [Cited by in Crossref: 17] [Cited by in F6Publishing: 15] [Article Influence: 2.1] [Reference Citation Analysis]
553 Keung MYT, Wu Y, Vadgama JV. PARP Inhibitors as a Therapeutic Agent for Homologous Recombination Deficiency in Breast Cancers. J Clin Med 2019;8:E435. [PMID: 30934991 DOI: 10.3390/jcm8040435] [Cited by in Crossref: 46] [Cited by in F6Publishing: 40] [Article Influence: 23.0] [Reference Citation Analysis]
554 Neiger HE, Siegler EL, Shi Y. Breast Cancer Predisposition Genes and Synthetic Lethality. Int J Mol Sci 2021;22:5614. [PMID: 34070674 DOI: 10.3390/ijms22115614] [Reference Citation Analysis]
555 Mazzotta A, Partipilo G, De Summa S, Giotta F, Simone G, Mangia A. Nuclear PARP1 expression and its prognostic significance in breast cancer patients. Tumour Biol 2016;37:6143-53. [PMID: 26614429 DOI: 10.1007/s13277-015-4465-0] [Cited by in Crossref: 19] [Cited by in F6Publishing: 18] [Article Influence: 3.2] [Reference Citation Analysis]
556 Liu J, Cristea MC, Frankel P, Neuhausen SL, Steele L, Engelstaedter V, Matulonis U, Sand S, Tung N, Garber JE, Weitzel JN. Clinical characteristics and outcomes of BRCA-associated ovarian cancer: genotype and survival. Cancer Genet 2012;205:34-41. [PMID: 22429596 DOI: 10.1016/j.cancergen.2012.01.008] [Cited by in Crossref: 31] [Cited by in F6Publishing: 26] [Article Influence: 3.4] [Reference Citation Analysis]
557 Cavallo F, Graziani G, Antinozzi C, Feldman DR, Houldsworth J, Bosl GJ, Chaganti RS, Moynahan ME, Jasin M, Barchi M. Reduced proficiency in homologous recombination underlies the high sensitivity of embryonal carcinoma testicular germ cell tumors to Cisplatin and poly (adp-ribose) polymerase inhibition. PLoS One 2012;7:e51563. [PMID: 23251575 DOI: 10.1371/journal.pone.0051563] [Cited by in Crossref: 55] [Cited by in F6Publishing: 50] [Article Influence: 6.1] [Reference Citation Analysis]
558 Jiang Y, Dai H, Li Y, Yin J, Guo S, Lin SY, McGrail DJ. PARP inhibitors synergize with gemcitabine by potentiating DNA damage in non-small-cell lung cancer.Int J Cancer. 2019;144:1092-1103. [PMID: 30152517 DOI: 10.1002/ijc.31770] [Cited by in Crossref: 15] [Cited by in F6Publishing: 10] [Article Influence: 5.0] [Reference Citation Analysis]
559 Boukerroucha M, Josse C, ElGuendi S, Boujemla B, Frères P, Marée R, Wenric S, Segers K, Collignon J, Jerusalem G, Bours V. Evaluation of BRCA1-related molecular features and microRNAs as prognostic factors for triple negative breast cancers. BMC Cancer 2015;15:755. [PMID: 26490435 DOI: 10.1186/s12885-015-1740-9] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 2.3] [Reference Citation Analysis]
560 Niraj J, Färkkilä A, D'Andrea AD. The Fanconi Anemia Pathway in Cancer. Annu Rev Cancer Biol 2019;3:457-78. [PMID: 30882047 DOI: 10.1146/annurev-cancerbio-030617-050422] [Cited by in Crossref: 124] [Cited by in F6Publishing: 79] [Article Influence: 41.3] [Reference Citation Analysis]
561 Radovich M, Clare SE, Atale R, Pardo I, Hancock BA, Solzak JP, Kassem N, Mathieson T, Storniolo AM, Rufenbarger C, Lillemoe HA, Blosser RJ, Choi MR, Sauder CA, Doxey D, Henry JE, Hilligoss EE, Sakarya O, Hyland FC, Hickenbotham M, Zhu J, Glasscock J, Badve S, Ivan M, Liu Y, Sledge GW, Schneider BP. Characterizing the heterogeneity of triple-negative breast cancers using microdissected normal ductal epithelium and RNA-sequencing. Breast Cancer Res Treat 2014;143:57-68. [PMID: 24292813 DOI: 10.1007/s10549-013-2780-y] [Cited by in Crossref: 19] [Cited by in F6Publishing: 16] [Article Influence: 2.4] [Reference Citation Analysis]
562 Jhan JR, Andrechek ER. Effective personalized therapy for breast cancer based on predictions of cell signaling pathway activation from gene expression analysis. Oncogene 2017;36:3553-61. [PMID: 28135251 DOI: 10.1038/onc.2016.503] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 2.3] [Reference Citation Analysis]
563 O'Reilly EM, Lee JW, Lowery MA, Capanu M, Stadler ZK, Moore MJ, Dhani N, Kindler HL, Estrella H, Maynard H, Golan T, Segal A, Salo-Mullen EE, Yu KH, Epstein AS, Segal M, Brenner R, Do RK, Chen AP, Tang LH, Kelsen DP. Phase 1 trial evaluating cisplatin, gemcitabine, and veliparib in 2 patient cohorts: Germline BRCA mutation carriers and wild-type BRCA pancreatic ductal adenocarcinoma. Cancer 2018;124:1374-82. [PMID: 29338080 DOI: 10.1002/cncr.31218] [Cited by in Crossref: 53] [Cited by in F6Publishing: 44] [Article Influence: 17.7] [Reference Citation Analysis]
564 Slavin TP, Niell-Swiller M, Solomon I, Nehoray B, Rybak C, Blazer KR, Weitzel JN. Clinical Application of Multigene Panels: Challenges of Next-Generation Counseling and Cancer Risk Management. Front Oncol 2015;5:208. [PMID: 26484312 DOI: 10.3389/fonc.2015.00208] [Cited by in Crossref: 15] [Cited by in F6Publishing: 48] [Article Influence: 2.5] [Reference Citation Analysis]
565 Cohen PR, Tomson BN, Elkin SK, Marchlik E, Carter JL, Kurzrock R. Genomic portfolio of Merkel cell carcinoma as determined by comprehensive genomic profiling: implications for targeted therapeutics. Oncotarget 2016;7:23454-67. [PMID: 26981779 DOI: 10.18632/oncotarget.8032] [Cited by in Crossref: 26] [Cited by in F6Publishing: 25] [Article Influence: 8.7] [Reference Citation Analysis]
566 Drew Y. The development of PARP inhibitors in ovarian cancer: from bench to bedside. Br J Cancer 2015;113 Suppl 1:S3-9. [PMID: 26669452 DOI: 10.1038/bjc.2015.394] [Cited by in Crossref: 32] [Cited by in F6Publishing: 27] [Article Influence: 6.4] [Reference Citation Analysis]
567 McMullin RP, Wittner BS, Yang C, Denton-Schneider BR, Hicks D, Singavarapu R, Moulis S, Lee J, Akbari MR, Narod SA, Aldape KD, Steeg PS, Ramaswamy S, Sgroi DC. A BRCA1 deficient-like signature is enriched in breast cancer brain metastases and predicts DNA damage-induced poly (ADP-ribose) polymerase inhibitor sensitivity. Breast Cancer Res 2014;16:R25. [PMID: 24625110 DOI: 10.1186/bcr3625] [Cited by in Crossref: 35] [Cited by in F6Publishing: 25] [Article Influence: 5.0] [Reference Citation Analysis]
568 Tian S, Lou L, Tian M, Lu G, Tian J, Chen X. MAPK4 deletion enhances radiation effects and triggers synergistic lethality with simultaneous PARP1 inhibition in cervical cancer. J Exp Clin Cancer Res 2020;39:143. [PMID: 32711558 DOI: 10.1186/s13046-020-01644-5] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
569 Marmé F, Schneeweiss A. Targeted Therapies in Triple-Negative Breast Cancer. Breast Care (Basel) 2015;10:159-66. [PMID: 26557820 DOI: 10.1159/000433622] [Cited by in Crossref: 34] [Cited by in F6Publishing: 31] [Article Influence: 5.7] [Reference Citation Analysis]
570 Zhan T, Boutros M. Towards a compendium of essential genes - From model organisms to synthetic lethality in cancer cells. Crit Rev Biochem Mol Biol 2016;51:74-85. [PMID: 26627871 DOI: 10.3109/10409238.2015.1117053] [Cited by in Crossref: 32] [Cited by in F6Publishing: 19] [Article Influence: 5.3] [Reference Citation Analysis]
571 Kurman RJ, Shih IeM. Molecular pathogenesis and extraovarian origin of epithelial ovarian cancer--shifting the paradigm. Hum Pathol. 2011;42:918-931. [PMID: 21683865 DOI: 10.1016/j.humpath.2011.03.003] [Cited by in Crossref: 681] [Cited by in F6Publishing: 547] [Article Influence: 68.1] [Reference Citation Analysis]
572 Santana Dos Santos E, Lallemand F, Petitalot A, Caputo SM, Rouleau E. HRness in Breast and Ovarian Cancers. Int J Mol Sci 2020;21:E3850. [PMID: 32481735 DOI: 10.3390/ijms21113850] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 5.0] [Reference Citation Analysis]
573 Plantamura I, Cosentino G, Cataldo A. MicroRNAs and DNA-Damaging Drugs in Breast Cancer: Strength in Numbers. Front Oncol 2018;8:352. [PMID: 30234015 DOI: 10.3389/fonc.2018.00352] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 2.7] [Reference Citation Analysis]
574 Swanton C, Burrell RA, Futreal PA. Breast cancer genome heterogeneity: a challenge to personalised medicine? Breast Cancer Res 2011;13:104. [PMID: 21345264 DOI: 10.1186/bcr2807] [Cited by in Crossref: 40] [Cited by in F6Publishing: 33] [Article Influence: 4.0] [Reference Citation Analysis]
575 Tommasi S, Pinto R, Danza K, Pilato B, Palumbo O, Micale L, De Summa S. miR-151-5p, targeting chromatin remodeler SMARCA5, as a marker for the BRCAness phenotype. Oncotarget 2016;7:80363-72. [PMID: 27385001 DOI: 10.18632/oncotarget.10345] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 3.0] [Reference Citation Analysis]
576 Pasculli B, Barbano R, Fontana A, Biagini T, Di Viesti MP, Rendina M, Valori VM, Morritti M, Bravaccini S, Ravaioli S, Maiello E, Graziano P, Murgo R, Copetti M, Mazza T, Fazio VM, Esteller M, Parrella P. Hsa-miR-155-5p Up-Regulation in Breast Cancer and Its Relevance for Treatment With Poly[ADP-Ribose] Polymerase 1 (PARP-1) Inhibitors. Front Oncol 2020;10:1415. [PMID: 32903519 DOI: 10.3389/fonc.2020.01415] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 6.0] [Reference Citation Analysis]
577 Gerhards NM, Blomen VA, Mutlu M, Nieuwenhuis J, Howald D, Guyader C, Jonkers J, Brummelkamp TR, Rottenberg S. Haploid genetic screens identify genetic vulnerabilities to microtubule-targeting agents. Mol Oncol 2018;12:953-71. [PMID: 29689640 DOI: 10.1002/1878-0261.12307] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 2.7] [Reference Citation Analysis]
578 Liedtke C, Kiesel L. Current Issues of Targeted Therapy in Metastatic Triple-Negative Breast Cancer. Breast Care (Basel) 2011;6:234-9. [PMID: 21779231 DOI: 10.1159/000328964] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 0.9] [Reference Citation Analysis]
579 Guidugli L, Shimelis H, Masica DL, Pankratz VS, Lipton GB, Singh N, Hu C, Monteiro ANA, Lindor NM, Goldgar DE, Karchin R, Iversen ES, Couch FJ. Assessment of the Clinical Relevance of BRCA2 Missense Variants by Functional and Computational Approaches. Am J Hum Genet 2018;102:233-48. [PMID: 29394989 DOI: 10.1016/j.ajhg.2017.12.013] [Cited by in Crossref: 33] [Cited by in F6Publishing: 25] [Article Influence: 11.0] [Reference Citation Analysis]
580 Zimmer AS, Gillard M, Lipkowitz S, Lee JM. Update on PARP Inhibitors in Breast Cancer. Curr Treat Options Oncol 2018;19:21. [PMID: 29644491 DOI: 10.1007/s11864-018-0540-2] [Cited by in Crossref: 44] [Cited by in F6Publishing: 36] [Article Influence: 14.7] [Reference Citation Analysis]
581 Press DJ, Miller ME, Liederbach E, Yao K, Huo D. De novo metastasis in breast cancer: occurrence and overall survival stratified by molecular subtype. Clin Exp Metastasis 2017;34:457-65. [PMID: 29288366 DOI: 10.1007/s10585-017-9871-9] [Cited by in Crossref: 15] [Cited by in F6Publishing: 13] [Article Influence: 3.8] [Reference Citation Analysis]
582 Baldwin P, Ohman AW, Tangutoori S, Dinulescu DM, Sridhar S. Intraperitoneal delivery of NanoOlaparib for disseminated late-stage cancer treatment. Int J Nanomedicine 2018;13:8063-74. [PMID: 30555227 DOI: 10.2147/IJN.S186881] [Cited by in Crossref: 6] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
583 Gupta I, Burney I, Al-Moundhri MS, Tamimi Y. Molecular genetics complexity impeding research progress in breast and ovarian cancers. Mol Clin Oncol 2017;7:3-14. [PMID: 28685067 DOI: 10.3892/mco.2017.1275] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
584 Chen A. PARP inhibitors: its role in treatment of cancer. Chin J Cancer. 2011;30:463-471. [PMID: 21718592 DOI: 10.5732/cjc.011.10111] [Cited by in Crossref: 44] [Cited by in F6Publishing: 44] [Article Influence: 5.5] [Reference Citation Analysis]
585 Ordonez LD, Hay T, McEwen R, Polanska UM, Hughes A, Delpuech O, Cadogan E, Powell S, Dry J, Tornillo G, Silcock L, Leo E, O'Connor MJ, Clarke AR, Smalley MJ. Rapid activation of epithelial-mesenchymal transition drives PARP inhibitor resistance in Brca2-mutant mammary tumours. Oncotarget. 2019;10:2586-2606. [PMID: 31080552 DOI: 10.18632/oncotarget.26830] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 3.5] [Reference Citation Analysis]
586 Daemen A, Wolf DM, Korkola JE, Griffith OL, Frankum JR, Brough R, Jakkula LR, Wang NJ, Natrajan R, Reis-Filho JS, Lord CJ, Ashworth A, Spellman PT, Gray JW, van't Veer LJ. Cross-platform pathway-based analysis identifies markers of response to the PARP inhibitor olaparib. Breast Cancer Res Treat 2012;135:505-17. [PMID: 22875744 DOI: 10.1007/s10549-012-2188-0] [Cited by in Crossref: 52] [Cited by in F6Publishing: 43] [Article Influence: 5.8] [Reference Citation Analysis]
587 Prasad CB, Prasad SB, Yadav SS, Pandey LK, Singh S, Pradhan S, Narayan G. Olaparib modulates DNA repair efficiency, sensitizes cervical cancer cells to cisplatin and exhibits anti-metastatic property. Sci Rep 2017;7:12876. [PMID: 28993682 DOI: 10.1038/s41598-017-13232-3] [Cited by in Crossref: 28] [Cited by in F6Publishing: 25] [Article Influence: 7.0] [Reference Citation Analysis]
588 Maxwell KN, Domchek SM. Cancer treatment according to BRCA1 and BRCA2 mutations. Nat Rev Clin Oncol 2012;9:520-8. [PMID: 22825375 DOI: 10.1038/nrclinonc.2012.123] [Cited by in Crossref: 52] [Cited by in F6Publishing: 47] [Article Influence: 5.8] [Reference Citation Analysis]
589 Hiller DJ, Chu QD. Current Status of Poly(ADP-ribose) Polymerase Inhibitors as Novel Therapeutic Agents for Triple-Negative Breast Cancer. Int J Breast Cancer 2012;2012:829315. [PMID: 22295252 DOI: 10.1155/2012/829315] [Cited by in Crossref: 5] [Cited by in F6Publishing: 8] [Article Influence: 0.5] [Reference Citation Analysis]
590 Bianchini G, Balko JM, Mayer IA, Sanders ME, Gianni L. Triple-negative breast cancer: challenges and opportunities of a heterogeneous disease. Nat Rev Clin Oncol 2016;13:674-90. [PMID: 27184417 DOI: 10.1038/nrclinonc.2016.66] [Cited by in Crossref: 903] [Cited by in F6Publishing: 801] [Article Influence: 180.6] [Reference Citation Analysis]
591 Ricks TK, Chiu HJ, Ison G, Kim G, McKee AE, Kluetz P, Pazdur R. Successes and Challenges of PARP Inhibitors in Cancer Therapy. Front Oncol 2015;5:222. [PMID: 26528434 DOI: 10.3389/fonc.2015.00222] [Cited by in Crossref: 44] [Cited by in F6Publishing: 36] [Article Influence: 7.3] [Reference Citation Analysis]
592 Matulonis UA, Wulf GM, Barry WT, Birrer M, Westin SN, Farooq S, Bell-McGuinn KM, Obermayer E, Whalen C, Spagnoletti T, Luo W, Liu H, Hok RC, Aghajanian C, Solit DB, Mills GB, Taylor BS, Won H, Berger MF, Palakurthi S, Liu J, Cantley LC, Winer E. Phase I dose escalation study of the PI3kinase pathway inhibitor BKM120 and the oral poly (ADP ribose) polymerase (PARP) inhibitor olaparib for the treatment of high-grade serous ovarian and breast cancer. Ann Oncol 2017;28:512-8. [PMID: 27993796 DOI: 10.1093/annonc/mdw672] [Cited by in Crossref: 103] [Cited by in F6Publishing: 81] [Article Influence: 25.8] [Reference Citation Analysis]
593 Burgess M, Puhalla S. BRCA 1/2-Mutation Related and Sporadic Breast and Ovarian Cancers: More Alike than Different. Front Oncol 2014;4:19. [PMID: 24579064 DOI: 10.3389/fonc.2014.00019] [Cited by in Crossref: 15] [Cited by in F6Publishing: 19] [Article Influence: 2.1] [Reference Citation Analysis]
594 O'Neil NJ, van Pel DM, Hieter P. Synthetic lethality and cancer: cohesin and PARP at the replication fork. Trends Genet 2013;29:290-7. [PMID: 23333522 DOI: 10.1016/j.tig.2012.12.004] [Cited by in Crossref: 22] [Cited by in F6Publishing: 18] [Article Influence: 2.8] [Reference Citation Analysis]
595 Pouptsis A, Swafe L, Patwardhan M, Stavraka C. Surgical and Systemic Treatment of Hereditary Breast Cancer: A Mini-Review With a Focus on BRCA1 and BRCA2 Mutations. Front Oncol 2020;10:553080. [PMID: 33194613 DOI: 10.3389/fonc.2020.553080] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
596 Hochberg ME, Thomas F, Assenat E, Hibner U. Preventive evolutionary medicine of cancers. Evol Appl 2013;6:134-43. [PMID: 23396860 DOI: 10.1111/eva.12033] [Cited by in Crossref: 21] [Cited by in F6Publishing: 16] [Article Influence: 2.3] [Reference Citation Analysis]
597 Zhang L, Zhang F, Zhang W, Chen L, Gao N, Men Y, Xu X, Jiang Y. Harmine suppresses homologous recombination repair and inhibits proliferation of hepatoma cells. Cancer Biol Ther 2015;16:1585-92. [PMID: 26382920 DOI: 10.1080/15384047.2015.1078021] [Cited by in Crossref: 21] [Cited by in F6Publishing: 16] [Article Influence: 3.5] [Reference Citation Analysis]
598 Zhang JF, Liu J, Wang Y, Zhang B. Novel therapeutic strategies for patients with triple-negative breast cancer. Onco Targets Ther. 2016;9:6519-6528. [PMID: 27799799 DOI: 10.2147/ott.s105716] [Cited by in Crossref: 16] [Cited by in F6Publishing: 8] [Article Influence: 3.2] [Reference Citation Analysis]
599 Zhang Y, Liao XH, Xie HY, Shao ZM, Li DQ. RBR-type E3 ubiquitin ligase RNF144A targets PARP1 for ubiquitin-dependent degradation and regulates PARP inhibitor sensitivity in breast cancer cells. Oncotarget 2017;8:94505-18. [PMID: 29212245 DOI: 10.18632/oncotarget.21784] [Cited by in Crossref: 14] [Cited by in F6Publishing: 10] [Article Influence: 3.5] [Reference Citation Analysis]
600 Rowley M, Ohashi A, Mondal G, Mills L, Yang L, Zhang L, Sundsbak R, Shapiro V, Muders MH, Smyrk T. Inactivation of Brca2 promotes Trp53-associated but inhibits KrasG12D-dependent pancreatic cancer development in mice. Gastroenterology. 2011;140:1303-1313.e1-3. [PMID: 21199651 DOI: 10.1053/j.gastro.2010.12.039] [Cited by in Crossref: 44] [Cited by in F6Publishing: 46] [Article Influence: 4.4] [Reference Citation Analysis]
601 Goldhirsch A, Wood WC, Coates AS, Gelber RD, Thürlimann B, Senn HJ; Panel members. Strategies for subtypes--dealing with the diversity of breast cancer: highlights of the St. Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011. Ann Oncol 2011;22:1736-47. [PMID: 21709140 DOI: 10.1093/annonc/mdr304] [Cited by in Crossref: 2110] [Cited by in F6Publishing: 1729] [Article Influence: 211.0] [Reference Citation Analysis]
602 Pirinen E, Cantó C, Jo YS, Morato L, Zhang H, Menzies KJ, Williams EG, Mouchiroud L, Moullan N, Hagberg C, Li W, Timmers S, Imhof R, Verbeek J, Pujol A, van Loon B, Viscomi C, Zeviani M, Schrauwen P, Sauve AA, Schoonjans K, Auwerx J. Pharmacological Inhibition of poly(ADP-ribose) polymerases improves fitness and mitochondrial function in skeletal muscle. Cell Metab 2014;19:1034-41. [PMID: 24814482 DOI: 10.1016/j.cmet.2014.04.002] [Cited by in Crossref: 156] [Cited by in F6Publishing: 146] [Article Influence: 22.3] [Reference Citation Analysis]
603 Verdial FC, Bartek MA, Anderson BO, Javid SH. Genetic testing and surgical treatment after breast cancer diagnosis: Results from a national online cohort. J Surg Oncol 2021;123:1504-12. [PMID: 33735483 DOI: 10.1002/jso.26372] [Reference Citation Analysis]
604 Jara L, Morales S, de Mayo T, Gonzalez-Hormazabal P, Carrasco V, Godoy R. Mutations in BRCA1, BRCA2 and other breast and ovarian cancer susceptibility genes in Central and South American populations. Biol Res 2017;50:35. [PMID: 28985766 DOI: 10.1186/s40659-017-0139-2] [Cited by in Crossref: 16] [Cited by in F6Publishing: 12] [Article Influence: 4.0] [Reference Citation Analysis]
605 O'Reilly EM, Lee JW, Zalupski M, Capanu M, Park J, Golan T, Tahover E, Lowery MA, Chou JF, Sahai V, Brenner R, Kindler HL, Yu KH, Zervoudakis A, Vemuri S, Stadler ZK, Do RKG, Dhani N, Chen AP, Kelsen DP. Randomized, Multicenter, Phase II Trial of Gemcitabine and Cisplatin With or Without Veliparib in Patients With Pancreas Adenocarcinoma and a Germline BRCA/PALB2 Mutation. J Clin Oncol 2020;38:1378-88. [PMID: 31976786 DOI: 10.1200/JCO.19.02931] [Cited by in Crossref: 83] [Cited by in F6Publishing: 36] [Article Influence: 83.0] [Reference Citation Analysis]
606 Guidugli L, Carreira A, Caputo SM, Ehlen A, Galli A, Monteiro AN, Neuhausen SL, Hansen TV, Couch FJ, Vreeswijk MP; ENIGMA consortium. Functional assays for analysis of variants of uncertain significance in BRCA2. Hum Mutat 2014;35:151-64. [PMID: 24323938 DOI: 10.1002/humu.22478] [Cited by in Crossref: 73] [Cited by in F6Publishing: 64] [Article Influence: 9.1] [Reference Citation Analysis]
607 de Haan R, van Werkhoven E, van den Heuvel MM, Peulen HMU, Sonke GS, Elkhuizen P, van den Brekel MWM, Tesselaar MET, Vens C, Schellens JHM, van Triest B, Verheij M. Study protocols of three parallel phase 1 trials combining radical radiotherapy with the PARP inhibitor olaparib. BMC Cancer 2019;19:901. [PMID: 31500595 DOI: 10.1186/s12885-019-6121-3] [Cited by in Crossref: 15] [Cited by in F6Publishing: 11] [Article Influence: 7.5] [Reference Citation Analysis]
608 Runkle EA, Zhang H, Cai Z, Zhu Z, Karger BL, Wu SL, O'Rourke DM, Zhou Z, Wang Q, Greene MI. Reversion of the ErbB malignant phenotype and the DNA damage response. Exp Mol Pathol 2012;93:324-33. [PMID: 23022358 DOI: 10.1016/j.yexmp.2012.09.007] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
609 Orth M, Lauber K, Niyazi M, Friedl AA, Li M, Maihöfer C, Schüttrumpf L, Ernst A, Niemöller OM, Belka C. Current concepts in clinical radiation oncology. Radiat Environ Biophys 2014;53:1-29. [PMID: 24141602 DOI: 10.1007/s00411-013-0497-2] [Cited by in Crossref: 92] [Cited by in F6Publishing: 77] [Article Influence: 11.5] [Reference Citation Analysis]
610 Sharma P. Update on the Treatment of Early-Stage Triple-Negative Breast Cancer. Curr Treat Options Oncol 2018;19:22. [PMID: 29656345 DOI: 10.1007/s11864-018-0539-8] [Cited by in Crossref: 32] [Cited by in F6Publishing: 30] [Article Influence: 10.7] [Reference Citation Analysis]
611 Nur Husna SM, Tan HT, Mohamud R, Dyhl-Polk A, Wong KK. Inhibitors targeting CDK4/6, PARP and PI3K in breast cancer: a review. Ther Adv Med Oncol 2018;10:1758835918808509. [PMID: 30542378 DOI: 10.1177/1758835918808509] [Cited by in Crossref: 19] [Cited by in F6Publishing: 16] [Article Influence: 6.3] [Reference Citation Analysis]
612 Klein AP. Identifying people at a high risk of developing pancreatic cancer. Nat Rev Cancer. 2013;13:66-74. [PMID: 23222481 DOI: 10.1038/nrc3420] [Cited by in Crossref: 90] [Cited by in F6Publishing: 73] [Article Influence: 10.0] [Reference Citation Analysis]
613 Song W, Tang L, Xu Y, Xu J, Zhang W, Xie H, Wang S, Guan X. PARP inhibitor increases chemosensitivity by upregulating miR-664b-5p in BRCA1-mutated triple-negative breast cancer. Sci Rep 2017;7:42319. [PMID: 28176879 DOI: 10.1038/srep42319] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 2.3] [Reference Citation Analysis]
614 van der Wijst MG, Huisman C, Mposhi A, Roelfes G, Rots MG. Targeting Nrf2 in healthy and malignant ovarian epithelial cells: Protection versus promotion. Mol Oncol 2015;9:1259-73. [PMID: 25841766 DOI: 10.1016/j.molonc.2015.03.003] [Cited by in Crossref: 9] [Cited by in F6Publishing: 12] [Article Influence: 1.5] [Reference Citation Analysis]
615 Velic D, Couturier AM, Ferreira MT, Rodrigue A, Poirier GG, Fleury F, Masson JY. DNA Damage Signalling and Repair Inhibitors: The Long-Sought-After Achilles' Heel of Cancer. Biomolecules 2015;5:3204-59. [PMID: 26610585 DOI: 10.3390/biom5043204] [Cited by in Crossref: 60] [Cited by in F6Publishing: 47] [Article Influence: 10.0] [Reference Citation Analysis]
616 Mini E, Landini I, Lucarini L, Lapucci A, Napoli C, Perrone G, Tassi R, Masini E, Moroni F, Nobili S. The Inhibitory Effects of HYDAMTIQ, a Novel PARP Inhibitor, on Growth in Human Tumor Cell Lines With Defective DNA Damage Response Pathways. Oncol Res 2017;25:1441-51. [PMID: 28429680 DOI: 10.3727/096504017X14926854178616] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
617 Qu J, Sun W, Zhong J, Lv H, Zhu M, Xu J, Jin N, Xie Z, Tan M, Lin SH, Geng M, Ding J, Huang M. Phosphoglycerate mutase 1 regulates dNTP pool and promotes homologous recombination repair in cancer cells. J Cell Biol 2017;216:409-24. [PMID: 28122957 DOI: 10.1083/jcb.201607008] [Cited by in Crossref: 28] [Cited by in F6Publishing: 28] [Article Influence: 7.0] [Reference Citation Analysis]
618 Litton JK, Scoggins M, Ramirez DL, Murthy RK, Whitman GJ, Hess KR, Adrada BE, Moulder SL, Barcenas CH, Valero V, Gomez JS, Mittendorf EA, Thompson A, Helgason T, Mills GB, Piwnica-Worms H, Arun BK. A feasibility study of neoadjuvant talazoparib for operable breast cancer patients with a germline BRCA mutation demonstrates marked activity. NPJ Breast Cancer 2017;3:49. [PMID: 29238749 DOI: 10.1038/s41523-017-0052-4] [Cited by in Crossref: 26] [Cited by in F6Publishing: 24] [Article Influence: 6.5] [Reference Citation Analysis]
619 Curtin NJ. Inhibiting the DNA damage response as a therapeutic manoeuvre in cancer. Br J Pharmacol 2013;169:1745-65. [PMID: 23682925 DOI: 10.1111/bph.12244] [Cited by in Crossref: 47] [Cited by in F6Publishing: 36] [Article Influence: 6.7] [Reference Citation Analysis]
620 Yadav S, Sehrawat A, Eroglu Z, Somlo G, Hickey R, Yadav S, Liu X, Awasthi YC, Awasthi S. Role of SMC1 in overcoming drug resistance in triple negative breast cancer. PLoS One 2013;8:e64338. [PMID: 23717600 DOI: 10.1371/journal.pone.0064338] [Cited by in Crossref: 18] [Cited by in F6Publishing: 19] [Article Influence: 2.3] [Reference Citation Analysis]
621 Labrie M, Kim TB, Ju Z, Lee S, Zhao W, Fang Y, Lu Y, Chen K, Ramirez P, Frumovitz M, Meyer L, Fleming ND, Sood AK, Coleman RL, Mills GB, Westin SN. Adaptive responses in a PARP inhibitor window of opportunity trial illustrate limited functional interlesional heterogeneity and potential combination therapy options. Oncotarget 2019;10:3533-46. [PMID: 31191824 DOI: 10.18632/oncotarget.26947] [Cited by in Crossref: 9] [Cited by in F6Publishing: 4] [Article Influence: 4.5] [Reference Citation Analysis]
622 Rottenberg S, Vollebergh MA, de Hoon B, de Ronde J, Schouten PC, Kersbergen A, Zander SA, Pajic M, Jaspers JE, Jonkers M, Lodén M, Sol W, van der Burg E, Wesseling J, Gillet JP, Gottesman MM, Gribnau J, Wessels L, Linn SC, Jonkers J, Borst P. Impact of intertumoral heterogeneity on predicting chemotherapy response of BRCA1-deficient mammary tumors. Cancer Res 2012;72:2350-61. [PMID: 22396490 DOI: 10.1158/0008-5472.CAN-11-4201] [Cited by in Crossref: 36] [Cited by in F6Publishing: 19] [Article Influence: 4.0] [Reference Citation Analysis]
623 Lobo J, Constâncio V, Guimarães-Teixeira C, Leite-Silva P, Miranda-Gonçalves V, Sequeira JP, Pistoni L, Guimarães R, Cantante M, Braga I, Maurício J, Looijenga LHJ, Henrique R, Jerónimo C. Promoter methylation of DNA homologous recombination genes is predictive of the responsiveness to PARP inhibitor treatment in testicular germ cell tumors. Mol Oncol 2021;15:846-65. [PMID: 33513287 DOI: 10.1002/1878-0261.12909] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
624 Ancot F, Arcand SL, Mes-Masson AM, Provencher DM, Tonin PN. Double PALB2 and BRCA1/BRCA2 mutation carriers are rare in breast cancer and breast-ovarian cancer syndrome families from the French Canadian founder population. Oncol Lett 2015;9:2787-90. [PMID: 26137147 DOI: 10.3892/ol.2015.3123] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
625 Smith MA, Hampton OA, Reynolds CP, Kang MH, Maris JM, Gorlick R, Kolb EA, Lock R, Carol H, Keir ST, Wu J, Kurmasheva RT, Wheeler DA, Houghton PJ. Initial testing (stage 1) of the PARP inhibitor BMN 673 by the pediatric preclinical testing program: PALB2 mutation predicts exceptional in vivo response to BMN 673. Pediatr Blood Cancer 2015;62:91-8. [PMID: 25263539 DOI: 10.1002/pbc.25201] [Cited by in Crossref: 52] [Cited by in F6Publishing: 43] [Article Influence: 7.4] [Reference Citation Analysis]
626 Gaceb H, Cherbal F, Bakour R, Ould-Rouis A, Mahfouf H. Clinicopathological and Molecular Study of Triple-Negative Breast Cancer in Algerian Patients. Pathol Oncol Res 2018;24:297-308. [PMID: 28478614 DOI: 10.1007/s12253-017-0242-2] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
627 Caruso LB, Martin KA, Lauretti E, Hulse M, Siciliano M, Lupey-Green LN, Abraham A, Skorski T, Tempera I. Poly(ADP-ribose) Polymerase 1, PARP1, modifies EZH2 and inhibits EZH2 histone methyltransferase activity after DNA damage. Oncotarget 2018;9:10585-605. [PMID: 29535829 DOI: 10.18632/oncotarget.24291] [Cited by in Crossref: 16] [Cited by in F6Publishing: 13] [Article Influence: 5.3] [Reference Citation Analysis]
628 Lord CJ, Ashworth A. PARP inhibitors: Synthetic lethality in the clinic. Science 2017;355:1152-8. [PMID: 28302823 DOI: 10.1126/science.aam7344] [Cited by in Crossref: 882] [Cited by in F6Publishing: 720] [Article Influence: 220.5] [Reference Citation Analysis]
629 Ma J, Deng H, Li J, Hu S, Yang Y, Liu S, Han X. Efficacy and safety of olaparib maintenance therapy in platinum-sensitive ovarian cancer patients with BRCA mutations: a meta-analysis on randomized controlled trials. Cancer Manag Res 2019;11:3061-78. [PMID: 31114351 DOI: 10.2147/CMAR.S191107] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
630 Feng Y, Li X, Cassady K, Zou Z, Zhang X. TET2 Function in Hematopoietic Malignancies, Immune Regulation, and DNA Repair. Front Oncol 2019;9:210. [PMID: 31001476 DOI: 10.3389/fonc.2019.00210] [Cited by in Crossref: 36] [Cited by in F6Publishing: 28] [Article Influence: 18.0] [Reference Citation Analysis]
631 Visconti R, Morra F, Guggino G, Celetti A. The between Now and Then of Lung Cancer Chemotherapy and Immunotherapy. Int J Mol Sci 2017;18:E1374. [PMID: 28653990 DOI: 10.3390/ijms18071374] [Cited by in Crossref: 27] [Cited by in F6Publishing: 23] [Article Influence: 6.8] [Reference Citation Analysis]
632 Peddi PF, Ellis MJ, Ma C. Molecular basis of triple negative breast cancer and implications for therapy. Int J Breast Cancer. 2012;2012:217185. [PMID: 22295242 DOI: 10.1155/2012/217185] [Cited by in Crossref: 58] [Cited by in F6Publishing: 62] [Article Influence: 5.8] [Reference Citation Analysis]
633 Caster JM, Sethi M, Kowalczyk S, Wang E, Tian X, Nabeel Hyder S, Wagner KT, Zhang YA, Kapadia C, Man Au K, Wang AZ. Nanoparticle delivery of chemosensitizers improve chemotherapy efficacy without incurring additional toxicity. Nanoscale 2015;7:2805-11. [PMID: 25584654 DOI: 10.1039/c4nr07102f] [Cited by in Crossref: 24] [Cited by in F6Publishing: 10] [Article Influence: 4.0] [Reference Citation Analysis]
634 Patel AG, Sarkaria JN, Kaufmann SH. Nonhomologous end joining drives poly(ADP-ribose) polymerase (PARP) inhibitor lethality in homologous recombination-deficient cells. Proc Natl Acad Sci U S A 2011;108:3406-11. [PMID: 21300883 DOI: 10.1073/pnas.1013715108] [Cited by in Crossref: 333] [Cited by in F6Publishing: 278] [Article Influence: 33.3] [Reference Citation Analysis]
635 Tang Y, Hamed HA, Poklepovic A, Dai Y, Grant S, Dent P. Poly(ADP-ribose) polymerase 1 modulates the lethality of CHK1 inhibitors in mammary tumors. Mol Pharmacol 2012;82:322-32. [PMID: 22596349 DOI: 10.1124/mol.112.078907] [Cited by in Crossref: 28] [Cited by in F6Publishing: 22] [Article Influence: 3.1] [Reference Citation Analysis]
636 Ma CX, Janetka JW, Piwnica-Worms H. Death by releasing the breaks: CHK1 inhibitors as cancer therapeutics. Trends Mol Med 2011;17:88-96. [PMID: 21087899 DOI: 10.1016/j.molmed.2010.10.009] [Cited by in Crossref: 189] [Cited by in F6Publishing: 173] [Article Influence: 17.2] [Reference Citation Analysis]
637 Maxwell KN, Wubbenhorst B, Wenz BM, De Sloover D, Pluta J, Emery L, Barrett A, Kraya AA, Anastopoulos IN, Yu S, Jiang Y, Chen H, Zhang NR, Hackman N, D'Andrea K, Daber R, Morrissette JJD, Mitra N, Feldman M, Domchek SM, Nathanson KL. BRCA locus-specific loss of heterozygosity in germline BRCA1 and BRCA2 carriers. Nat Commun. 2017;8:319. [PMID: 28831036 DOI: 10.1038/s41467-017-00388-9] [Cited by in Crossref: 116] [Cited by in F6Publishing: 92] [Article Influence: 29.0] [Reference Citation Analysis]
638 Lee A, Moon BI, Kim TH. BRCA1/BRCA2 Pathogenic Variant Breast Cancer: Treatment and Prevention Strategies. Ann Lab Med 2020;40:114-21. [PMID: 31650727 DOI: 10.3343/alm.2020.40.2.114] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 9.0] [Reference Citation Analysis]
639 Yuan Y, Liao YM, Hsueh CT, Mirshahidi HR. Novel targeted therapeutics: inhibitors of MDM2, ALK and PARP. J Hematol Oncol. 2011;4:16. [PMID: 21504625 DOI: 10.1186/1756-8722-4-16] [Cited by in Crossref: 87] [Cited by in F6Publishing: 79] [Article Influence: 8.7] [Reference Citation Analysis]